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Patients affected by a respiratory disease or injury experience a substantially
impaired respiratory system and as a consequence are unable to obtain a sufficient
amount of oxygen. Hypoxia can quickly result in developing permanent tissue damage or
death. Currently, the medical methods of treating hypoxia are mechanical ventilation or
extracorporeal membrane oxygenation. However, these treatments are ineffective in
certain cases and possess significant additional risks including barotrauma, infection,
hemorrhage, and thrombosis.
The extrapulmonary method of peritoneal oxygenation has been investigated by
other research groups as a potential alternative to providing supplemental oxygen in
hypoxic animals. In peritoneal oxygenation, the peritoneum, the serous membrane that
lines the abdominal cavity and organs, functions as an interface for gas exchange.
However, previous attempts using artificial perfluorocarbons and hemoglobin based
oxygen carriers have demonstrated limited increase in oxygenation and substantial health
concerns. In this work, peritoneal microbubble oxygenation (PMO) therapy has been
investigated as a viable method for delivering supplemental oxygen to hypoxic patients
with critical lung injury. PMO therapy is accomplished with a custom infusion device
designed to safely deliver oxygen microbubbles (OMBs), an innovative oxygen carrier,
into the abdomen.

Animal models of acute lung trauma and respiratory disease were used to validate
PMO therapy. The first model was a small animal feasibility study where fatal hypoxia
was induced by pneumothorax. The second model was asphyxia by tracheal occlusion to
test PMO therapy in the most severe lung injury. When animals were infused with
OMBs, the average survival times after the incidence of injury increased significantly.
PMO treatment increased mean survival time in fatal pneumothorax by 650% and by
180% in asphyxia. Finally, a respiratory disease model was developed and characterized
to replicate acute respiratory distress syndrome (ARDS) in rats. ARDS pathology was
reproduced by aerosolizing an endotoxin, lipopolysaccharide, into the lungs to incite an
antagonistic immune response. Additionally, delivering OMBs for prolonged PMO
treatment to rats was facilitated by comparing the efficiencies of multiple catheters
implanted into the peritoneal cavity. The ARDS and treatment model could then be used
to evaluate PMO therapy and other new methods of supplemental oxygen delivery.
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Chapter 1: Introduction
Patients affected by a respiratory disease or injury experience a substantially
impaired ability for oxygen intake and as consequence can develop life-threating
hypoxemia. The condition of hypoxia can quickly result in permanent tissue damage or
death if proper intervention is not provided. At least one third of the patients admitted to
intensive care units (ICUs) will have conditions that require respiratory support from
mechanical ventilation [1–5]. A major cause of patients developing hypoxia is from acute
respiratory failure (ARF) due to coma, respiratory diseases such as pneumonia, and
physical trauma [2,6]. ARF is the most common organ failure observed in ICUs as 35%
of patients are admitted with or will develop it [3,6]. ARF encompasses a wide range of
respiratory disorders and conditions including acute respiratory distress syndrome
(ARDS). Both ARF and ARDS have reported mortality rates between 30-45% with
severe cases having mortality rates as high as 75% [7–12]. Most deaths in patients with
ARF or ARDS are attributed to multiple organ failure while 16% of patients with ARDS
die from refractory hypoxemia [12,13].
ARDS has gained significant focus in respiratory research as multiple sources
trigger the incidence of ARDS including infections, sepsis, chemical or fluid aspiration,
and physical trauma [3,9]. ARDS is characterized by an antagonistic immune response,
release of inflammatory mediators such as TNF-α and interleukin cytokines, irritation of
cells in the alveolocapillary membrane, and the alveolar space accumulates pulmonary
edema with a high concentration of proteins [9,14,15]. Lung injury and respiratory
dysfunction in ARDS is caused by inhibited gas diffusion from the increased thickness of
the gas exchange membrane and the decreased surface area in alveoli from being filled
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with edema fluid. Current medical methods are ill-suited for treating hypoxia stemming
from ARDS and similar pathologies of respiratory disruption and injury. In these
respiratory conditions, current oxygen delivery methods of mechanical ventilation and
extracorporeal oxygenation are unable to supply sufficient oxygen and can contribute to
increased risk of complications including barotrauma, pneumonia, hemorrhage, and
thrombosis [14–19].
Thus, new oxygenation methods are needed to increase survivability during
pulmonary failure by providing supplemental oxygen in cases of severe refractory
hypoxemia. The extrapulmonary method of peritoneal oxygenation uses the large surface
area of the peritoneum, the serous membrane that lines the abdominal cavity, as a gas
exchanger [20,21]. The main advantages of peritoneal oxygenation are easy access for
catheterization; relative safety of circulating oxygen through the intraperitoneal cavity
(IPC), where the mesothelium acts as a gas permeable barrier between the perfusate and
the blood; and avoidance of extracting and reintroducing blood. The technique is
analogous to peritoneal dialysis, a simple, low-tech form of renal replacement therapy
that is less expensive and complex than conventional hemodialysis [22,23].
1.1 Research objectives
In this work, a new extrapulmonary method of peritoneal microbubble
oxygenation (PMO) was explored, with future objectives for delivering supplemental
oxygen to hypoxic patients with critical lung injury. PMO therapy involves infusing
oxygen microbubbles (OMBs), an innovative oxygen carrier, into the abdominal cavity
where the peritoneum functions as a membrane for gas exchange and diffusion. The
ultimate objective of the research was to demonstrate that PMO therapy is a viable
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treatment option for incidents of hypoxia. To progress towards the ultimate objective, the
principles of PMO therapy were validated by refining methods of OMBs delivery into the
peritoneal cavity, developing a disease model of hypoxia, and investigating PMO therapy
in multiple animal models of hypoxia.
The first goal of the research was to develop methods of infusing OMBs into the
peritoneal cavity. An automated system was created to safely and accurately administer
treatment to the peritoneal cavity in a bolus or continuous perfusion. Another aspect of
infusing OMBs studied was to determine the best peritoneal catheter for performing
prolonged PMO therapy involving repeated infusions of OMBs. The next goal of this
dissertation was development and characterization of a respiratory disease model in rats
to replicate chronic hypoxia. The respiratory disease selected was acute respiratory
distress syndrome (ARDS) because of the considerable research performed on the disease
and the current lack of an effective treatment for hypoxia attributed to ARDS. ARDS
pathology was reproduced in rats by aerosolizing an endotoxin, lipopolysaccharide
(LPS), into the lungs to incite an antagonistic immune response.
Finally, PMO therapy was investigated in multiple animal models of hypoxia to
confirm that infusion of OMBs delivered oxygen in vivo, increased survival, and
increased systemic oxygenation. To validate these properties of PMO therapy, OMBs
were administered as peritoneal treatment for hypoxia in three animal models. The first
animal model in rats induced fatal hypoxia by the lung injury of a right pneumothorax.
The second model in rabbits replicated asphyxia by tracheal occlusion. The third model
evaluated PMO therapy in the ARDS model of hypoxemia characterized in rats. The
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goals of these studies were to test the limits of PMO therapy in several possible
occurrences of respiratory failure compared to the control groups treated with saline.

5

Chapter 2: Background
Respiration of oxygen is a critical component to the survival of humans and most
vertebrates. When respiration is disrupted or impaired, medical intervention is often
necessary to assist in delivering oxygen. To gain an understanding of the medical
treatments for respiratory problems, their disadvantages, and the role PMO therapy can
fulfill, basic knowledge of the respiratory system and oxygen dynamics is presented.
Chapter 2 overviews how oxygen is normally processed and measured in humans and
other mammals, and then details the current medical devices employed to deliver oxygen
and the limitations they possess.
2.1 Physiological respiration
Oxygen is a necessary reactant for the continued life of most vertebrates on Earth
[24]. Energy is synthesized through cellular respiration in the mitochondria of cells only
when there is a source of oxygen. A continuous supply of oxygen must be obtained from
the surrounding atmosphere and distributed to every cell of the organism as most animals
are unable to store oxygen. Animals have evolved the ability to accomplish the task of
procuring oxygen through a specialized process. Physiological respiration is the process
of transporting oxygen into and throughout the body while eliminating carbon dioxide
waste [25–27]. Physiological respiration is performed by the cooperation of the
respiratory and cardiovascular systems. The respiratory system, composed of the trachea,
lungs, alveoli, diaphragm, and intercostal muscles, transports oxygen into the body
(Figure 2.1). The transport of oxygen within the body is performed by the cardiovascular
system composed of the heart, vasculature, and blood. Both the respiratory and
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cardiovascular systems transport oxygen and carbon dioxide by the mechanisms of bulk
flow and diffusion [26–28].
In order to intake air from the atmosphere, the intercostal muscles and diaphragm
contract to increase the volume of the lungs. The greater volume in the lungs decreases
the internal pressure within the alveoli to be less than that of the atmosphere. The
negative pressure of the lungs creates a pressure gradient that facilitates the bulk flow of
air through the trachea and into the lower airways of the conducting zone. The
conducting zone is the respiratory tree composed from the branching structure of the
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Figure 2.1: Human respiratory system.
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bronchi and bronchioles that ends in the respiratory zone at the alveoli. In the respiratory
zone, the oxygen concentration of the inhaled air is significantly higher than that of the
capillary blood surrounding the alveoli. Thus, oxygen diffuses down its concentration
gradient by crossing the alveolocapillary membrane into the blood where it binds to the
protein hemoglobin within red blood cells [26,28,29]. In contrast, carbon dioxide diffuses
into the alveoli because the blood has a higher concentration of CO2 than in the inspired
air (Figure 2.2). The intercostal muscles and the diaphragm relax as the pressure gradient
equalizes, which allows the lungs to return to their original volume and increases their
internal pressure. The positive pressure created assists in the exhalation of gas out of the
lungs. RBCs in the blood are circulated within the body by the heart functioning as a
pressure pump. The pumping of the blood transports the oxygen by bulk flow through the
vascular system (Figure 2.3). When the oxygenated blood in the arteries flows across the
capillary beds, oxygen unbinds from hemoglobin and diffuses from red blood cells to the
surrounding tissue due to the concentration gradient of oxygen between the tissue and
blood. Carbon dioxide waste from cellular respiration diffuses from the high
concentration in the tissue to the low concentration in the blood. Blood in the veins then
returns to the lungs where the entire process will be repeated [26–28].
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Figure 2.2: Alveolar structure and the alveolocapillary membrane (Figure modified from
[26,28]).
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Figure 2.3: Main features and organs of human’s cardiovascular system (Figure derived
and modified from [30]).
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2.1.1 Interactions of blood and oxygen
The dynamics of oxygen transport from the surroundings into tissue is facilitated
by passive diffusion from pressure and concentration gradients produced by the
respiratory system and the heart. In the environment, Earth’s atmosphere at sea level has
an average composition of 78.08% nitrogen, 20.95% oxygen and 0.04% carbon dioxide
by volume. Thus, the fraction of inspired oxygen, FiO2, under normal conditions is 0.21
[27,31]. The partial pressure of oxygen, PO2, in an inhaled breath is calculated to be
approximately 160 mmHg from a standard atmospheric pressure of 760 mmHg. The
partial pressure of carbon dioxide, PCO2, in an inhaled breath is approximated as 0
mmHg due to the low concentration of carbon dioxide in the atmosphere. Air that is
inhaled is completely humidified as it passes through the trachea and bronchial tree,
decreasing the PO2 before reaching the alveoli. The PO2 of air in the alveoli, PAO2, where
gas exchange occurs is approximately 114 mmHg when calculated using average values
at sea level for human oxygen consumption, VO2, and total lung volume, Vlung [32].
𝑉𝑂2

𝑃𝐴 𝑂2 = (𝑃𝑎𝑡𝑚 − 𝑃𝐻2 𝑂 ) (𝐹𝑖𝑂2 − 𝑉

𝑙𝑢𝑛𝑔

)

[Eq. 2.1]

The oxygen in the alveolar space diffuses across the thin alveolocapillary
membrane and into venous blood flowing through the pulmonary capillaries. However,
oxygen is a gas with a low solubility in liquids. Thus, for oxygen to be distributed
throughout the body, a special cell dedicated to binding and carrying oxygen molecules
evolved. The mammalian red blood cell (RBC) is a non-nucleated cell with 96% of its
dry weight is hemoglobin (Hb), a metalloprotein comprised of iron [33]. A single
hemoglobin protein is capable of binding four oxygen molecules at once. Oxygen’s
binding affinity to Hb is a sigmoidal relationship where higher pressures of oxygen and
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Hb with more oxygen bound to it has increased affinity for oxygen [34] (Figure 2.4). The
factors of temperature, carbon dioxide concentration, and blood pH also affect
hemoglobin’s affinity to oxygen. These properties shift the oxygen-Hb dissociation curve
to the right, decreasing the affinity, or the left, increasing Hb’s affinity [26–28,34]. When
humans and other mammals breathe atmospheric air, the diffusion of oxygen from the
alveolar space saturates between 95-100% of the Hb in blood with oxygen [35]. The
partial pressure of arterial blood, PaO2, as it leaves the pulmonary circulation is
approximately 100 mmHg. The strength of the oxygen-hemoglobin bond is weakened
due to the decreasing oxygen tension in the systemic circulation. The decreasing binding
affinity of Hb allows oxygen to unbind from and diffuse into the adjacent tissue. When
the blood returns to the pulmonary capillary bed, the SvO2 and PO2 of venous blood has
decreased to ~75% and 40 mmHg from delivering oxygen [26–28,32,34]. The cycle of
oxygenating and deoxygenating the blood in the pulmonary capillaries repeats providing
that the respiratory and cardiovascular systems continue to operate without
complications.

Figure 2.4: Oxygen saturation of Hb in blood at normal body pH and temperature
(Figure derived from [28]).
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2.1.2 Impairment
Physiological respiration is the process of transporting and utilizing oxygen for
energy production by cellular metabolism. The process of respiration depends on the
respiratory and cardiovascular systems effectively working in unison. Because of the
cooperation between multiple systems, respiration can be compromised by a wide range
of conditions. In these conditions, the exact epidemiological nature in how the body is
affected varies considerably, involves multiple sources, or is not well understood. The
most common impairments have been divided into four categories: airway obstruction,
ventilation disruption, cardiovascular complications, and lung damage.
Airway obstruction is the occlusion of the trachea or bronchi preventing the
passage of air into and out of the lungs. Obstruction of air occurs from inflammation and
constriction of the bronchial tubes in medical conditions such as asthma and bronchitis.
Asthma is exemplified by “attacks” where the inflammation and constriction in the
conducting zone, primarily of the bronchi and bronchioles, becomes exacerbated.
Although people with asthma are known to recover from the disorder, it is not possible to
be medically cured [36,37]. Typically, only the symptoms of asthma are treated by
inhaling corticosteroids and bronchodilators. Acute bronchitis is a common illness mainly
caused by viral infections. Chronic cases of bronchitis are less frequent and stem from
extended smoking or exposure air pollution [38]. Similar to asthma, bronchitis cannot be
cured by medical means, though patients can recover over time.
Ventilation disruption is the inhibition of the inhalation and exhalation processes.
Ventilation disruption can occur by damage or disturbance of the mechanisms for
ventilation. The simplest case is swallowing or inhaling a foreign object or fluid that
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obstructs the passage of air. Drowning is the most common case where the inhalation of
liquid or gas prevents oxygen diffusion in the lung. To return respiratory function, the
object or fluid is removed and in severe circumstances surgical intervention is necessary.
In a pneumothorax, the pleural cavity or membrane is compromised, which alters the
internal pressures of the lung causing them to collapse. Removal of the air pocket by a
chest tube and repairing the pleural membrane is necessary to treat severe cases of
pneumothorax [31,38]. An additional interruption of ventilation occurs when the
contraction of the intercostal muscles and diaphragm is inhibited. The primary causes of
respiratory muscle inhibition are muscle injury and neuromuscular shutdown from certain
drugs and spinal cord or head injuries. Supplemental oxygen from a mechanical
ventilator is the most common treatment for cases of ventilation disruption [39,40].
Mechanical is also commonly employed to treat cardiovascular complications
capable of impeding respiratory function [5,41]. Cardiovascular complications include
heart failure, heart defects, and arrhythmias that cause disrupted or limited blood flow in
the body limiting the efficiency of oxygen transport [24,25]. Pulmonary embolism, a
blood clot in the pulmonary circulation, prevents blood from passing through the lungs to
be oxygenated and remove carbon dioxide [42]. Another type of cardiovascular
complication that impairs respiratory function is anemia, a reduced quantity of RBCs in
the blood. Severe anemia and other the cardiovascular complications can lead to
significant hypoxia due to the decreased oxygen carrying capacity and circulatory flow of
the blood.
The final category of respiratory impairment that causes hypoxia is damage and
injury to the lungs. Damage to the lung tissue can instigate multiple methods of inhibited
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oxygen diffusion. Alveoli and lung tissue damage reduces the surface area available for
the airflow to experience gas exchange in the respiratory zone. Lung damage can also
trigger excessive immune and inflammatory responses from the cells. These excessive
responses lead to swelling of the alveolocapillary membrane and developing pulmonary
edema, the accumulation of fluid in the alveoli. Pulmonary edema significantly inhibits
the capabilities of the lungs by limiting the surface area that air can exchange gas with the
alveolocapillary membrane and forcing oxygen to dissolve in the fluid to diffuse into the
blood [14]. Bacterial and viral infections are predominant sources of lung damage and
include pneumonia, tuberculosis, SARS, and MERS. Other leading causes of lung
damage include lung cancer, emphysema, smoke, and chemical inhalation [36,43,44].
Similarly, pulmonary fibrosis and interstitial lung disease lead to scarring and thickening
of the alveoli and lung tissue which decreases the elasticity of the lung [31,37,38,42]. If
damage from lung injury or disease becomes significant, a patient can develop acute
respiratory distress syndrome (ARDS), a severe medical complication with no known
treatment and a high mortality [11]. In these cases where the respiratory system is
impaired by a respiratory illness or injury, the condition of oxygenation in the patients is
critical to their treatment and survival.
2.2 Measuring oxygen saturation in the body
The amount of oxygen in the body is an important metric that medical
professionals depend on to care and treat their patients. The primary focus for patient care
is determining the oxygen saturation of hemoglobin in arterial blood (SaO2). Determining
oxygen saturation of the patient is used to verify the degree of hypoxia, the deficiency of
oxygen in the tissue, (Table 2.1). The SaO2 is commonly measured or estimated with
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pulse oximetry, blood gas analysis, and hemoximetry. These methods of determining
oxygen saturation are used by physicians to determine the efficiency of the respiratory
system, status of the patient, and interventions that should be applied.
Table 2.1: Degrees of hypoxia and corresponding oxygen measurements
[24,34,45–48].
Degree of hypoxia

SpO2 (%)

PaO2 (mmHg)

FO2Hb (%)

Mild
Moderate
Severe

85-92
75-84
<75

60-79
40-59
<40

90-95
75-89
<75

2.2.1 Pulse oximetry
The most commonly utilized method of determining the oxygenation status of a
patient is pulse oximetry [46]. Pulse oximetry is a noninvasive method to quickly and
continuously approximate the oxygen levels of the body. Pulse oximetry results in an
indirect measure of oxygen saturation referred to as peripheral oxygen saturation (SpO2),
as it is primary measured on thin external body parts such as the fingertip or earlobes.
The pulse oximeter is a device employed in most medical settings including intensive
care, surgery, emergency rooms, and ambulances due to being simple to use and accurate
in many scenarios.
2.2.1a Operating principles
Pulse oximetry operates on the principles of the unique light absorption properties
of hemoglobin and spectrometry. Pulse oximetry is capable of measuring only the oxygen
saturation of arterial blood by taking advantage of two physiological properties. A
property of unbound or reduced hemoglobin is that hemoglobin possesses a distinct
absorbance spectrum that is considerably altered when it binds to oxygen
(oxyhemoglobin) and changes the protein’s structure. Hb and oxyhemoglobin (O2Hb)
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have the greatest difference in absorbance spectrums at the wavelengths of red, 660 nm,
and near-infrared (NIR), 940 nm [49]. Red light is absorbed more effectively by Hb,
while NIR light is absorbed better by O2Hb. These wavelengths are optimal as they
transmit through tissue more efficiently than blue, green, yellow, and infrared light [49].
Thus, the quantity of O2Hb and Hb is determined by transmitting the red and NIR
wavelengths of light through a thin layer of tissue and measuring the transmitted intensity
of red and NIR with a photodiode (Figure 2.5). The physiological property of the tissue
the light is transmitted through is then exploited to estimate the oxygen saturation of only
arterial blood.
The exploited physiological property is that the volume of arterial blood in the
tissue being measured fluctuates as it is pumped by the heart, while the volume of venous
blood remains constant [45]. The measured values of total absorbance can be considered
a linear combination of pulsatile arterial and static venous blood. As only the absorbance
of arterial blood varies over time, any change in the total absorbance is attributed to the
change in arterial blood [45]. The change in blood volume is measured as a pulse
waveform which classifies pulse oximeters to also be photoplethysmographs. Thus, a
pulse oximeter requires a steady pulse to generate an oscillating arterial absorbance and
multiple bursts of light at two different wavelengths to measure the change in absorbance
over time (Figure 2.5).
The two properties are used to approximate the SaO2 of an individual. The
red/NIR modulation ratio, R, is a ratio of the different measured combinations of
absorbance, A, and is calculated by the equation [45]:
𝑅=

𝐴𝑟𝑒𝑑,𝑝𝑢𝑙𝑠𝑎𝑡𝑖𝑙𝑒
𝐴𝑟𝑒𝑑,𝑠𝑡𝑎𝑡𝑖𝑐

×𝐴

𝐴𝑁𝐼𝑅,𝑠𝑡𝑎𝑡𝑖𝑐

𝑁𝐼𝑅,𝑝𝑢𝑙𝑠𝑎𝑡𝑖𝑙𝑒

[Eq. 2.2]
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Healthy volunteers whose SaO2 levels are altered from 75-100% then have their red/NIR
modulation ratios measured and compared. The red/NIR modulation ratios are calibrated
to a curve for matching to SaO2 and result in a pulse oximetry approximation of oxygen
saturation, SpO2 [45,49]. The normal range for oxygen saturation in the body measured
by pulse oximetry ranges from a SpO2 between 95-100%, 93-95% for smokers, while a
SpO2 value below 90% is to be indicative of hypoxia [46]. The two properties from which
pulse oximetry is developed from give it many advantages such as a rapid reading of
oxygen saturation and compact components to allow the oximeter to be portable.
Light emitting diode

Pulse oximeter clip

Bursts of red/NIR light

Light absorbance

Finger

Arterial (pulsing)

Venous (static)

Time
Light transmitted through finger

Photodiode

Figure 2.5: Functionality of a pulse oximeter.
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2.2.1b Limitations
The method of pulse oximetry possesses several advantages resulting from the
properties of hemoglobin and arterial blood. However, these properties result in
limitations in the performance of pulse oximeters. The first acknowledged limitation of
pulse oximeters relates to how the calibration curves between the red/NIR modulation
ratios and SaO2s were developed. The validity of the calibrations has been questioned
when applied to the elderly or individuals with certain medical conditions such as sickle
cell anemia [46,49]. The pulse oximeter calibrations were performed in healthy
volunteers from a relatively small population sample. The volunteers had their SaO2
levels artificially changed from 75-100% while a pulse oximeter measured the
modulations ratios. These modulation ratios were related to the SaO2s of the volunteers to
generate calibration curves for the pulse oximeter that ranged from SpO2 between 70100%. Thus, pulse oximeter measurements below SpO2 of 70% are not considered as
accurate or reliable because these values are extrapolated from the calibration curves
generated [45,46,49]. Also, only healthy volunteers were included in the calibration trials
because of the health and safety concerns of artificially inducing hypoxia during the
trials. As a consequence, the readings of pulse oximeters in cases with abnormal pulses
and tissue perfusions have been mostly untested and contribute to poor transmittance of
signals and incorrect readings hindering the performance of pulse oximeters. Pulse and
perfusion disruptions that lead to failure of the pulse oximeter are caused by conditions
including hypothermia, hypotension, low cardiac output, septic shock, vasoconstriction,
and tremors [46,49]. The more recognized and examined limitation of pulse oximeters
relates to the light absorbance spectra for the varieties of hemoglobin.
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As pulse oximeters use light to measure O2Hb, results are obtained noninvasively,
quickly, and continuously from a patient. Light and absorbance properties also are the
source of several of the limitations inherent to pulse oximeters. The absorption spectrum
of hemoglobin deviates depending on the structure of the protein as it binds oxygen.
However, hemoglobin will bind to several other ligands if present such as carbon
monoxide, which has approximately a 240 times greater binding affinity to hemoglobin
than oxygen [50]. Carbon monoxide bound to hemoglobin forms carboxyhemoglobin
(COHb), which absorbs red light to an equivalent extent as O2Hb [50]. Pulse oximeters
then mistakenly measure COHb as O2Hb because the absorbance of red light is increased.
Because it cannot distinguish between the absorbance of red light from COHb and O2Hb,
a pulse oximeter overestimates SpO2 when high concentrations of carbon monoxide is
inhaled [51]. Pulse oximeters measure the absorption of light incorrectly from another
form of hemoglobin, methemoglobin (MetHb). MetHb differs from Hb in that the iron
ion has a charge of +3 instead of +2, which prevents it from binding oxygen. MetHb
normally composes less than 1% of hemoglobin and absorbs NIR light to a much more
effectively than both O2Hb and Hb [50,52]. Thus, high levels of MetHb in the blood
results in the SpO2 to be measured between 80-85% as the MetHb absorbs both red and
NIR light the pulse oximeter transmits [45,52]. Because pulse oximeters are limited in
several medical conditions and in interpreting differences between the hemoglobin types,
other methods of measuring oxygen are used to confirm the oxygenation of a patient.
2.2.2 Blood gas analysis
When pulse oximetry readings are suspect or if the oxygenation status of a patient
needs confirmation, blood gas analysis is commonly used in clinical practice. Blood gas
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analysis is an invasive method to approximate the oxygen levels in the body from a blood
sample. Blood analyzers are trusted in most medical settings including intensive care,
surgery, and emergency rooms. Analysis of blood gases results in an indirect measure of
oxygen saturation referred to as partial pressure of oxygen (PO2) or oxygen tension, as it
is measures the pressure of free gaseous oxygen that is dissolved in the blood.
2.2.2a Operating principles
The processes for measuring oxygen in blood are similar to that of measuring the
acid/base balance of the blood. Blood gas analysis measures the chemical interactions of
the blood with several types of electrodes. Using multiple electrodes, blood analyzers
measure the qualities of acid/base, oxygen, and carbon dioxide concentrations in a
patient’s blood. Blood gas analysis consists of three parameters: pH, PO2, and PCO2
(Table 2.2). Only the balance of acid and base in the blood can be accurately determined
from a venous blood sample. To determine the oxygenation status of the patient, blood
gas analysis is performed on arterial blood sampled from the radial artery [48,53].
Table 2.2: Parameters measured by blood analysis.
Acceptable range
Human
Rat
[27,28,48,54]
[55–57]
7.3-7.5
7.34-7.46

Variable

Abbreviation

Units

pH
Partial pressure of carbon
dioxide in arterial blood
Partial pressure of oxygen
in arterial blood
Bicarbonate
Base excess
Total CO2

pH

--

PaCO2

mmHg

30-50

34.6-53.9

PaO2

mmHg

80-100

80-100

HCO3BE
tCO2

mmol/L
mmol/L
mmol/L

22-26
-2 to 2
23-30

17.7-26.8
-2 to 2
18-27
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Once the blood is collected from the patient, the analyzer pumps the blood across
the series of electrodes. All the electrodes in the blood analyzers are maintained at 37°C
because the chemical reactions of the electrodes depend on a fixed temperature to
calibrate values based on the normal body temperature. A glass electrode is used to
measure pH of the blood [58,59]. The concentration of H+ ions in the blood interacts
withthe measuring electrode, while a reference electrode contacts a solution with a
known and stable pH. The voltage generated between the two electrodes is then
calculated based on the calibrated relationship between the outputted voltage and pH.
Similarly to measuring pH, the partial pressure of carbon dioxide is measured in blood
analyzers with a modified glass electrode, the Severinghaus electrode [47]. With a
Severinghaus electrode, carbon dioxide in the blood sample diffuses through a gas
permeable membrane into a bicarbonate solution in the measuring electrode. The
diffusing CO2 disrupts the chemical balance of the bicarbonate solution. The bicarbonate
solution then releases H+ ions to return to equilibrium. The pH adjustment from the H+
ions generates a voltage with a standard glass electrode. The voltage from the glass
electrode is compared to the reference electrode for calculating the PCO2 from calibrated
samples [47,58,60]. Because the measurement of pH and PCO2 is closely connected, they
are often measured in parallel. However, measuring oxygen requires a completely
different electrode.
𝐶𝑂2 + 𝐻2 𝑂 ⇋ 𝐻2 𝐶𝑂3 ⇌ 𝐻 + + 𝐻𝐶𝑂3−

[Eq. 2.3]

The measurement of PaO2 is performed with a Clark electrode [47,59]. The Clark
electrode is a silver anode and a platinum cathode suspended in a potassium chloride or
potassium bromide electrolyte solution. In the electrolyte solution, the reference and
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measurement electrodes are applied with a known voltage [47,60,61]. The voltage
between the electrodes is increased when free oxygen dissolved in the blood plasma
diffuses through a semipermeable membrane into the electrolyte solution. The current is
generated from the oxygen being reduced at the cathode and silver being oxidized at the
anode. Thus, the more the current increases, the higher the oxygen tension is within the
blood. However, at a PO2 greater than 150 mmHg, the relationship between the oxygen
reaction and increase in current becomes increasingly nonlinear and results in error in the
analysis [59]. Additionally, deterioration of the electrolyte solutions and electrodes from
the oxygen reactions causes the signal from the Clark electrode to continually drift from
its initial values. The drifting of the Clark electrode’s signal requires the electrode of the
blood analyzer to be periodically recalibrated and the solutions replaced [47,58–61]. The
drifting of the Clark electrode’s signal is the only limitation inherent from the principle
used to measure the oxygen tension in the blood. However, other limitations are
attributed to the method of measuring oxygen saturation with blood gas analysis.
2.2.2b Limitations
Blood gas analysis is notably more reliable than pulse oximetry with fewer
inaccuracies resulting from the technique of using electrodes to measure oxygen. The
major limitation in measuring oxygen saturation with blood gas analysis is the Clark
electrode is not a direct measurement of the patient’s oxygenation. The Clark electrode
measures the oxygen that is dissolved in the blood and not the oxygen in the tissue or
bound to hemoglobin. Thus, the oxygen saturation is estimated by the hemoglobin
saturation curve (Figure 2.4) [53,54]. The Hb saturation curve shifts depending on
multiple factors including temperature, content of CO2, blood pH, carbon monoxide, and
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MetHb. The shifts in the Hb saturation curve are not always accounted for resulting in the
calculations relating PaO2 to oxygen saturation to be slightly inaccurate [48,59,62].
Other limitations of blood gas analysis are related to sampling and handling of the
blood. If venous or mixed venous blood is mistakenly collected instead of arterial blood,
the patient’s respiratory status is poorly assessed from the venous blood sample. The
blood is also analyzed incorrectly if the blood sample is diluted by adding excessive
amounts of heparin to the collection syringes. The blood sample is also contaminated
when bubbles of air are in the syringe, potentially increasing the oxygen in the blood
sample and resulting in an artificially high measurement of PO2. The PO2 of the blood
sample significantly decreases when leukocytes and platelets in the blood continue to
metabolize O2 and CO2. Therefore, the blood gases in the sample are altered if the sample
is not refrigerated or analyzed quickly after it is collected [48,59]. In most clinical
settings, blood gas analysis is not immediately performed as the analyzer is located in the
lab and not by the patient [48,54]. The final limitation of blood analyzers is the expenses
and calibration protocols associated with the analyzer. The blood analyzer requires
comprehensive operation and maintenance procedures to ensure that quality of analysis is
preserved [47,48,53,58,59]. The pulse oximetry and blood gas analysis are both indirect
methods of measuring oxygen saturation, but oxygen saturation is directly measured
when principles from each method are combined in hemoximetry.
2.2.3 Hemoximetry
Hemoximetry or CO-oximetry is a method to directly measure the oxygen
saturation of peripheral tissue or the blood. The peripheral tissue or blood sample is
measured for the fraction of oxyhemoglobin, carboxyhemoglobin, methemoglobin, and
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deoxyhemoglobin with hemoximetry (Table 2.3). Hemoximetry can be analyzed with two
methods based upon pulse oximetry and blood gas analysis.
The noninvasive variation of pulse hemoximetry is comparable to pulse oximetry
as the principles of spectrometry are applied to the unique light absorption properties of
hemoglobin. However, hemoximetry measures the light absorption spectra of
oxyhemoglobin, carboxyhemoglobin, methemoglobin, and deoxyhemoglobin. A light
emitting diode transmits burst of red and NIR light at several wavelengths and measures
the transmitted light with a photodiode [67]. From the measured modulation ratios, the
pulse hemoximeter then calculates the fractions of O2Hb, COHb, MetHb, and Hb based
upon the absorption spectra of the Hb types and calibrated values obtained from hypoxic
and healthy volunteers. Measuring the spectra from the multiple Hb variants eliminates
the errors that pulse oximetry generates in measurement of Hb and O2Hb absorption
spectra when the structure of hemoglobin is altered. Though it does not have the
limitation from other forms of Hb confounding the spectra, disruptions of the pulse and
tissue perfusion contributes to poor transmittance of signals and incorrect pulse oximeter
readings [66,68].
The invasive variation of hemoximetry is related to blood gas analysis as they
both require collection of an arterial blood sample. The arterial blood is pumped through
an opaque fluid channel while the transmitted light spectra from multiple wavelengths is
Table 2.3: Parameters measured by hemoxim etry [63–66].
Variable

Abbreviation

Acceptable range in arterial blood

Fraction of oxyhemoglobin
Fraction of carboxyhemoglobin
Fraction of methemoglobin
Fraction of deoxyhemoglobin

FO2Hb

95-98%

FCOHb
FMetHb
FHHb

0-3%
0-3.8%
0-2%
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measured [65]. Measuring the spectra after light transmits through arterial blood, the
oxygen saturation of hemoglobin in the sample is directly determined without the
inconsistencies from pulse or tissue perfusion as in pulse oximetry. Unlike blood gas
analysis, blood hemoximetry does not utilize a Clark electrode that requires regular
calibration. Blood hemoximetry also does not approximate oxygen saturation by relating
oxygen tension to the oxygen-hemoglobin saturation curve. However, because a blood
sample is used similar in blood gas analysis, procedures in handling and analyzing the
sample are followed to minimize errors occurring from air contamination and living cells
consuming the oxygen. The methods of pulse oximetry, blood gas analysis, and
hemoximetry are employed by physicians to determine the status of the patient. If the
patient is found to be experiencing hypoxia, oxygen is delivered to the patient with one of
two approaches.
2.3 Current O2 delivery methods
Currently there are only two medically accepted methods for delivering oxygen to
a patient suffering from respiratory dyfunction or hypoxia. These approved interventions
are mechanical ventilation and extracorporeal membrane oxygenation, and both
implement different principles for oxygen delivery. Mechanical ventilation and
extracorporeal oxygenation possess several advantages and drawbacks. In specific cases
of respiratory failure, neither of these methods has proven to be an optimum treatment as
the mortality rate of patients with respiratory failure remains high.
2.3.1 Mechanical ventilation
Mechanical ventilation (MV) is the oldest and currently the most common
treatment method for oxygen delivery to a patient. The origins of MV begin in the fifth

25
century B.C. when Hippocrates conceptualized that sticking a reed into the trachea allows
for air to be forced into the lungs [69]. Further reported development of MV is
nonexistent for centuries until the 16th century when Andreas Vesalius records the use of
a MV device. The MV device consisted of a tube inserted into the trachea of an animal
attached to bellows that inflated and deflated the lungs when compressed [70]. In the
1700s, bellows were then used as a positive pressure ventilator to resuscitate drowning
victims. Derivatives of the bellows design continued to be developed and still exist today
in the form of bag valve masks typically used in ambulatory care and anesthesia.
However, due to common disuse and over-inflation with these devices, victims can suffer
pneumothorax or severe pulmonary barotrauma. The poor outcome of these early devices
led them to be temporarily abandoned for most cases of medical practice when newly
developed negative pressure ventilators became popularized [69,70].
The first negative pressure ventilator, the body-tank ventilator, was developed by
John Dalziez in 1838. The body-tank ventilator used a hand pump to change the pressure
in an air-tight box the patient would sit in. The body-tank ventilator circulated and altered
by several others, but no design ever established widespread use. The body-tank
ventilator proved unwieldy to operate and caused patients to suffer from “tank shock” or
accumulation of blood in the lower extremities [39,70]. Body-tank ventilators were
eventually operated automatically and more efficiently with the accessibility of electricity
in the 1900s. The most notable body-tank ventilator, the iron lung, was created by a
Harvard collaboration of engineer Philip Drinker, physiologist Louis Shaw, and physician
Charles McKhann. The iron lung passed animal trials in the late 1920s and later became a
valuable device in treating patients with respiratory distress during the poliomyelitis
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epidemics of the 1950s [39,69,70]. However, iron lungs still induced “tank shock”, were
expensive to manufacture, and not widely available. Because of the problems with the
iron lung, negative pressure ventilators experienced a rapid decline in use despite the
success of the iron lung in the poliomyelitis epidemics.
The resurgence of positive pressure ventilators occurred after a 1952 outbreak of
poliomyelitis in Copenhagen, Denmark. At their only hospital, Copenhagen had a
mortality rate of 87% in polio patients treated with a small number of negative pressure
ventilators. The doctors quickly decided to switch to a different treatment strategy due the
high mortality and lack of iron lung ventilators for the large number of polio patients
admitted. Doctors instead performed a tracheostomy and positive pressure ventilation
with a manual bag valve mask. This procedure using bag masks reduced the mortality
rate to 40% in the 200 polio patients for whom this was implemented [70,71]. Due to the
polio epidemic, the principles of MVs underwent considerable refinement to improve
their efficiency at treating respiratory complications in ICUs and hospitals.
2.3.1a Operating principles
The central principle of MV is to deliver oxygen to the patient by assisting with
the transport of gases into the lungs. Oxygen can be delivered noninvasively with a face
mask, but leaks around the mask seal and face inhibit airflow control and limit the
effectiveness of oxygen supply [72]. The most effective methods for oxygen delivery to
the lungs are tracheal intubation with an endotracheal tube (ETT) or surgical placement
of a tracheotomy tube. Modern MVs increase oxygen delivery to the body with two
methods. The first method is increasing the concentration of oxygen inhaled, FiO2. The
FiO2 is increased by mixing air with oxygen from an external source before being
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supplied to the patient. The higher FiO2 increases the oxygen gradient within the alveoli
and facilitates greater diffusion into the blood. However, if the patient is having severe
difficulty breathing on their own, MV assists the patient through the second method. MV
assists the patient with labored breathing or MV completely performs the ventilation
process for the patient. MV facilitates the movement of gas for the patient by
manipulating pressure differentials by two methods: negative or positive pressure.
Negative-pressure ventilators function with the same principle as the respiratory
system of mammals to facilitate the transport of oxygen into the lungs. In negative
pressure ventilators, a chamber encloses the chest or body and is sealed from the
surrounding atmosphere (Figure 2.6). Air is pumped out of the chamber to decrease the
pressure in the chamber to be lower than the pressure in the lungs. The altered pressure
causes the lungs to expand and draw in air from the surrounding atmosphere to facilitate
inspiration. In order to facilitate expiration, air is pumped into the chamber to increase the
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Rigid chamber
Figure 2.6: Schematic of negative pressure ventilation.
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pressure until it is greater than that in the lungs [73]. In contrast, positive-pressure
ventilators operate by a simpler principle. Positive-pressure ventilators force an airoxygen mixture through a tracheal tube to directly inflate and deliver oxygen to the lungs.
Depending on the condition of the patient, the positive-pressure ventilator allows the
patient to breathe on their own or imposes ventilation by pumping gas into and out of the
lungs [74]. Though positive-pressure ventilators operate with a simpler principle, the
design of these ventilators is more complex (Figure 2.7). Regulating the breathing of a
patient with MV operates with two different cycles to provide measured airflow within
the lungs. In the cycle of volume control, a fixed volume of air, determined from the
patient’s tidal volume, is delivered to the patient for each breath. For the cycle of pressure
control, the lungs are inflated with the air-oxygen mixture until a selected positive
pressure is reached in the circuit. These cycles of MV possess numerous variations in
settings and strategies for treating different respiratory conditions [74,75]. One of the
more successful strategies of MV is low tidal volume ventilation which reduces the risk
of barotrauma and ventilator induced injury. Low tidal volume ventilation is the preferred
treatment for several conditions, including ARDS. However, with the strategy of low
tidal volume ventilation, there is increased risk of insufficient oxygen supply and
hypercapnia, excessive carbon dioxide in the blood [76,77].
2.3.1b Clinical utility
MV is used in many scenarios where oxygen needs to be provided to patients. MV is
utilized in cases including ARF, COPD, ARDS, pneumonia, neuromuscular disorders,
and non-pulmonary sepsis [41,78]. When used to treat these conditions, the overall
mortality rate ranges widely from 10-52% and highly depends on the condition affecting

29
the patient [79–81]. The mortality rate is lower in patients with conditions where the
lungs were not impaired, such as in neuromuscular disorders. In cases of ARDS, where it
is known that the functionality of the lungs is significantly decreased, the mortality was
greater at 41-52% [80,81]. The high mortality demonstrates that MVs are capable of
forcing air into the lungs and delivering sufficient oxygen to a patient for survival if there
is something wrong with the musculature or nervous system which controls normal
respiratory function. However, in an injured lung, gas exchange through the
alveolocapillary membrane is compromised and MV is unable to adequately provide the
necessary amount of oxygen to the patient for respiration.
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Figure 2.7: Schematic of modern positive-pressure mechanical ventilators.
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Not only is MV ill-suited for supplying oxygen to damaged lungs, but several
prominent risks are associated when used to treat these cases. When MV is done by an
ETT or tracheotomy, a direct pathway is made to the lungs. Direct access to the lungs
greatly increases the possibility of the patient contracting bacterial infections, such as
pneumonia [82,83]. MV treatment with a tracheotomy is also uncomfortable for patients
and limits their ability to communicate. Another recognized risk of MV is ventilator
induced lung injury or pulmonary barotrauma [84,85]. These conditions are when the
forced air creates excessive stress on the lungs causing tears in the capillary endothelium,
epithelium, and basement membrane. The damage from excessive stress can lead to fluid
leakage into the lungs and atelectasis which further inhibits the ability to breathe and
transfer oxygen into the body. An additional risk of MV is significant atrophy of the
diaphragm and respiratory muscles when used for at least 18 hours [86].
2.3.2 Extracorporeal membrane oxygenation
Extracorporeal membrane oxygenation (ECMO) is a relatively new medical
treatment procedure. ECMO is currently the only form of extrapulmonary respiration
treatment that has been shown to facilitate survival for prolonged treatment periods where
the lungs are nonfunctional. The clinical benefit of ECMO has taken many years to attain
sufficient support and was plagued by moral issues, highly criticized trials, and continual
advancement of the technology. Beginning in the 1950s, the advancement of medical
technologies and surgical techniques cumulated in the development and success of the
heart-lung machine in human patients [87]. The heart-lung machine is used to keep a
patient alive by circulating and oxygenating the blood while surgery is performed on the
heart and lungs. However, first generations of the heart-lung machine were only able to
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be used for a maximum of four hours. The four hour limitation was because the device
oxygenated the blood being in direct contact with oxygen gas. The direct contact
extracorporeal oxygenators caused severe hemolysis, clotting, protein denaturation of the
blood, and air embolism during prolonged procedures [88].
To limit the blood trauma of direct contact extracorporeal oxygenators, research
was directed towards developing membrane oxygenators that could exchange oxygen and
carbon dioxide through a gas permeable membrane, while preventing blood from
interacting with air surfaces. Progress stalled due to a lack of biomaterials with
acceptable mechanical properties and that were permeable to oxygen and carbon dioxide
gases. After years of development, the first successful human trial of prolonged ECMO
support was accomplished for 75 hours in an adult patient with respiratory failure
experienced from trauma of being hit by a car [89]. In 1974, the first success of ECMO
treatment in neonate care was accomplished for a case of meconium aspiration causing
severe pneumonia [90].
These encouraging results spurred the medical community into research to
confirm the clinical benefit of ECMO treatment for respiratory failure. However, a
randomized trial of adult ARDS patients treated with mechanical ventilation or VA
ECMO had mortality rates of 90% in both groups [91] which led to ECMO treatment in
adults with respiratory failure being recognized as impractical. In contrast, randomized
clinical trials in neonates revealed a dramatic increase in survival when ECMO was
utilized [92–94]. In the 1980s, previous work in using ECMO to treat adults was
questioned by the supporters of ECMO under the basis that the equipment used was
primitive, the staff was not highly trained in its use, and ECMO was used in conjunction
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with mechanical ventilation which confounded the results. Due to the evident success of
ECMO in neonates, improvement in technology, and the controversy over previous
studies, interest in adult ECMO treatment was renewed. Results of more recent ECMO
clinical trials detail promising outcomes from treatment. ECMO was found to reduce the
rate of disability 6 months after treatment compared to conventional MV [95].
Additionally, ECMO has been successfully utilized in treating patients with ARDS
contracted from H1N1 influenza [96]. Finally, the overall survival rate of ECMO patients
has been increased to 56% [97]. With the amount of progress made in the field of
medicine and biomaterials, ECMOs have become more efficient in oxygen exchange and
have been utilized more often in patient care.
2.3.2a Operating principles
ECMO is an example of an extrapulmonary respiration treatment method and
currently the only clinically accepted method for prolonged use. The basis of ECMO is to
circumvent the necessity of the lungs by removing venous blood from the body, adding
oxygen, and returning the re-oxygenated blood to the body [98]. ECMO’s procedure
requires several specialized components to operate efficiently. These components include
a heat exchanger to warm the blood to body temperature before reinfusion into the
patient, a gas trap to prevent air embolism, and access ports for introduction of
anticoagulants and drugs or analysis of blood oxygen saturation levels (Figure 2.9).
In order to access the patient’s blood to remove, oxygenate and return it to the
body, large catheters are inserted into major veins. There are two types of cannulation
techniques used for ECMO: veno-venous (VV) and veno-arterial (VA). The most
common technique is VV ECMO, which only provides respiratory assistance to the
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Figure 2.8: Schematic of ECMO circuit.
patient. VV ECMO is more efficient at carbon dioxide removal and oxygenation of the
blood compared to VA ECMO. VV ECMO is accomplished by placement of a drainage
cannula into the inferior vena cava via the femoral vein and a return cannula into the right
atrium of the heart via the internal jugular vein and superior vena cava. If more blood
circulation is required to further increase oxygenation, then drainage cannula will be
placed in both the inferior and superior vena cavae [99,100]. With new cannula designs,
it is possible to do VV ECMO with only one dual lumen catheter inserted into the right
atrium [88,100]. The VV ECMO setup decreases recirculation of blood in the ECMO
circuit, bleeding issues from cannulation, and increases the mobility of the patient [101].
VA ECMO is able to provide both cardiac and respiratory assistance. VA ECMO is
accomplished by placing the drainage cannula in the inferior vena cava via the femoral
vein or the right atrium via the internal jugular vein. The return cannula is inserted into
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the ascending aorta or the femoral artery. The method of VA ECMO has a higher chance
of serious arterial injury, air embolism, and thrombosis [99].
A pump is required to control the flow of blood from the patient into the ECMO
machine. Current ECMO machines typically use peristaltic, also called roller, pumps, but
advances with centrifugal pumps have increased their use. Both types of pumps are
known to cause hemolysis and platelet breakdown, which increases the chance of
thrombosis and decreases the oxygen carrying capacity of the blood. Peristaltic pumps do
not need to be primed with fluid to begin pumping and the blood does not interact
directly with the pumping mechanism. The disadvantage of peristaltic pumps is that
excessive wear on the tubing from the rollers can cause ruptures in the line and the
drainage of blood is assisted by gravity and a reservoir, so clotting is more likely to occur
[102]. Centrifugal pumps allow for a shorter circuit length and smaller surface area for
blood-prosthetic surface interaction, which decreases the activation of inflammatory
factors. However, centrifugal pumps have been documented to increase the amount of
hemolysis and risk of acute renal failure [103].
The next critical component is the membrane oxygenator, which has always been
the major limiting factor of ECMO. Initial oxygenators were direct-contact oxygenators
such as the Mayo-Gibbon pump-oxygenator, Kay-Cross disc oxygenator and the DeWall
bubble oxygenator. These designs were revolutionary at the time, but they could not be
used longer than four hours without serious risks. Complications of damage of the red
blood cells and platelets, thrombosis, and protein denaturation stemmed from the direct
contact of blood with air. To reduce damage to the RBCs, a membrane composed of a
biomaterial was incorporated into the oxygenator to act as an interface between the air
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and blood. The membrane interface has to be gas permeable for transfer of oxygen and
carbon dioxide, rigid, and prevent the adhesion of blood to its surface [104]. Current
membranes are composed of silicone, microporous hollow polypropylene fibers, or
polymethyl pentene (PMP). Silicone membranes are very durable, have a high resistance
to flow, and the lowest gas exchange efficiency of modern membranes. Microporous
hollow-fiber oxygenators are used in cardiopulmonary bypass machines due to their
efficient gas exchange properties. However, plasma leakage from the micropores occurs
within a few hours of use and therefore they must be replaced frequently. PMP
oxygenators are the newest type of membrane with gas exchange efficiency similar to
microporous hollow-fiber and the longevity of silicone membranes. They also slowly
develop leaking of plasma and have increased resistance of blood flow from deposition of
fibrous networks [105].
2.3.2b Clinical utility
ECMO was originally developed as a long term solution for cardiopulmonary
bypass in surgeries on the heart or the lungs, as the current bypass machine could only be
used for short periods of time. With the development of the membrane oxygenator, long
term ECMO treatment was possible. ECMO is utilized as a bridge to lung transplantation,
cardiac failure, hypoxia, and respiratory failure caused by lung trauma, pneumonia,
influenza, sepsis, COPD, or ARDS [17,102]. According to the registry of the
Extracorporeal Life Support Organization (ELSO), the mortality rate for pneumonia
patients treated with ECMO in 2013 was 38.5%, while mortality in patients with ARDS
or ARF was 47% [97]. These mortality rates for clinical trials of ECMO treatment remain
within the 34-53% range that has been reported for the past 20 years [88,95,100,106–
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108]. Despite the lack of improvement seen, cases have shown that ECMO treatment can
possibly improve the outcome of respiratory failure and ARDS. Patients diagnosed with
severe ARDS have an expected mortality greater than 80%, yet mortality for those treated
with ECMO is 48% [106]. Another influential study in respiratory failure showed that the
mortality rate for ECMO patients was 37% compared to 45% for patients treated with
conventional MV [95]. However, ECMO involves a significant chance for complications
to occur regardless of current advancements in clinical procedures and components.
There are many recognized risks associated with ECMO which affect the outcome
of the patient. The most prevalent risks are bleeding related complications including
cannulation site bleeding, cardiac arrest, thrombosis, hemorrhaging, and hemolysis
[99,100,106]. Bleeding complications are not only the most common risks of ECMO, but
thrombosis and hemorrhaging have the greatest capacity to negatively impact survival
[97,107,109]. Bleeding risks have also been indicated as more likely in VA ECMO
compared to VV ECMO [99,109]. The risk of bleeding complications also increases
when high doses of anticoagulants, such as heparin, are given to the patient. To reduce
the amount of anticoagulants needed to prevent clotting in the circuit, ECMO
components have been developed with heparin coatings [98,101,102]. However, ECMO
treatment can still result in hemolysis and thrombosis despite utilization of heparin
coatings, more stable flow from pumps, and biocompatible membranes. Another
prevalent complication is infection from either contamination of the blood while in the
circuit or from the catheter placement site [99,109]. Other major complications include
renal failure, pneumothorax, seizures, and mechanical failures [99,100,106,107,109].
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Seizures and intracranial hemorrhaging though rare in adult patients, are more common
in pediatric and neonatal patients [97].
ECMO retains considerable stigma as a clinical treatment of “last resort” despite
confirmed clinical benefit in certain cases of respiratory failure. The stigma remains
because ECMO still exhibits a wide range of risks, requires continuous oversight by
experienced perfusionists, and remains unable to be used in ambulatory cases due to its
large size. Thus, considerable research and development occurs to realize an alternative
method for delivering oxygen to a patient suffering from respiratory failure and hypoxia.

38

Chapter 3: Peritoneal oxygenation
Peritoneal oxygenation is a proposed alternative to MV and ECMO treatments for
patients with hypoxia or respiratory failure in ambulatory, emergency, and long-term
care. Peritoneal oxygenation is a method of extrapulmonary oxygenation without the
limitations or associated risks of MV and ECMO. Peritoneal oxygenation is
accomplished by utilizing the peritoneum as a location for gas exchange in place of or in
addition to the lungs. The peritoneum is the serous membrane that lines the abdominal
cavity and the peritoneal organs (Figure 3.1) [22,110]. The peritoneum qualifies as a
location for the supportive delivery of oxygen because it possesses a large surface area
for diffusion [111,112], close proximity to multiple organs [26], extensive vascular
structure [22,110], and considerable circulation of blood (Figure 3.2) [113–115]. The
main advantages of peritoneal oxygenation are easy access for catheterization, relative
safety of cycling oxygen gas through the intraperitoneal cavity (IPC) as the mesothelium
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Figure 3.1: Anatomy of peritoneum and intraperitoneal organs.
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acts as a gas permeable barrier between the perfusate and the blood, undiminished gas
exchange properties during respiratory failure, and avoidance of the external circulation
of blood. Peritoneal oxygenation is analogous to peritoneal dialysis, which is used in
cases of renal failure. Peritoneal dialysis is a simple, low-tech form of renal replacement
therapy that is less expensive and complex than conventional in-center hemodialysis
[22,110]. When the IPC is filled with dialysis solution, waste compounds such as urea
and creatinine diffuse out of the bloodstream and into the dialysis solution. After a period
of dwell, the fluid is drained and the IPC refilled with fresh dialysis solution [116].
Similarly, in peritoneal oxygenation, an oxygen carrying perfusate is infused into the IPC
where the oxygen will diffuse into the blood and be transported throughout the body
(Figure 3.3). However, as with MV and ECMO using peritoneal oxygenation as an
alternative method of supportive oxygen delivery possesses several inherent limitations.
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Figure 3.2: Splanchnic circulation and average blood flow rates of human at rest (Figure
derived and modified from [117]).

40

Figure 3.3: Pathway of oxygen diffusion for peritoneal oxygenation.
3.1 Limitations
There are five acknowledged limitations when utilizing the peritoneal cavity for
extracorporeal oxygenation (Table 3.1). Though the surface area of the peritoneum is
large compared to other structures in the body, it is relatively small when compared to
lungs [118–120]. The smaller surface area of the peritoneum indicates that the potential
for gas exchange is also less than the lungs. Further limiting the delivery of oxygen to the
body, only 20-30% of total blood flow passes through the splanchnic circuit at any time
[113,115,121]. The thickness of the peritoneum membrane is greater than that of the
alveolocapillary membrane, which slows down diffusion of oxygen into the capillary bed
of the splanchnic circulation [22,110,122]. Also, the intra-abdominal pressure (IAP) must
be carefully regulated to not surpass 10 mmHg. IAP increased above 10 mmHg is
documented to reduce splanchnic blood flow, cardiac output, and peripheral tissue
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oxygen saturation [21,123–126]. Inciting hemodynamic changes negatively impacts the
potential effectiveness of oxygen delivery through the IPC. The final limitation of
peritoneal oxygenation is a complication that also occurs in MV and ECMO. The long
term cannulation into the peritoneal cavity increases chances for infection of the
peritoneum, peritonitis [22,116]. However, in contrast to ECMO, peritoneal oxygenation
possesses no direct pathways to the bloodstream or risks of bleeding unless a
complication occurs during implanting the abdominal catheter.
Despite these limitations, peritoneal oxygenation continues to demonstrate
potential to be utilized as a method of supplemental extrapulmonary oxygenation. In a
study to validate the effectiveness of peritoneal oxygenation, normoxic dogs had their
peritoneal cavity implanted with an inflow and outflow catheter [21]. The catheters were
attached to a centrifugal pump and a membrane oxygenator. The peritoneal cavity of the
dogs was then circulated for 2 hours with unoxygenated saline, oxygenated saline, or
oxygenated human RBCs while arterial blood gases were periodically measured. While
dogs that were circulated with unoxygenated saline maintained a constant PaO2,
oxygenated saline and human RBCs increased the PaO2 by 15 and 30 mmHg, respectively
[21]. The experiment of peritoneal oxygenation in dogs confirmed that though the
method of peritoneal oxygenation may not be as efficient as ECMO or MV due to several
Table 3.1: Limitations of peritoneal cavity when compared to the lungs.
Gas Exchange
Locations

Surface
Area
(m2)

Volume
(L)

Blood
flow
(L/min)

% of total
blood flow, ie
cardiac output

Membrane
thickness
(μm)

Lung
[43,44,119,120]

24-75

4-6

4.4-8.4
[127,128]

100
[127,128]

0.1-2.2

Peritoneum
[22,110,116,118]

1-2

2-3

1.4-2
[113,114]

17-30
[113,115,121]

24 -500
[22,122]
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inherent limitations, peritoneal oxygenation is capable of delivering a clinically relevant
increase to oxygen saturation with an effective oxygen carrier. However, an optimal and
safe oxygen carrier has not yet been developed for peritoneal oxygenation to be feasible
as a method of supplemental oxygenation.
3.2 Previous peritoneal oxygenation methods
Peritoneal oxygenation is developed as an extrapulmonary method of supplying
oxygen to the body. However, previous techniques of peritoneal oxygenation attempted
in animals were unable to demonstrate a consistent clinical improvement in models of
hypoxia (Table 3.2). The previous techniques of peritoneal oxygenation attempted
ventilating the peritoneal cavity or infusing different artificial oxygen carriers to deliver
supplemental oxygen through the peritoneum in animal models of hypoxia.
3.2.1 Beginning of peritoneal oxygenation
The first method of peritoneal oxygenation reported was by the infusion of
hydrogen peroxide (H2O2) in 1968 [129]. The theory was that when hydrogen peroxide
was infused into the IPC, H2O2 would decay into water and oxygen, which would
increase systemic oxygenation during hypoxia. In animal trials, a momentary increase in
arterial oxygen saturation was observed. The increase in oxygen saturation was minor
and indicated no clinical benefit as an outcome. Based on the results of several studies,
hydrogen peroxide infusion for peritoneal oxygenation was determined to be ineffective
and hazardous due to high risk of gas emboli formation [129,136]. However, the idea of
peritoneal oxygenation remained and researchers continued attempts at validating
peritoneal oxygenation with different techniques.
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Table 3.2: Summary of peritoneal oxygenation studies.
Animal
model

Hypoxia
method

Rabbit
[129]

FiO2 reduced
to 10%

Rabbit
[130]
Rabbit
[131]
Swine
[132]
Rabbit
[133]

Pulmonary
lavage with
saline
Pulmonary
lavage with
saline
FiO2 reduced
to 15%
Clamped
trachea

Duration of
experiment
(minutes)

Perfusate

FiO2 reduced
until PaO2 
55 mmHg

SaO2 increased 2-9% for 2
min; decreased after 10 and
30 min
1.7 fold increase in PaO2 and
80% survival; controls had
0% survival
100% survival, 2.2 and 4.8
fold increase in PaO2 without
and with cisapride

30

H2O2

120

O2 gas (PV)

120

O2 gas (PV)

180

O2 gas (PV)

No increase in SvO2

10

O2 gas (PV)

No relevant increase in PaO2

PFC (FC43)
Rat
[134]

Outcomes in
survival/oxygenation

60

PFC
(Haemaccel)
None

Canine
[122]

FiO2 reduced
variably

270

PFC
(decalin)

Swine
[20]

FiO2 reduced
to 10%

300

PFC
(decalin)

Rat
[135]

Pneumothorax

45

Synthetic Hb
(TRM-645)

PaO2 and SaO2 increased ~20
mmHg and ~6%
PaO2 and SaO2 increased ~10
mmHg and ~4%
PaO2 increased ~10 mmHg
and SaO2 decreased 2%
PaO2 increased 5-25 mmHg
during mild hypoxia, but
decreased in severe hypoxia
PaO2 increased an average of
12.8 mmHg
Survival time increased
360% and PaO2 increased
740% compared to saline
controls

3.2.2 Peritoneal ventilation
Another attempted method was application of mechanically ventilating the
peritoneal cavity. In peritoneal ventilation (PV), the peritoneal cavity is inflated and
deflated with pure oxygen from a positive pressure ventilator similar to traditional MV of
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the lungs. The first reported study of peritoneal ventilation was in 1994 when rabbits
were submitted to a pulmonary lavage of saline to induce severe ARDS symptoms [130].
The animals were divided into the control group, which was treated with conventional
MV, or the experimental group, which was treated with conventional MV in parallel with
PV. All six animals in the control group rapidly developed severe hypoxia and died
within 75 minutes after the lavage, while four of the five rabbits in the peritoneal
ventilated group lived with an average PaO2 of 81 mmHg until the two hour endpoint
[130].
In 1996, the same research group reported on a modified peritoneal ventilation
therapy, which significantly increased the oxygenation in rabbits with ARDS induced by
pulmonary lavage [131]. The modified PV therapy used a dose of cisapride, an agent that
increases gastric emptying, to improve the blood flow through the splanchnic circuit. The
study showed that healthy rabbits dosed with cisapride had splanchnic blood circulation
increase by 188%, but did not exhibit changes in PaO2 while on conventional MV.
Rabbits with ARDS were injected with a dose of cisapride or saline and treated with
conventional MV. The MV groups treated with only cisapride or saline did not show any
increase in PaO2 and all died 45 minutes after the lavage. In contrast, all rabbits with
ARDS treated with PV in addition to MV survived until the two hour endpoint.
Additionally, the peritoneal ventilated rabbits injected with cisapride developed
significantly higher levels of PaO2 after 30 minutes than those injected the saline vehicle
[131].
With the results from studies in rabbits, peritoneal ventilation with oxygen
demonstrated potential in improving the outcome in cases of respiratory failure and
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hypoxia. However, a subsequent large animal study published in 1998 challenged the
clinical potential of peritoneal ventilation [132]. Six pigs were mechanically ventilated
with a normal FiO2 of 0.2 then a hypoxic FiO2 of 0.15. Pigs underwent peritoneal
ventilation after being stabilized for 30 minutes at each FiO2. All pigs had their SvO2
measured and peritoneal oxygen uptake determined with a spirometer. No increase was
found in oxygen uptake or SvO2 of pigs with PV compared to when the peritoneal cavity
was not ventilated [132]. The study with pigs revealed that PV with oxygen yielded little
potential for clinical applications. The potential of PV was tested once more in the most
recent study of asphyxiated rabbits.
The most recent study of peritoneal ventilation was published in 2010 and
detailed an experiment where 24 rabbits experienced asphyxia by tracheal clamp [133].
Rabbits were randomly assigned treatment of no PV, PV with air, or PV with pure
oxygen. Groups with peritoneal ventilation were found to have a marginal increase in the
PaO2 measured compared to the control group without PV. The control group survived an
average of 5.0 minutes after the tracheal clamp and was not significantly different from
the air ventilation group average of 5.3 minutes. The oxygen ventilated group had an
average survival time of 6.5 minutes and was significantly different than the other two
groups [133]. The increase in survival time and PaO2, however, was not substantial
enough to be of any clinical benefit and supported the claim that peritoneal ventilation
has a low clinical utility. Despite the failure of peritoneal ventilation, other techniques
using artificial oxygen carriers have demonstrated a greater clinical relevance regarding
the treatment of hypoxia with peritoneal oxygenation.
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3.2.3 Artificial oxygen carriers
The technique of peritoneal oxygenation that is investigated in addition to
peritoneal ventilation is infusing the peritoneal cavity with artificial oxygen carriers.
Artificial oxygen carriers were originally developed for liquid ventilation or as blood
substitutes. The blood substitutes of perfluorocarbons and hemoglobin-based oxygen
carriers have demonstrated carrying capacities for oxygen that are greater than blood. The
potential of these blood substitutes as oxygen carriers gained interest for their use in
peritoneal oxygenation.
3.2.3a Perfluorocarbons
The most studied method of peritoneal oxygenation involves infusion of
perfluorocarbon (PFCs) variants into the intraperitoneal space. PFCs are fluorinated
carbon chains similar to hydrocarbons and are extremely hydrophobic. Aqueous PFCs are
inert colorless liquids twice as dense as water with a high solubility for oxygen and
carbon dioxide gases [137,138]. Because the solubility of oxygen in PFCs is a linear
relationship to the partial pressure of oxygen, PFCs are poor oxygen carriers compared to
RBCs and hemoglobin at physiological pressures of oxygen. However, PFCs are very
efficient at delivering oxygen as the oxygen is never bound [137,138]. The delivering
efficiency of oxygen sparked interest in the use of PFCs as an alternative method of
oxygenating tissue. PFCs were researched thoroughly in the area of liquid ventilation due
to a sensationalist experiment in 1966 where mice and cats were submerged in a
container filled with PFCs and survived while “breathing” the fluid [139]. When removed
from the container, the animals returned to breathing air. However, the PFC formulation
was not ideal because animals undergoing liquid ventilation treatment only lived for
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several weeks afterwards as the inhalation of PFCs caused significant pulmonary damage.
Despite the long term effects, the demonstrations of liquid ventilation showcased the
biocompatibility and medical applications of PFCs. Since then, alternative oxygen
delivery methods with PFCs have been investigated including peritoneal oxygenation.
The first study of peritoneal oxygenation with oxygenated PFCs was performed in
1986 with slightly hypoxic rats (PaO2 ≈ 55 mmHg and SaO2 ≈ 87%) caused by reduced
FiO2 [134]. In the experiment, only one of the two PFC variants (FC43) provided a
significant increase in PaO2 and SaO2 from the induced hypoxic baseline compared to the
untreated controls [134]. In a subsequent study in dogs, oxygenated PFCs were infused
into the IPC during normoxic, mild hypoxic (SaO2 > 80%), or severe hypoxic (SaO2 <
80%) conditions [122]. The PaO2 of dogs was increased 5-25 mmHg above the baseline
during mild hypoxia, while the PaO2 continually decreased in dogs with severe hypoxia
despite infusion of oxygenated PFCs. The studies with PFCs in small animal displayed
moderate potential to be utilized as an oxygen carrier for peritoneal oxygenation. The
benefit of peritoneal oxygenation with PFCs was then attempted in pigs to determine if
there was potential for clinical use.
The most recent study in peritoneal oxygenation with PFCs was in 2006 with
hypoxic pigs [20]. The animals were intubated and mechanically ventilated. The
experiment consisted of a dwell period and a circulation period with either oxygenated
saline or PFC. The dwell period consisted of infusing a volume of perfusate based upon
body weight into the peritoneal cavity and then decreasing the FiO2 from 18% to 10% by
2% intervals every 30 minutes. After the dwell period, the perfusate was circulated
through an oxygenation circuit into the peritoneal cavity while FiO2 was elevated from

48
10% to 18% by 2% intervals every 30 minutes. The administration of PFC showed an
overall effective increase of 12.8 mmHg in PaO2 when compared to the saline treatment.
The greatest increase in PaO2 with PFC treatment observed was 15.9 mmHg which
occurred when FiO2 was set at 14% [20]. The large animal study in pigs demonstrated
promising results for peritoneal oxygenation with PFCs being utilized as an alternative
method of extrapulmonary support. However, the use of PFCs as an oxygen carrier
encounters several severe disadvantages.
Though the results of peritoneal oxygenation with PFC are significantly more
promising than those of peritoneal ventilation with oxygen, there are factors that prevent
PFCs from being the ideal oxygen carriers for supportive oxygenation. PFCs for
biomedical and oxygen carrying purposes are required to be emulsified because of the
PFCs highly hydrophobic and lipophobic properties. The hydrophobic and lipophobic
properties of PFCs also causes the manufacture and emulsion process to prepare PFCs for
biomedical applications to be complicated and difficult [137,140]. Gaseous PFCs are also
extremely stable compounds with lifespans of thousands of years and entrap heat in the
atmosphere 103-104 times greater than CO2 [141]. Thus, gaseous PFCs are recognized as
an environmental hazard and under strict emission standards according to the Kyoto
Protocol because gaseous PFCs possess exceptional potency as greenhouse gases with
significant impact for increasing global warming [142]. Also, despite extensive research,
an optimal PFC for peritoneal oxygenation has not been developed and many PFCs
previously approved by the FDA have been removed from the market [143,144]. During
multiple preclinical and clinical trials, PFCs were tested as a blood substitutes in cases of
hemorrhagic shock and ischemia. In the trials, PFC treatment caused a significant
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increase in flulike symptoms, stroke, and thrombocytopenia [133,144,145]. In addition to
these health concerns, early evidence suggested that PFC emulsions would be
metabolized and removed from the body by the reticuloendothelial system of the liver,
spleen, and bone marrow [137]. However, in the trials of PFC treatments, the PFCs were
observed to cycle through and suppress the reticuloendothelial system. The suppression
of the reticuloendothelial system lead to PFC particles being retained for long durations
in the body, particularly in the liver, spleen and lungs [144,145]. The retention of PFCs in
the lungs was recognized to cause chemical pneumonitis and death by accumulation of
gas emboli [145,146]. Retention of PFCs was attributed to the PFC compounds being so
biologically inert and unable to diffuse through cell membranes. Due to the multiple
health risks from PFC treatments in preclinical and clinical trials, the FDA has suspended
clinical trials where PFCs were used as blood substitutes or oxygen carriers. Due to the
health concerns PFCs have encountered as blood substitutes, the biocompatibility of
PFCs is now suspect and its future as an oxygen carrier for peritoneal oxygenation is
uncertain.
3.2.3b Hemoglobin based oxygen carriers (HBOCs)
The second type of artificial oxygen carrier currently being developed are
hemoglobin based oxygen carriers (HBOCs). HBOCs are originally designed for use as
an allogenic substitute for blood while alleviating the substantial shortage in donations.
The optimal HBOC would be able to replace the need for blood transfusions in surgeries
or cases of hemorrhage shock and anemia without being concerned about compatibility
[144,147]. Because of their oxygen carrying properties, HBOCs are also being
investigated for use as oxygen carriers to treat local tissue ischemia and tumor hypoxia
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and for preserving donated organs [143,144]. The hemoglobin used for creating HBOCs
is obtained from the lysis of human or bovine red blood cells or by altering the genome of
Escherichia coli to produce human hemoglobin proteins. Because of the inadequate and
limited sources for hemoglobin protein, the cost of HBOCs is three times that of donated
human blood [148,149]. Most HBOCs developed are categorized as acellular HBOCs
where the hemoglobin proteins remain unbound by a membrane [143,150,151]. The
hemoglobin is heavily modified by crosslinking, polymerizing, or conjugating to increase
its intravascular and room temperature stability while maintaining its oxygen affinity
[138,151]. Recently, nanoparticle HBOCs have been developed where the hemoglobin
proteins are encapsulated in a lipid or polymer membrane [143,147,152].
HBOCs have seldom been used as an oxygen carrier for peritoneal oxygenation.
However, the most successful application of peritoneal oxygenation in previous literature
was using a nanoparticle HBOC [135]. The HBOC, TRM-645, is produced from donated
human blood that is not acceptable for transfusion because it is too aged. The expired
blood is lysed and the hemoglobin is encapsulated in liposomes synthesized from
phosphatidylcholine, cholesterol, and stearic acid with the surface modified by the
addition of PEG [152]. Hypoxia from a fatal right pneumothorax was created by stabbing
the ribcage with a scalpel blade and piercing through the pleural membrane. After
inducing the pneumothorax, rats were treated with a peritoneal injection of the same
volume of saline, oxygenated human blood, or oxygenated TRM-645. Saline treated rats
rapidly developed respiratory acidosis and hypoxia leading to cardiac arrest. Rats treated
with TRM-645 showed a significant increase of PaO2 compared to rats treated with saline
and human blood. Another factor indicating the effectiveness of peritoneal oxygenation
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with TRM-645 was that the survival time after pneumothorax was significantly increased
to 32.9 minutes from 9.2 and 22 minutes with saline and human blood, respectively
[135].
HBOCs require further development in order to accomplish their purpose as an
ideal blood substitute and artificial oxygen carrier. The progress in acellular HBOCs has
mostly been discontinued because multiple clinical trials reported health complications
and negligible benefits and were suspended by the FDA [143,149–151]. Treatment with
acellular HBOCs is responsible for causing vasoconstriction from excessive nitric oxide
scavenging, neurotoxicity when the blood brain barrier was compromised, severe
gastrointestinal distress, producing oxygen free radicals, and degrading into
methemoglobin. There is also concern that treatments with acellular HBOC may lead to
an increased risk of myocardial lesions and infarctions [153,154]. To remedy the issues
with acellular HBOCs, nanoparticle HBOCs were developed to mimic how RBCs safely
transport hemoglobin. Nanoparticle HBOCs have demonstrated lower methemoglobin
formation, limited scavenging of nitric oxide, and similar behavior to RBCs in binding
and releasing ligands [155–157]. Currently, nanoparticle HBOCs are limited by their
lower oxygen affinity, short in vivo half-life, membrane stability, obtaining a stable
inexpensive source of hemoglobin, and hepatosplenomegaly at large dosages [143,147–
149,152]. Overall, results in research and development of nanoparticle HBOCs is
encouraging, but they could possibly produce the negative symptoms recognized by
acellular HBOCs if the encapsulated hemoglobin were to be released when the membrane
degrades or fails. Currently, the limitations and safety concerns of using HBOCs and
PFCs as oxygen carriers prevents peritoneal oxygenation from being considered as a
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feasible method of supplemental oxygenation. To fulfill the role of a safe and effective
artificial oxygen carrier, an alternative method of delivering oxygen is needed for
peritoneal oxygenation.
3.3 Peritoneal microbubble oxygenation with oxygen microbubbles
Advances in developing peritoneal oxygenation as a treatment method for
delivering supplemental oxygen in cases of acute hypoxia is evidenced to be difficult.
Current methods of peritoneal oxygenation attempted in hypoxic animal models provided
marginal clinical benefit in improving oxygenation. The lack of progress is mainly from
the disadvantages of current oxygen carriers, PFCs and HBOCs, which include limited
oxygen carrying capacities, manufacturing obstacles, and health concerns [144,148]. Due
to these significant limitations current artificial oxygen carriers are ineffective for
delivering short or long term supplemental oxygen through the peritoneum.
Oxygen microbubbles (OMBs) have been proposed as an alternative to fulfill the
role as an efficient and safe oxygen carrier. OMBs are derived from gas microbubbles
originally used as contrast agents for ultrasound, vehicles for drug and gene delivery, and
potential blood substitutes [158–161]. Gas microbubbles are formed by a thin membrane
which encloses a gas core. The membrane of the microbubbles is typically composed of
amphiphilic proteins, polymers, or most commonly lipids and phospholipids. Using
amphiphilic molecules like phospholipids for the membrane material of the gas
microbubbles allows for greater control of the surface structure and for self-assembly into
a monolayer that can surround gas [162,163]. Microbubbles used as contrast agents
generally encapsulate biologically inert gases such as perfluorobutane, while
microbubbles for gene delivery contain DNA suspended perfluorocarbons [158,160,163].
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Because of the long history and widespread use of microbubbles in the medical field,
phospholipid microbubbles have been extensively characterized, optimized, and
investigated [164–170].
3.3.1 Microbubbles as a blood substitute
Lipidic oxygen-containing microparticles (LOMs) are a variant of oxygen
microbubbles composed of a DSPC lipid monolayer with polyoxyethylene stearyl ether
(BRIJ 100) linked to the surface. LOMs were tested as a blood substitute for short-term
oxygen delivery by intravenous injection [171]. The LOMs were tested in rabbits
experiencing one of two scenarios, hypoxic ventilation with a FiO2 of 11% or asphyxia
by clamping of the endotracheal tube (ETT) for 15 minutes. Rabbits under hypoxic
ventilation had no hemodynamic instability and oxyhemoglobin saturations between 6575%. When the rabbits were administered 80 mL of 50% per volume LOMs for two
minutes (40 mL LOM50/min), their oxyhemoglobin saturations were increased to normal
levels of ~90%. Once the LOM injection was completed, the oxyhemoglobin saturation
of the rabbits returned to hypoxic levels [171]. Asphyxia rabbits were intravenously
administered 70% LOMs at 4.5 mL/kg or a control solution at 1.3 mL/kg per minute for
15 minutes after the clamp was placed. All the control rabbits suffered cardiac arrest
within 10 minutes and only 75% were able to be resuscitated by continuous chest
compressions for the remaining five minutes. Their oxyhemoglobin saturation decreased
below 20% three minutes after the clamp was placed and never increased until removed.
However, the rabbits injected with LOMs maintained oxyhemoglobin saturations above
40% during the entire 15 minutes, never had to be resuscitated by chest compressions,
and had a survival of 85% by the end of the period of asphyxia [171].
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The study with intravenous LOMs demonstrates that phospholipid oxygen
microbubbles have significant potential as an oxygen carrier for clinical cases of hypoxia.
However, intravenous injection of LOMs is limited to cases of short term hypoxia as
several factors prohibit the use of intravenous injection of microbubbles. The first
problem is that injecting a large volume of fluid into the bloodstream for long periods
will result in hypervolemia, pulmonary edema, hemodynamic instabilities, and decreased
hematocrit [24,28,36]. Another problem is that injecting large quantities of lipid into the
blood could result in clotting and thrombosis within the vasculature. When the oxygen
diffuses out of the bubbles, the membrane collapses and the lipids more readily coalesce
[168,169]. The coalesced lipids could then obstruct the blood vessels before they can be
removed. The multiple problems associated with using microbubbles as a blood substitute
can be circumvented by employing oxygen microbubbles as an efficient and safe oxygen
carrier for peritoneal oxygenation.
3.3.2 Properties of oxygen microbubbles
The OMBs used in my investigation of peritoneal microbubble oxygenation
therapy are phospholipid microbubbles, which encapsulate pure O2 gas and are suspended
in sterile saline (Figure 3.4). The outer surface of the lipid monolayer is modified by PEG
covalently linked to the hydrophilic head. The PEG molecules form a “brush” that
stabilizes the lipid monolayer and prevents coalescence of the microbubbles. The
phospholipid and PEG monolayer only comprises ~1% of the OMBs volume. The
oxygen gas core and saline constitute the remaining volume of the OMB solution. The
volume of saline can be decreased for a suspension with a higher density of microbubbles
or increased for a suspension with a lower density of microbubbles. Increasing the
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density of the microbubbles increases both the oxygen carrying capacity and the viscosity
of the OMB solution. Thus, to more greatly mimic the fluid properties of blood, OMBs
are often diluted to ~70% per volume mixture with the remaining 30% being saline. Even
with the OMB fraction only comprising 70% of the solution, the selected OMB solution
has the greatest capacity for carrying oxygen compared to all other existing artificial
carriers (Table 3.3).
Oxygen microbubbles were designed to comprise a phospholipid coating
stabilizing a microscopic bubble of oxygen gas (Figure 3.5a). This design was chosen to
mimic the naturally occurring surfactant that lines the lung alveolus, which is primarily
composed of diacyl phosphatidyl-choline (DPC) [175]. Saturated DPC lipids selfassemble at the gas/water interface to form a 3-nm thick monomolecular layer that can be
compressed to achieve very low interfacial tensions [176], which is necessary to avoid
premature microbubble dissolution [177]. Distearoyl phosphatidyl-choline (DSPC) was

Figure 3.4: Structure of oxygen microbubbles used for PMO therapy.
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Table 3.3: Comparison of artificial and biological oxygen carriers.
Carrier
Saline, water,
blood plasma
[28,32,34,38]
RBC
[28,32,34,38]
PFC
[20,143,172]
HBOC
[135,143,173]
OMB
OMB90

O2 carrying capacity,
BO2 (mgO2/mL)

Volume O2/volume
carrier (%)

Size/diameter
(μm)

0.038

0.03



0.31

17-20

6-8

0.57

5-7.2

0.01-0.35

0.62

5-15

0.05–0.3

0.88
1.13

70
90

5-7
5-7

chosen as the main lipid component because it provides an optimal tradeoff between inplane rigidity to stabilize microbubbles for long durations in storage [166] and relatively
low gas permeation resistance [164]. The lipid monolayer is permeable to oxygen and
other gases, so the bubble is in continuous diffusive exchange with surrounding dissolved
gases [167]. While highly permeable, the lipid shell modulates gas exchange by resisting
monolayer expansion and compression beyond the close-packed lipid configuration at the
microbubble resting radius [168]. A polyethylene glycol (PEG) conjugated lipopolymer
with a matching stearate lipid anchor was also chosen as an emulsifying agent to improve
yield by promoting lipid adsorption onto newly formed oxygen microbubbles and
inhibiting microbubble coalescence. Self-consistent field theory calculations indicate that
under these conditions the PEG chains form a ~10-nm thick hydrated brush layer [165],
which can lead to very high repulsive pressures between closely approaching
microbubbles [178]. The DSPC/PEG shell comprises only ~1% of the total microbubble
volume, but is essential for stabilizing the microbubbles against coalescence and
dissolution.
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Figure 3.5: Lipid-coated oxygen microbubbles [179]. (a) Oxygen gas comprises 99% of
the microbubble volume. The oxygen core is stabilized by a thin (~3 nm) phospholipid
monolayer membrane, which reduces surface tension and provides in-plane rigidity. A
hydrated PEG brush (~10 nm height) grafted to the lipid surface provides steric repulsion
to prevent microbubble coalescence. (b) A scaled-up OMB manufacturing process is used
to generate up to 2 L of OMBs (~70 vol%) per day. (c) Bright field microscopy of diluted
OMBs showed discrete, spherical microbubbles. (d) OMBs have a milky white
appearance and can be stored and transported in 500-mL serum bottles. (e) Shown are the
volume and number weighted size distributions for freshly generated OMBs. The dashed
lines are the number (blue) and volume (red) mean diameters. The shaded area covers the
size range for 90% of the total OMB gas volume.
Oxygen microbubbles were prepared by adapting the process design developed by
Swanson et al. [174] for synthesizing large volumes of concentrated (~70 vol%)
microfoam (Figure 3.5b-c). OMBs were synthesized and stored in sealed 500-mL serum
bottles for storage and transport (Figure 3.5d). The microbubbles were stable to several
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days of storage and transport for animal studies. The OMBs were polydisperse in size
(Figure 3.5e), with a number-weighted mean diameter of 3.4 ± 1.9 μm (mean ± SD) and a
volume-weighted mean diameter of 7.7 ± 4.2 μm. 90% of the total gas volume was
contained in microbubbles with diameters less than 14 μm.
3.3.3 Quantity of OMBs required for PMO therapy
Supplemental oxygen with PMO therapy was administered to animals suffering
hypoxia by infusing predetermined quantities of OMBs. The quantity of OMBs infused
for PMO therapy was derived from the total resting oxygen consumption of the animals,
not the level of hypoxia or depression of lung function. The amount of OMBs delivered
corresponded to the animals’ total oxygen consumption because a greater quantity of
OMBs would be required to provide sufficient oxygenation with the limitations inherent
to peritoneal oxygenation. When a bolus of OMBs was used for PMO treatment, the
OMBs were infused until the intra-abdominal pressure reached the accepted limit of 8
mmHg to prevent collapse of the microvasculature [21,123–125,183]. Continuous PMO
therapy required circulating OMBs at a flow rate, QOMB, based on the reported total
oxygen consumption of the animal while at rest, VO2, calculated by the equation:

𝑄𝑂𝑀𝐵 =

𝑚∙𝑉𝑂2 ∙𝜌𝑂2
𝐵𝑂2𝑂𝑀𝐵

[Eq. 3.1]

Where density of oxygen, ρO2, and carrying capacity of OMBs, BO2OMB, were known and
the animals’ mass, m, was measured at the start of the experiments. To keep the
administration of PMO therapy consistent between trials, a peritoneal infusion device was
created for accurate and autonomous delivery of OMBs.
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Table 3.4: Dosage of OMBs used for PMO treatments.
Animal

VO2 (𝐤𝐠∙𝐦𝐢𝐧𝟐 )

𝐐𝐎𝐌𝐁 𝐦𝐋 𝐎𝐌𝐁
(
)
𝐦
𝐤𝐠 ∙ 𝐦𝐢𝐧

Rat [184,185]
Rabbit [186,187]
Pig [188–190]

12

17.7

9.2
7

13.7
10.3

𝐦𝐋 𝐎
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Chapter 4: Development of a peritoneal infusion device
Validating PMO therapy required the accurate and repeated administration of
OMBs into the peritoneal cavity. To perform the function of administrating PMO therapy
and limit human error, an infusion device was developed to deliver OMBs or saline
treatments into the peritoneal cavity for the acute hypoxia experiments in animals. The
infusion device was designed to perform peritoneal infusion and fulfill several criteria for
delivery, safety, and effectiveness. The first criterion was that the infusate must not be
exposed to outside contaminants or the atmosphere. If the OMBs are not isolated from
their surroundings, the encapsulated oxygen rapidly diffuses out of the bubbles and into
the air before it can reach the peritoneal cavity. In addition, isolating the infusate prevents
potential contaminants from entering the body directly reducing the risk of infection. The
second criterion was that the system must continuously infuse fluid to the animal while
maintaining pressures within the peritoneal cavity below 8 mmHg. If the intra-abdominal
pressure (IAP) is greater than 8 mmHg, there is risk of damaging the organs within the
abdomen, but collapsing the capillary beds in the splanchnic circuit [123–126].
Collapsing the capillary bed of the splanchnic circuit alters the normal cardiac function
and limits the amount of blood flow in the region, thus decreasing the effectiveness of
PMO therapy. Thus, the balance between continuously supplying OMBs and limiting the
intra-abdominal pressure is essential and must be precisely controlled. The third criterion
was the device must be programmed to infuse treatment into the peritoneal cavity
autonomously with minimal supervision. The program of the device also must be
implemented with a simple user interface to monitor the sensor outputs and manually

61
control the device when necessary. The final criterion was that the device must be
durable and portable to be transported between facilities.
The infusion device developed was designated as the peristaltic peritoneal
perfuser and infuser (Peri3). The Peri3 is a pressure controlled dosing pump designed to
deliver infusate into the IPC of animal subjects during the administration and evaluation
of PMO therapy (Figure 4.1). The function and the criteria of the Peri3 are fulfilled by
implementing several subsystems. The Peri3 delivers infusate with a peristaltic pump to
prevent contamination of the fluid, as well as isolate OMBs from the surrounding
atmosphere. The Peri3 continually monitors the IAP with pressure transducers attached to
secondary catheters implanted into the abdomen. By continually measuring the IAP of
the animals, the volume in the abdomen can be controlled to increase oxygenation,
promote circulation of OMBs, and prevent over-pressurizing the cavity. The Peri3 is
controlled by a LabVIEW program with an interface to set several key parameters for the
experiment including animal mass, species, and the IAP range.

Figure 4.1: Peri3 system hooked up to in vitro replica abdomen without fluid warmer.
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4.1 Fluid infusion
The first critical component of the Peri3 is the fluid infusion subsystem required
to deliver the infusate solution the peritoneal cavity. A peristaltic pump was chosen as it
does not expose the infusing fluid to the pump, will not damage the OMBs, and is
capable of pumping viscous fluids. For the Peri3, the FH100M peristaltic pump from
Thermo Fisher Scientific was utilized. The FH100M peristaltic pump was selected
because of its main features and versatility. The FH100M is capable of a flow rate range
of 0.013-760 mL/min and a maximum output of 200 rpm. The wide range of flow rates
allows the pump to be used for infusion of small animals such as rats and rabbits and
large animals such as pigs. The FH100M pump also includes an extended rotor head for
multiple tubing lines which facilitates infusing multiple animals or fluids. The FH100M
pump features adjustable cartridges to accommodate a range of tubing diameters for
infusing. At greater flow velocities, small diameter tubing yields higher pressures that
could potentially damage the OMBs. Thus, the option of using tubing with larger
diameters is desirable for the higher flow rates required in treating larger animals. For
experiments in acute hypoxia of animal, the infusion line tubing selected was 3.2 mm
inner diameter (ID) Tygon tubing (5155T16, McMaster-Carr, Elmhurst, IL).
Additionally, the FH100M possesses a DB-25 input/output for controlling the pump
remotely through a 0-10 V input.
The second component of the fluid infusion subsystem is a fluid warmer. OMBs
are required to be heated before infusion into the peritoneal cavity because they are
cooled between 4-8°C during storage. To prevent the risk of hypothermia, the infused
fluids are warmed to body temperature before entering the abdomen. The infusion line
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was heated by positioning the tubing in an external IV heater (iWarm, Midmark, Dayton,
OH) set at 40.4°C. The infusion system is completed by attaching the tubing of the Peri3
to a catheter implanted in the peritoneal cavity. Once the infusions system of the Peri3 is
connected to the peritoneal cavity, the pump is then controlled by a voltage input for
infusing fluid treatment.
4.2 Data acquisition and controller
The Peri3 utilizes two myDAQs (781326-01, National Instruments, Austin, TX)
to send the voltage signals of the pump. A DB-25 break-out board (BRKSD25M-C,
Winford Engineering, Auburn, MI) with screw terminal blocks and a six-foot extension
cable (02665, Cables to Go, Moraine, Ohio) connects the FH100M pump to the myDAQ
for simple replacement and disassembly. The myDAQ is a multipurpose data acquisition
and control device that operates with LabVIEW. The myDAQ can generate supply
voltages of ±15 V and +5 V while it acquires and generates analog ±10 V signals. The
myDAQ is able to acquire millivolt signals without requiring an external amplifier. The
myDAQs of the Peri3 also acquire and measure the output signals from temperature and
pressure sensors.
4.3 Electronic sensors
Multiple sensors are included into the Peri3 for monitoring and regulating the
infusion of fluid treatment to the abdomen. For measuring the pressure within the
peritoneal cavity, pressure transducers are attached to a catheter. The sensor is then
outside the body and is not required to be water resistant or biocompatible. Two 0-5 psi
pressure transducers (MS4426, Measurement Specialties, Hampton, VA) are used to
measure the IAP with reliability. The pressure transducers have a linear relationship
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between voltage outputs and pressure that was calibrated to a digital pressure sensor to
confirm the measurement precision of the transducers.
The final sensor in the Peri3 system is a thermocouple (a14053000ux0250, REED
Instruments, Wilmington, NC) placed in the infusion line after the fluid warmer exit to
measure the temperature of the infusate. The thermocouple output is amplified with a
cold junction compensator (CJC) chip (AD595-AQ, Burr-Brown, Tucson, AZ) The
electronic sensors are placed onto a custom printed circuit board (PCB) designed with
Altium Designer (Figure 4.2). The PCB was then fabricated by the UNL Engineering
Electronics Shop with a ProtoMat S103 (LPKF Laser & Electronics AG, Garbsen,
Germany).

Figure 4.2: (a) Wiring and (b) routing diagram for PCB of Peri3 designed in Altium.
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The complete electronics of the Peri3 is presented in Figure 4.3 and the wiring
diagram for each electrical component is presented in Figure 4.4. All electronic
components except for the solenoid, peristaltic pump, and fluid warmer are powered by
the myDAQs. The myDAQs connect to any laptop through a USB port for data
communication and power supply. The electronic components and sensors are protected
by enclosing them in a modified acrylic case. The acrylic case was modified with holes
on the bottom to secure the electrical components into the case (Appendix A). The
secured electronic sensors are connected to the myDAQs for measuring and recording the
data with a LabVIEW program. The LabVIEW program uses the output of the sensors to
control various functions of the Peri3 including the regulation of fluid flow through the
peritoneal cavity.

Figure 4.3: The electrical components and sensors used in the Peri3.
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Figure 4.4: Wiring diagram for all data acquisition, sensing, and control components of
the Peri3.
4.4 Control of intraperitoneal volume and LabVIEW
To control the fluid volume contained in the IPC, the flow into and out of the
abdomen is regulated with the Peri3. As a fixed rate of OMBs is delivered into the
abdomen to provide PMO therapy, the inflow is not a factor considered for controlling
the IPC volume. Thus, the fluid flow out of the IPC is controlled to limit the cavity’s
pressure while oxygenating the animal. A 36 V solenoid (ROB-10391, Sparkfun,
Boulder, CO) clamps the tubing of the drainage line to prevent the fluid flow from exiting
the cavity (Figure 4.5, Appendix A). A length of drainage tubing is fixed to a custom
mount for the solenoid to clamp the drainage line as the solenoid actuates. The tubing
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Figure 4.5: Solenoid assembly for restricting outflow from peritoneal cavity.
mount consists of two metal plates bolted to the top and bottom of the solenoid. The
tubing is secured to the solenoid mount with a fixture designed in SolidWorks and then
3D printed (Objet30 Pro, Stratasys, Eden Prairie, MN). When the solenoid actuates, the
secured section of the drainage tubing is clamped, prevents fluid from exiting the IPC,
and increases the IAP. When the peritoneal pressure reaches the set value of 5 mmHg, the
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solenoid is switched off releasing the drainage tubing for fluid to flow out of the cavity.
The solenoid actuates with a supply voltage as low as 12 V, but the current required (0.8
A) is too high for the myDAQ because the myDAQ only supplies a current of 32 mA. A
120 V AC to 24 V DC power adapter (US24DC-100, Electro-Harmonix, New York City,
NY) is used as an external power supply for the solenoid. A low current solid state relay
(RSDC-DC-108-000, Continental Industries, Tulsa, OK) is used as an intermediary
between the solenoid, myDAQ, and power adapter in order to control the solenoid via
LabVIEW.
LabVIEW is a unique system design platform that uses graphical programming
called dataflow programming instead of typical line coding. Graphical programming
permits the programmer to visualize how different code fragments interact. However,
drawback of graphical programming is that complicated systems and programs can
quickly become disorganized. Disorganized programs are avoided by nesting virtual
instruments (VI, basically graphical subroutines) just like nesting functions in Matlab or
other programming software. The general control scheme of nested VIs used for the Peri3
is presented in Figure 4.6. The LabVIEW program for operating the Peri3 is divided into
4 main functions: temperature measurement (red), pressure measurement (blue), pump
control (yellow), and solenoid control (green).
The LabVIEW program of the Peri3 also incorporated a user interface to set the
animal’s mass, species, and IAP range for the experiment (Figure 4.7). The animal
species is selected from a drop-down menu including: rat, rabbit, and pig. From the mass
and species inputted, the LabVIEW program calculates the necessary flow rate of OMBs
to provide supplemental oxygenation with PMO therapy. When the program is initiated,
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Figure 4.6: General control scheme utilized for the Peri3 LabVIEW program.
the start time, flow rate of OMBs for the animal, and the number of required infusion
lines is displayed. While the Peri3 is activated, the program provides feedback to the user
from the two pressure transducers and the thermocouple through 4 graphs. The LabVIEW
interface also includes manual controls as a safety precaution. The manual controls
override the solenoid to open and close the drainage line on the user’s demand. The
manual controls also selects which pressure transducer is used as a reference to control
the solenoid without stopping the procedure in the event where one of the pressure
transducers fails. An additional safety precaution of the Peri3 is the peristaltic pump is
not fully controlled with the LabVIEW program. Though the pump is remotely activated
and controlled with LabVIEW through the DB-25 pins, the peristaltic pump can still be
manually deactivated if the laptop or LabVIEW program becomes unresponsive. After
the assembly of the subsystems, the function of Peri3 was tested to confirm that all the
design criteria are accomplished.
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Figure 4.7: LabVIEW Peri3 interface and sensor feedback.
4.5 Testing of the Peri3 system
Section 4.5 details the materials and methods used to test that the Peri3 system
operates appropriately and accomplishes the design criteria. The results of the tests
performed with the Peri3 are then presented and evaluated.
4.5.1 Materials and methods
The performance of the Peri3 was evaluated in a series of four benchtop tests. The
first test was to confirm the manual override features operated correctly. The Peri3 was
activated and saline was pumped into a beaker. At random times, the pump was stopped
and the flow rate increased or decreased with the manual LabVIEW controls. The second
test was to confirm that the Peri3 was infusing fluid at the correct flow rates designated
by the input parameters. The Peri3 system was activated with a random number between
1-3 kg inputted as the animal’s mass. The system pumped saline into a glass beaker for
30 minutes. Every five minutes, the saline in the beaker was measured and compared to
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the volume that was expected from the calculated flow rate of the random mass. The third
test confirmed if the pump and solenoid were triggered by the feedback from the pressure
sensors. The Peri3 was set to deactivate the pump and solenoid when the pressure was 5
mmHg. The Peri3 was activated and infused saline into a closed container where the
pressure sensors measured the increased internal pressure as the container filled. The
pump and solenoid of the Peri3 were then confirmed if they deactivated when pressure
was at or above 5 mmHg.
The final test was performed to replicate infusion into a peritoneal cavity of a
rabbit. The test confirmed that the Peri3 would maintain continuous infusion of fluid for
15 minutes with the pressure below 6 mmHg. The Peri3 was activated and pumped fluid
into the replica abdomen. The solenoid was initially engaged to clamp the drainage line
from the replica abdomen and set to disengage for fluid drainage when the pressure in the
replica abdomen reached 5 mmHg. The replica rabbit abdomen was a 1.5 L rubber water
bag (B00BNVHS6Y, Amazon, Seattle, WA) modified with inlets of 16G plastic catheters
and an outlet of 7.9 mm ID tubing. The replica abdomen was inserted with three balloons
filled with 250 mL of water, 25 and 60 mm square sections from rubber gloves, and 2.5 x
20 cm strips of synthetic intestine (T-INT-S-0005, SynDaver, Tampa, FL) and mesentery
tissue (T-MES-A-0005, SynDaver, Tampa, FL) to mimic the contents of a real abdomen
(Figure 4.8). The replica abdomen was confirmed to be capable of internal pressures of at
least 35 mmHg without developing leaks. The fluids used in the final tests were saline
and inert gas microbubbles (IMBs). IMBs are equivalent to OMBs in manufacturing
process, PEG surface structure, and composition of the lipid monolayer. The only
difference is that the IMBs are more stable because they encapsulate sulfur hexafluoride
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(SF6) gas, a biologically inert gas with greater molecular weight and less permeability
through the lipid monolayer [163,167].

Figure 4.8: Replica rabbit abdomen used for testing of Peri3 system.
4.5.2 Results
The performance of the Peri3 was evaluated in four benchtop tests. The Peri3 was
activated and at random times the pump was operated via the manual LabVIEW controls.
Trials of the first test confirmed the manual override features functioned correctly and the
pump speed could be increased, decreased, and stopped with minimal lag in operation.
The second test confirmed that the Peri3 was capable of infusing fluid at the correct flow
rates for randomly designated masses. The Peri3 system was activated for 30 minutes
with the pumped saline having an accuracy of ±1 mL from the calculated volume after
every 5 minutes. The third test confirmed that the pump and solenoid were triggered by
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feedback from the pressure sensors. The pump and solenoid of the Peri3 system was
deactivated whenever the pressure in the closed contained reached 5 mmHg.
The final test was performed to confirm that the Peri3 maintained continuous
infusion for 15 minutes without having the internal pressure increase above 6 mmHg. The
Peri3 system infused saline and IMBs into a replicated abdomen of a rabbit (Figure 4.9).
When the system was activated, the peristatic pump filled the replica abdomen as the
solenoid was engaged to clamp the drainage line. The solenoid was disengaged and fluid
flowed out of the replica into the waste container when the pressure within the replica
abdomen reached 5 mmHg (Figure 4.10). When IMBs were infused, the pressure in the
replica abdomen required more time to initially reach 5 mmHg and disengage the clamp
on the drainage line for the initial cycle. Removal of fluid from the replica rabbit was
never inhibited by the fake tissue and debris within the abdomen.

Figure 4.9: Setup of the Peri3 benchtop tests.
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Figure 4.10: Measured pressure in the replica abdomen from representative trials.
4.6 Subsequent iteration of the Peri3
Due to the success of the original iteration, the Peri3 was modified and developed
further for use as a peritoneal infusion device to administer long term PMO therapy. I
provided assistance in coding, design, building, and testing of subsequent iteration of the
Peri3 developed as a peritoneal infusion device for OMB and saline treatment of
conscious rats [191]. The subsequent iteration included four solid state relays and four
solenoid valves to control the flow of fluid into and out of the rat and to flush the tubing
with saline after every infusion. The second iteration contained two thermocouples to
measure the temperatures of the fluid infused into the animal and the OMB supply. A
new PCB was created to position the two thermocouples and the output from a different
pressure sensor (S7d, Gaeltec Devices Ltd., Isle of Skye, UK). Finally, the LabVIEW
program was updated to control the additional solenoids and record the measurements
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from the sensors. The second version of the peritoneal infusion system has undergone
successful preliminary testing in delivering OMBS to rats inflicted with ARDS [191]
4.7 Conclusion
The Peri3 system was confirmed to accomplish all the designated criteria and
functions for the required peritoneal infusion device through its successful performance
in four benchtop tests. The Peri3 system accomplished the required functions of
administering PMO therapy to animals with accuracy, consistency, and safety. Thus, the
Peri3 was implemented in all acute hypoxia experiments administered saline and OMB
treatments to the peritoneal cavities of both rats and rabbits. The Peri3 was successful in
delivering bolus treatments to the peritoneal cavities of rats and rabbits. However, the
Peri3 was only effective in administering continuous PMO therapy to rabbits in hypoxia
experiments. The inability of the Peri3 to provide continuous PMO therapy in rats was
attributed to catheters that were obstructed by the rat’s omental tissue. To provide
continuous and prolonged PMO therapy, the failure of the catheters to infuse and drain
perfusate was investigated by evaluating a catheter for use within the peritoneal cavity of
rats.
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Chapter 5: Evaluation of catheters for intraperitoneal infusing and
draining fluid
PMO therapy has been investigated in rat and rabbit models of acute hypoxia
[179,192,193]. The peritoneal infusion, removal, and circulation of OMBs and saline
experienced minimal complications in rabbits when using the Peri3 system. Conversely,
treatments in rats were restricted to a single bolus due to omental and intestinal tissue
obstructing the needles and catheters implanted in rats during preliminary trials with the
Peri3. To administer continual and prolonged PMO therapy, multiple catheters were
investigated for extracting OMBs after the OMBs briefly dwelled in the peritoneal cavity
of rats [191]. The Jackson-Pratt catheter (JP-7, MILA International Inc., Florence, KY)
facilitated the highest removal efficiency of OMBs at ~50% with no instances of tissue
obstruction. Thus, the Jackson-Pratt (JP) catheter was chosen to be implanted in rats for
delivering periodic OMB boluses during long-term studies validating PMO therapy.
However, when JP catheters were implanted in rats to validate PMO therapy in
long-term trials of ARDS, the JP catheters failed to remove saline and OMBs from the
abdominal cavity after a designated surgical recovery period of seven days. The failure of
the JP catheters imposed a premature end to the ARDS trials as the extraction of saline
and OMBs was unsuccessful and ultimately impossible. Being unable to remove the
previous treatment bolus prevented administration of subsequent treatments as the
accumulated volume and pressure posed a risk to the animal [21,123–126]. After the rats
in the PMO trials were euthanized, the implanted JP catheters were inspected. The pores
of the JP catheters were completely obstructed with omental, fat, and fascial tissue while
the JP catheters were implanted in the animal’s body. The porous structure of the
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Jackson-Pratt catheter was hypothesized to function as a scaffold for cell and tissue
growth [194–196]. Thus, an investigation was performed to identify a catheter more
effective than the JP catheter at periodically infusing and draining fluid from the
peritoneal cavity for prolonged periods of time. An optimal catheter was considered to
either prevent or overcome the obstructing tissue growth while the catheter dwells within
the peritoneal cavity. The most effective peritoneal catheter determined in the
investigation would be selected for future PMO therapy trials in rats inflicted with
ARDS.
5.1 Measuring catheter efficiency
The maximum bolus volumes that will be administered for future long-term
peritoneal OMB treatments in a ~500 gram conscious rat were determined to be 50 mL.
A 50 mL bolus volume was determined from experiments establishing that the maximum
volume, in mL, for intraperitoneal fluid injection in a sedated animal was 1/5 the body
weight in grams [21,135,179]. The maximum volume for a sedated rat was divided in
half to provide a safety factor of 2 for conscious rats that would be administered
treatment for ARDS. The OMBs used in evaluation of PMO therapy are composed of
30% saline, thus each OMB bolus of 50 mL contains 15 mL saline [179,191,192,197].
Therefore, 15 mL saline was infused into the peritoneal cavity to quantify the efficiency
of the catheters implanted because, after pure oxygen gas, saline is the primary
constitutive component of OMBs [170,179,192]. Saline is also the main constituent of the
OMBs that will dwell within the peritoneal cavity as the O2 gas will more rapidly diffuse
into the vasculature than saline and the phospholipid membrane comprises only ~1% of
the OMB volume. Thus, the residual saline volume must be removed from the cavity

78
after the dwell period of the bolus to allow the following bolus to be administered. Some
of the saline will diffuse into the tissue surrounding the peritoneal membrane because the
peritoneum is highly permeable to fluid transport and adsorption from the cavity. The
permeability of the peritoneum enables peritoneal dialysis to be a viable treatment for
renal replacement [198–200]. The fluid adsorption rate from the peritoneum of rats is
approximately 20 μL/min after the injection of a large volume of fluid, but the adsorption
rate decreases over time [201,202]. Typically, 10-18% of the fluid volume injected is
absorbed after 4 hours with the remaining fluid requiring considerably more time to be
absorbed as the adsorption rate from the peritoneum decreases [201,203]. Therefore, an
average of 3 mL of saline is estimated to be absorbed from the 15 mL infused through the
rat’s peritoneum after 4 hours, which prohibits the ability to remove the total infused
volume of 15 mL saline after a dwell period of 12 hours. To offset the absorbed volume
and prevent significant negative pressures and the aspiration of tissue into the catheter,
the maximum extraction volume after each dwell period was considered to be 12 mL.
The maximum extraction volume after a period of dwell was considered an important
criterion for determining the efficiency of the catheters evaluated.
The effectiveness of each implanted catheter was scored by three weighted
criteria: extraction volume of fluid after a dwell period, ease of function for fluid
drainage from the catheter, and time the catheter remained patent. The extraction volume
of a saline bolus was measured for the entire duration of the study twice daily after a 15
mL bolus of saline was infused and dwelled in the cavity for 12 hours. The dwell
extraction with the evaluated catheters was not performed 12 hours after the surgery to
implant the catheter. During each measurement of extraction volume, 12 mL of saline
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was the maximum volume drained with the catheters after the dwell period and
contributed to the efficiency score of the catheter (1 point per mL). The extraction
performance of the catheter was then determined from a maximum score of 276 points
(11.5 days × 2 measurements daily × 12 mL per extraction). The second scoring criterion
was the ease of function for extracting the fluid bolus with the catheter and was measured
as the relative force to draw the plunger of the syringe. The relative force of drawing the
plunger to extract saline from the peritoneal catheter was scored on a 1-4 point scale. The
score correlated to the force to draw the plunger of the syringe and how well the fluid
flowed from the catheter: 1) drawing the plunger was difficult with minimal to no fluid
flow; 2) drawing the plunger was moderately hard with slight fluid flow; 3) the plunger
was drawn moderately simple with a steady and slow flow of fluid; 4) the plunger draw
was effortless with quick and consistent fluid flow. The ease of function score of the
catheters’ efficiency was from a maximum 96 points (12 days × 2 measurements daily ×
4 points per extraction). The final criterion of scoring efficiency was the time the catheter
remained patent. Every day the catheter functioned contributed one point to the efficiency
score with a maximum of 12 points if the catheter was patent for the entire study. The
catheter was considered not patent when the catheter failed to remove saline during three
consecutive measurements (36 hours). The ease of function and patency scoring criteria
were weighted to contribute equally to the final efficiency score (288 points) with the
sum of the dwell extraction volumes being slightly less (276 points). The following
equation was used to normalize the efficiency scores:
Catheter
(Σ𝑉𝑜𝑙𝑢𝑚𝑒𝐸𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 )+(3×Σ𝐸𝑎𝑠𝑒 𝑆𝑐𝑜𝑟𝑒𝑠)+(24×𝑇𝑖𝑚𝑒 𝑃𝑎𝑡𝑒𝑛𝑡)
=
× 100
852
Efficiency

[Eq. 5.1]
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5.2 Materials and methods
All animal studies were performed in accordance with the University of
Nebraska-Lincoln, Institutional Animal Care and Use Committee. Male Wistar rats
(n = 12, m = 551.9 ± 0.2 g) were housed individually with free access to food and water.
The animals were randomly assigned housing by the animal facility staff and allowed to
acclimate 4 days before the study. Omental ingrowth into the JP catheter was previously
observed to prevent drainage of intraperitoneal fluid. A sample size of three rats per
catheter type was decided to distinguish catheter effectiveness. Rats were randomly
implanted with one of four catheter types. The catheter was surgically implanted and
routed subcutaneously to the back of the rat. The catheter types included: a Jackson-Pratt
(JP) catheter which had failed in previous PMO trials (JP-7, MILA International Inc.,
Florence, KY) [191], a 15 French round fluted drain catheter (072188, Bard Medical,
Covington, GA), a 7 mm flat ¾ fluted flat drain catheter (072210, Bard Medical,
Covington, GA), and an originally designed catheter (Figure 5.1, Appendix B). All
catheters were trimmed, so 10 cm of tubing was within the peritoneal cavity.
5.2.1 Surgical and implantation procedure of catheters
Rats were anesthetized in an induction chamber with 5% isoflurane and
maintained on 2% isoflurane during the surgery. Each animal was weighed and placed in
the supine position on a warming pad (Gaymar T/pump Classic, Stryker Corporation,
Kalamazoo, MI) set at 38°C. After the animal was fully sedated and unresponsive to paw
pinches, the back and left lateral abdomen was shaved and sterilized. A small incision
was made on the left lateral abdomen to expose the peritoneal cavity where a randomly
selected catheter was then inserted into the cavity (Figure 5.2a). The fascia was stitched
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Figure 5.1: Catheter types evaluated in the study (a) Jackson-Pratt, (b) round fluted
drain, and (c) flat fluted drain and their respective cross-sections (d-f).
around the catheter with a purse-string suture to prevent the catheter from sliding out
during the study [204–206]. The rat was then turned onto its right side, and a small
incision was made into the skin at the upper back. The catheter was subcutaneously
tunneled to the back incision and the extra length was trimmed so the end of the catheter
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was even with the back incision (Figure 5.2b). An access port for the catheter was
attached to the back by connecting the catheter end with a luer elbow fitting (EW-4550284, Cole-Parmer, Vernon Hills, IL). The fitting was sutured in place under the skin to the
back and closed off with a male luer lock cap (51525K38, McMaster-Carr, Elmhurst, IL).
Because both the luer elbow fitting and lock cap were not sterile, they were submersed in
glutaraldehyde plus for 20 minutes and rinsed with sterile saline before being placed in
the rat. The incisions on the abdomen and back were closed after pain medication was
administered into the abdominal incision (1.2 mg/kg, Buprenorphine SR, Zoopharm,
Windsor, CO). The rat was then allowed to recover from anesthesia and returned to its
home cage.

Figure 5.2: Experimental setup for implanting the catheter into the peritoneal cavity of
the rat. (a) The catheter was secured in the cavity with purse-string suture. (b) The back
access port of the rat with the elbow adapter inserted into catheter exit and closed with a
luer lock cap.
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5.2.2 Evaluation of the catheters
Every 12 hours for 12 days, the efficacy of the catheters was determined by an
infusion and drainage procedure to analyze the three efficiency criteria: ease of function,
the volume of saline extracted, and duration the catheter remained patent. The procedure
started with the drainage of the previously injected saline bolus after the bolus dwelled in
the peritoneal cavity for 12 hours. The drained volume of saline was measured to
determine the extraction efficiency after a dwell period. Next, 15 mL of fresh sterile
saline was infused into the catheter and immediately drained from the peritoneal cavity.
The extracted volume of fresh saline was measured and reinfused into the peritoneal
cavity to dwell 12 hours for the next measurement.
The extracted volumes of fresh saline were recorded but not used in determining
the efficiency of the catheters. The fresh saline extractions provided an indication for if
the catheters were functional and patent. If the catheter was unable to extract fresh saline
for three consecutive measurements (0 mL in 36 hours), the catheter was determined to
not be functional and the study for the catheter was then concluded.
5.2.3 End points and necropsy
End points for the observation of each animal were 12 days after the peritoneal
catheter was implanted or fresh saline was unable to be drained from the cavity with the
catheter after three consecutive measurements. The study also concluded when the
catheter was dislodged from the back incision either from movement or the incision reopening. The open wound from the back incision causes pain and risk of infection
requiring the animal to be withdrawn from the study and evaluation of the catheter to be
concluded. At the end of the study, the rats were euthanized by carbon dioxide inhalation
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following Institutional Animal Care and Use Committee (IACUC) procedure guidelines.
After death, the abdomen was opened by an incision along the medial plane. The
implanted catheter was removed from the peritoneal cavity without detaching any tissue
adhered to or obstructing the catheters. After the catheters were removed from the cavity,
images were taken to compare the amount of tissue adherence and obstruction of the
catheters.
5.2.4 Statistics
Analysis of variance (ANOVA) with separate means followed by the Tukey
multiple comparison test was performed on efficiency scores to test for any differences
between groups. All tests used the same level of significance (α = 0.05).
5.3 Results
Twelve catheters were implanted into the peritoneal cavity of rats to determine the
most efficient catheter type for infusion and drainage of saline boluses over 12 days. The
peritoneal catheter with the longest duration of patency was the flat fluted drain, which
remained patent for the entire12 days (Figure 5.3). The round fluted catheters remained
patent for 11.5±0.6 days with two catheters patent for 12 days. The third round fluted
catheter concluded early on day 11 because 15 mL of fresh saline was not able to be
infused. The saline leaked from the back incision where the round fluted catheter was
fixed instead of being infused into the peritoneal cavity. The JP and custom catheters
were patent for the shortest durations at 6.8±0.3 and 5.8±1.5 days, respectively. All three
JP catheters were removed from the study early (days 6.5 and 7) because fresh saline was
not drained for three consecutive measurements. All three of the custom design catheters
were removed from the study early (days 4, 6, and 7). Two of the custom catheters ended
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because they leaked from the back incision during infusion of fresh saline with one of
custom catheters unable to infuse the saline bolus. The third custom catheter was dropped
because three consecutive extractions of fresh saline failed to drain any volume.
The flat fluted catheter had the highest score for ease of function with an average
of 2.8±0.6 during study (Figure 5.4). The remaining catheters’ score for relative force
were similar with the round fluted catheters average score of 2.5±0.7, JP catheters
averaged a score of 2.0±0.8, and the custom catheters scored an average of 2.0±0.5.
During the 12 day study, all catheters except for the flat fluted catheters experienced a
decrease in the ease of function score.
The flat fluted catheter achieved the highest average volume of fresh saline
drained at 8.3±2.0 mL (Figure 5.5). The round fluted catheter was the second most
efficient at draining fresh saline with an average of 7.1±2.7 mL per measurement. The JP

Figure 5.3: Time the catheter remained patent within the peritoneal cavity.
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Figure 5.4: Ease of drawing the syringe plunger to extract saline from the peritoneal
cavity.

Figure 5.5: Volume of fresh saline drained from the peritoneal cavity after infusion.
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catheter drained an average of 6.1±4.5 mL of fresh saline while patent and the custom
catheter drained an average of 4.4±2.1 mL per measurement. The flat fluted catheter
drained an increased volume of fresh saline as the study progressed while all other
catheters drained less fresh saline. After 7 days, the JP and custom catheters removed
zero milliliters of fresh saline.
The catheter with the highest average volume of fluid extracted after a 12 hour
dwell period was the flat fluted drain catheter with 2.4±1.9 mL (Figure 5.6). The round
fluted catheter extracted the second highest amount of saline after the dwell period with
1.2±1.2 mL. The custom catheter extracted an average of 0.3±0.3 mL per measurement
while the JP catheter extracted the smallest average volume of saline at 0.1±0.2 mL per
measurement after the dwell period. While the JP and custom catheters did not extract an
average volume of saline greater than 1 mL per measurement four days after the catheters
were implanted, the round fluted drain would experience an increased extraction volume
of saline from day 4 to day 8. In contrast, the implanted flat fluted catheters exhibited an
increased average extraction volume of saline after the dwell period until the end of the
study.
The flat fluted catheter experienced the highest overall average efficiency from
the weighted scoring at 63.8±13.2% (Figure 5.7). The catheter with the second highest
weighted efficiency was the round fluted catheter with 56.3±4.0%. The third highest
score was the JP catheter with an average efficiency of 29.4±4.4%, while the least
efficient was the custom catheter with an average of 24.2±8.85%. The efficiency of the
flat and round fluted catheters was significantly greater than the JP and the custom
catheters (p < 0.05).
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Figure 5.6: Volume of saline extracted from the peritoneal cavity after the dwell period.

Figure 5.7: The efficiencies of the peritoneal catheter tested and calculated from their
weight scores. *Significantly different from Jackson-Pratt and the custom catheters (p <
0.05)
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Each implanted catheter was excised and photographed after the rat was
euthanized to examine the degree of tissue growth and obstruction. The pores of the JP
catheters were completely obstructed by ingrowth of omental, fat, fascia, and organ tissue
(Figure 5.8a). The ingrown tissue was found to be strongly attached to the surface and
pores of the JP catheters. In contrast, the flat and round fluted catheters were partially or
completely surrounded by a fibrotic capsule (Figure 5.8b, c). The fibrotic capsule around
the fluted catheters was highly vascularized and integrated to nearby organs such as the
liver, intestine, or colon. However, the flutes of the flat and round catheters were never
fully occluded by tissue. The fluted catheters were easily removed from the fibrotic
capsule with little to no tissue actually adhered to the surface (Figure 5.9). When the
custom catheters were removed from the peritoneal cavity, the tubing segments were
revealed to be unraveled (Figure 5.8d). Omental and fibrotic tissue was observed to grow
between the tubing segments separating the braid of the custom catheter. In addition,
tissue growth was focused predominately around the heat shrink bands which bound the
tubing segments of the custom catheters.

Figure 5.8: Representative images of excised (a) Jackson-Pratt, (b) round fluted drain,
(c) flat fluted drain, and (d) custom catheters after being implanted in the peritoneal
cavity.
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Figure 5.9: Images of the (a-b) round and (c-d) flat fluted catheters (a, c) in and (b, d)
removed from the fibrotic capsule.
5.4 Discussion
The purpose of this study was to evaluate catheters for providing reliable infusion
and drainage of liquid boluses from the peritoneal cavity for prolonged periods in rats. In
the previous investigation, the JP catheter was highly efficient at removing OMBs from
the peritoneal cavity after dwelling within the cavity less than 30 minutes [191]. The JP
catheters were used in experiments of treating rats suffering from ARDS with PMO
therapy of repeated OMB boluses. However, when the JP catheters were implanted into
the peritoneal cavity of rats, the JP catheters failed after recovering for seven days from
the implantation surgery. The omental tissue of the rat as grew around and into the pores
of the JP catheters preventing the flow of fluids into or out of the peritoneal cavity. Thus,
a different type of catheter was required to administer and drain repeated treatment
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boluses to the peritoneal cavity, while overcoming the growth of tissue into the catheter.
The flat fluted catheter and the round fluted catheter were selected for evaluation because
other variants of fluted catheters were successfully utilized for peritoneal dialysis of dogs
and humans [207,208]. Additionally, a custom catheter was attempted to combine the
best principled from designs of fluted catheters into a catheter able to be made
inexpensively.
The custom catheter was the lowest scoring catheter with an average efficiency of
29.6±14.5%. The duration of patency was 5.7±1.5 days with a low volume of dwell
extractions (0.27±0.25 mL) and ease of function (1.8±0.5). The low efficiency of the
custom catheter was attributed to omental tissue growing between the tubing segments
and compromising the braided structure and fluid transport in the channels. The custom
catheter functioned to a limited degree, but subsequent iterations require several
alterations to increase the catheters effectiveness. The braided segments of tubing
exhibited minimal tissue adherence and was not considered the cause of the custom
catheters failure. However, the peritoneal tissue was observed to grow and attach
specifically to the heat shrink tubing indicating the heat shrink material possessed surface
properties conducive to cell growth and adherence (Figure 5.8d). The heat shrink tubing
of the catheter needs to be replaced with a permanent method of binding the tubing
segments to construct future catheters. A permanently binding the tubing segments would
avoid tissue adherence and maintain the structure of the catheter’s fluid channels.
The flat and round fluted catheters were chosen because the flutes or channels on
the exterior face of the catheters were similar to peritoneal dialysis catheters that were
previously demonstrated to be successful (Figure 5.1b, c, e, f). The principle of the fluted
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catheters was to prevent tissue from blocking the fluid inlets and pathways by creating a
large surface area for fluid to flow [208,209]. The design principle of the fluted catheters
was highly successful in the rat peritoneal cavity as the two fluted catheters resulted in
significantly higher scores of the measured criteria and overall efficiencies (Figure 5.7).
Another property of the fluted catheters that contributed to their effectiveness was the
minimal tissue adhesion and obstruction on the surface of the catheters (Figure 5.9). The
surface of the fluted catheters was sufficiently hydrophobic that water, saline, and blood
would bead off the fluted catheters even after they were implanted in the peritoneal cavity
for 12 days [210]. The shape and profile of the flat fluted catheter was similar to the JP
catheter. However, the fluid flow of the JP catheter was facilitated by surface pores
instead of external channels.
The principle of the Jackson-Pratt catheter is supplying a large quantity of inlets
and outlets for fluid transport with pores on the catheter’s surface. The large number of
pores reduces the potential risk that the flow of fluid would be completely obstructed.
However, within the peritoneal cavity, the principle failed as the pores instead functioned
as a scaffold that facilitated cell and tissue ingrowth into the interior of the catheter [194–
196]. The drainage of fresh saline was very effective shortly after the JP catheter was
implanted, but the volume of fresh saline drained quickly decreased over time as the
pores of the catheter were obstructed by tissue (Figure 5.8a).
Another possible hindrance to the performance of the peritoneal catheters was the
formation of a fibrotic capsule that surrounded the fluted catheters (Figure 5.9). The
encapsulation of the fluted catheters indicated a strong foreign body response. The
foreign body response was triggered by the implanted catheters and activating the
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omentum that increased the expression of vascularization, growth, and healing factors
[211–213]. If omental tissue completely surrounded the fluted catheter in a fibrotic
capsule, the saline was infused into the fibrotic capsule and not into the peritoneal cavity.
Fresh saline being infused into the fibrotic capsule is a possible explanation to the high
volumes that were drained with the fluted catheters. After infusing the fresh saline, the
capsule possibly prevented infused saline from circulating throughout the cavity, but
remained localized in the capsule allowing the saline to be readily drained. The
entrapment of saline in the fibrotic capsule could also have affected the stability of the
catheter in the surgical incisions. Once the fibrotic capsule was full, infusion of additional
saline would result in saline to leak through the back incision the catheter was secured in
preventing the skin from properly healing around the catheter. Saline leakage from the
back incision was observed in several occasions during catheter evaluation and may have
contributing to the catheter being able to slide out of the back incision. Additionally, the
fibrotic capsule could have hindered the performance of the catheters while extracting
saline after the dwell period from tissue being aspirated against the catheter and
preventing fluid flow. Another possibility that may have hindered the efficiency of the
catheters evaluated was the small volume of saline extracted after the dwell period. The
fluted catheters were highly effective at draining fresh saline, but no catheter type was
effective at extracting saline after the dwell period. The low extraction of saline after
dwelling in the cavity for 12 hours was that significantly more saline was absorbed
through the peritoneum than the estimated 3 mL [201–203]. A greater absorbed volume
of saline would result in the maximum volume of 12 mL never being able to be extracted,
artificially decreasing the weighted score and the catheter efficiency.
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A limitation of the study was that the efficiency of the catheters was not
accurately assessed due to complications the peritoneal catheters experienced after being
implanted. One round fluted and two custom catheters were removed from the study early
due to the incision on the back reopening. When the back incision reopened, the catheter
was released from the suture securing it to the back allowing the catheter to extend and
retract when the rat moved. The open wound and movement of the catheter caused
noticeable discomfort in the animal. The movement of the catheter may have dislodged
the catheter from the peritoneal cavity and contributed to the saline leaking from the back
incision when infused into the catheter. The dislodgment and leakage of the catheters
decreased the weighted score and efficiency measured because the trials were concluded
early. In future implants of the catheters, the back incision will be closed more securely
and the elbow of the catheter access port will be fixed to the subcutaneous tissue below
the incision. The catheter will also not be stretched from the peritoneal to the back
incision as tightly when implanted to decrease tension on the suture, skin, and fascia from
the movement of the rat.
5.5 Conclusion
The purpose of this investigation was to determine which type of catheter would
remain patent while in the peritoneal cavity of a rat for a two-week PMO study. From the
study, the prolonged patency and efficient removal of infused saline with a catheter
implanted into the rat peritoneal cavity was confirmed as difficult tasks to achieve. An
effective peritoneal catheter required surmounting several substantial challenges that
included tissue ingrowth, an aggressive foreign body response, and securing the catheter
into the rat. However, two catheters were considered suitable to replace the JP catheters
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for repeated peritoneal infusion and drainage of OMBs. The 7mm flat ¾ fluted catheters
remained patent for the longest durations, extracted the highest average volumes of saline
after the dwell period, and drained the highest volume of fresh saline. Further study is
required to evaluate the effectiveness of the flat fluted catheter with OMB solutions to
justify the use of the flat fluted catheter for continuous OMB perfusion in rats. The flat
fluted catheter could potentially be implanted in other animal models (leporine, canine, or
porcine) for long-term studies of validating PMO therapy. The flat fluted catheters were
measured to be the most efficient catheter type evaluated and will be utilized in future
studies of validating PMO therapy in rats suffering hypoxia induced by a characterized
model of ARDS.
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Chapter 6: Characterization of hypoxia in a rat ARDS model
Development of viable alternative treatments to provide oxygenation in acute
respiratory distress syndrome (ARDS) requires an injury model that mimics its
pathophysiology in humans during the acute phase. To date, there have been few
publications that describe in detail a long-term murine model of ARDS focused on
oxygenation of the animal. Thus, we systematically described a long-term (up to seven
days) model of ARDS with daily characterization to provide a framework for evaluation
of new oxygen therapies, as well as to elucidate differing stages of development and
resolution of ARDS pathology. Primary emphasis of characterizing the rat ARDS model
will be in measuring the parameters that describe the animal’s level of oxygenation when
suffering from ARDS. The clinically relevant ARDS model with depressed oxygen levels
can then be used for validating the short and long term benefit of oxygenation with PMO
therapy in a respiratory disease.
6.1 Design
ARDS was decided to be the model of respiratory disease to replicate due to its
prevalence, limited treatment options, incidence of hypoxia, and extensive model
development in rodents. The current standard murine ARDS model is induced by directly
administering an aerosolized endotoxin, lipopolysaccharide (LPS), to the lung via the
trachea [214,215]. LPS is a major component of the outer cell membrane of Gramnegative bacteria such as Escherichia coli that performs several roles in sustaining the
bacteria’s health. Due to the prevalence of LPS on bacteria’s surface, LPS is an
endotoxin, which is recognized and stimulates an immune response in most animals.
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Aerosolizing LPS through the trachea induces an inflammatory response in the lungs
which accurately replicates many of the characteristics of moderate to severe ARDS in
humans. Most of the studies in ARDS research focus on the protective effect of
pharmacological agents based on the inflammatory and immune response to ARDS [216–
223]. These studies on ARDS models quantify the severity of ARDS and any potential
benefit of the pharmacological agents by measuring the concentration of surfactant
proteins, cytokines, or histological staining and imaging of lung samples. Few studies
extensively investigate the oxygenation of either the animal or their recovery past 24
hours, leading to a lack of experimental models for use in validating novel methods that
provide supplemental oxygenation [179,192]. In phase one of ARDS trials, the current
standard model for inducing ARDS in rats was reproduced to compare to previous studies
and confirm that ARDS pathology was replicated. Long-term ARDS was characterized
by several measurements to delineate the typical progression and recovery from the
disease at 3 and 7 days post-insult. Then, a second phase of ARDS trials were performed
to characterize the oxygen levels with arterial blood gas analysis and pulse oximetry to
determine severity of the reduced lung function and hypoxia for 3 days post-insult.
Baseline measurements were taken for mass, pulse oximetry, venous blood gases
(VBG), arterial blood gases (ABG), and chest radiographs on day 0 of the study. Animals
were then randomly assigned to one of three administration groups; negative control (Nv,
NC), saline control (Sv, SC), or lipopolysaccharide (Lv, LPS). In phase one, the sample
and data collection of validation trials (Nv, Sv, Lv) was performed after the intratracheal
administration of an aerosolized solution every 12 hours over a period of 3 or 7 days,
forming a total of six groups: Nv3, Nv7, Sv3, Sv7, Lv3, and Lv7. In phase two, the
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oxygenation trials were observed for only 3 days post-insult forming a total of three
groups: NC, SC, and LPS. Intra-tracheal administration of LPS typically results in a
mortality rate between 25-52% [214,215,219,222]; thus, to increase the probability of
having a sufficient population for characterizing ARDS, more animals were placed in the
three LPS groups. Also, because the ARDS validation focused on the extent of
respiratory recovery over a longer time, additional animals were distributed to the Lv7
group. All control groups were assigned fewer animals because of the minimal risk of
mortality within these groups. Rats that died before the end of their study period were
allocated to another group with other rats that had died within the same day for analysis
of lung injury scoring and cytokines. Animals were euthanized after data collection on
the final day of observation. The lungs were harvested for histology and either collected
bronchoalveolar lavage (BAL) fluid or measured wet and dry weights. Venous blood and
BAL fluid were collected for analysis in phase one while arterial blood and wet/dry
weights were sampled in phase two.
6.2 Materials and methods
The materials and methods section details the procedures used to establish and
characterize the proposed ARDS model. In the experiments, ARDS was induced by
administering an aerosolized LPS solution and performing daily sample collections.
When the observation period of the rats was completed, lung tissue was collected for
histology, BAL, and weights. The section ends with a summary of the statistical tests
used to determine significant differences between intratracheal aerosol groups.
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6.2.1 Aerosol administration
Prior to administration of intratracheal aerosol, animals were randomly assigned
to the negative control (Nv, NC), saline control (Sv, SC), or lipopolysaccharide (Lv, LPS)
groups. At the start of the study (day 0), baseline measurements for mass, pulse oximetry,
VBG, and ABG were collected. Rats were then sedated in an induction chamber with 5%
isoflurane. When the rats’ muscles were fully relaxed, they were removed from the
chamber for performing chest radiographs from the dorsal-ventral and left lateral views.
If they began to wake before both images were taken, rats were returned to the chamber
with 5% isoflurane. Upon completion of the radiographs, rats were placed in the prone
position on a warming pad set at 38°C (T/pump Classic, Gaymar Industries, Inc., Orchard
Park, NY) inclined at 30° with their head at the apex. To keep the rat motionless for the
aerosol administration, they were intermittently sedated using a nosecone with 2%
isoflurane. The rat’s head was lifted for insertion of a 3 or 3.5 cm (dependent on rat size),
oropharyngeal intubation wedge made from a 3 mL syringe (Monoject, Covidien,
Minneapolis, MN) into their oral cavity [224]. The wedge was positioned to view the
vestibular folds and guide an aerosolizer (MicroSprayer®Aerosolizer IA-1B-R,
PennCentury, Inc., Wyndmoor, PA) attached to a 1 mL syringe (Model B-SYR-PL1000,
PennCentury, Inc., Wyndmoor, PA) into the trachea. The end of the aerosolizer was
positioned through the trachea until it met resistance at the carina and then pulled back 2
mm (Figure 6.1). Both the saline and LPS groups received 0.5 mL aerosolized solution
while the negative control group was intratracheally cannulated with the aerosolizer, but
not administered aerosolized solution. The solution aerosolized to the SC rats was sterile
saline (0.9% NaCl solution, VetOne, Boise, ID). LPS rats were aerosolized with a
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solution containing a 7 mg/kg dose of lipopolysaccharide (Escherichia coli 0111:B4, L
2630, Sigma-Aldrich, St. Louis, MO). The LPS was dissolved with sterile saline to a
concentration of 10 mg LPS per mL. When the necessary solution volume of LPS
solution was less than 0.5 mL, sterile saline was added to increase the volume to 0.5 mL.
For 30 minutes after the aerosol administration, rats were periodically rotated in
the supine, prone, and side positions every 10 minutes until they awoke from anesthesia
to aide in an even distribution of the solution delivered to the lungs. Animals were
returned to their cages and observed while they recovered from anesthesia and endotoxin
administration.

Figure 6.1: Representation of the aerosol administration procedure used in the ARDS
studies.
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6.2.2 Daily sample collection
Baseline measurements were taken for mass, pulse oximetry, chest radiographs,
and venous or arterial blood samples before aerosol administration on day 0. After day 0,
periodic samplings of weight, pulse oximetry, and blood were collected approximately
every 12 hours while chest radiographs were recorded in the morning every 24 hours
(Figure 6.2). Every collection session started with removing the animal from the cage and
measuring its mass. The rat was restrained, but not sedated for pulse oximetry and the
collection of blood. The rat was not sedated because inhalant sedation techniques with
isoflurane vaporizers require the animal to be delivered ~100% O2, and injectable
anesthetics such as ketamine-xylazine cocktails and barbiturates cause severe blood
pressure and respiratory depression [55]. The aesthetic techniques would confound the
parameters of oxygen saturation, so therefore were not used during collection of pulse
oximetry and blood.

Figure 6.2: Timeline of surgical procedures and daily sampling schedule conducted in
the (a) validation and (b) oxygenation phase of ARDS characterization.
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6.2.2a Pulse oximetry
To observe the impact of LPS on lung function, peripheral oxygen saturation of
the blood (SpO2) was measured by pulse oximetry (PhysioSuite MouseSTAT®, Kent
Scientific Corporation, Torrington, CT). The pulse oximeter sensor was positioned on the
lateral edge of the plantar surface of the rat’s hind paw with the end of the pulse oximeter
clip over the fourth metatarsal (Figure 6.3). The position of the pulse oximeter sensor was
obtained through trial and error to be optimal for measuring consistent pulse waveforms
from the oximeter while the rat was awake. Measurements were monitored in 5 second
averages and recorded every second when the pulse oximeter waveform was sinusoidal
and consistent. The measurements over a period greater than one minute were then
averaged to establish a single value for the session.

Figure 6.3: Positioning of the sensor clip on the paw for pulse oximetry.
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6.2.2b Blood sampling
To completely observe the impact of ARDS induced LPS on lung function, partial
pressure of oxygen in the blood (PO2) was measured by blood gas analysis. In phase one,
blood was sampled from the tail vein of the rats. Blood from the tail vein was collected
with a 23G needle (Monoject 250 #8881250289, Covidien, Minneapolis, MN) which was
flushed with heparin (402-10, SAGENT Pharmaceuticals, Schaumburg, IL). Analysis of
venous blood was performed with a handheld blood analyzer (VetScan iSTAT 1, Abaxis,
Union City, CA) and single use cartridges (CG8+, Abaxis, Union City, CA) to measure
blood chemistry and gases. Analysis of blood chemistry included measurement of sodium
(Na), potassium (K), ionized calcium (iCa), and glucose (Glu) levels. Blood gas analysis
with the cartridges measured hematocrit (Hct), pH, partial pressure of carbon dioxide
(PCO2), and partial pressure of oxygen (PO2) and calculated values for hemoglobin (Hb),
bicarbonate (HCO3-), base excess (BE), total carbon dioxide (tCO2), and oxygen
saturation (SO2). Blood was observed to be difficult to sample from the tail vein
approximately 12 hours after aerosolized LPS was administered to rats. The difficulty of
collecting blood from the tail vein was thought to be attributed to hypotension resulting
from anesthesia and endotoxin-mediated shock. To reduce stress on the animals and
maintain consistency at this time point, no venous blood samples were collected for the
afternoon session of day 0 in the validation phase.
In phase two, arterial blood was sampled from the femoral artery through a
catheter implanted in surgery one week before the LPS was administered (Figure 6.2b).
In the catheter implant surgery, a small skin incision was made into the upper right hind
leg to expose the femoral artery. The femoral artery was isolated from the femoral vein
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and nerve, and then ligated distally. The artery was lightly pinched to limit blood flow
while a small cut was made into the artery. The femoral catheter (504118, World
Precision Instruments, Sarasota, FL) was then fed through the cut and secured in the
artery with suture. The femoral catheter was subcutaneously routed dorsally where it was
externalized through a small incision between the shoulder blades. A 21G blunt needle
(75165A679, McMaster-Carr, Elmhurst, IL) with a luer lock injection plug (SRIP2V
Surflo, Terumo Medical, Somerset, NJ) was then used to seal the catheter. During the
seven day recovery period, the catheter was flushed every 12 hours with heparinized
saline to maintain patency. Arterial blood was analyzed with the iSTAT and single use
cartridges (CG4+, Abaxis, Union City, CA). These cartridges solely analyzed blood gases
by measuring pH, partial pressure of carbon dioxide (PCO2), and partial pressure of
oxygen (PO2) and calculated bicarbonate (HCO3-), base excess (BE), total carbon dioxide
(tCO2), and oxygen saturation (SO2).
The sample volume of blood required for performing the blood analysis with the
test cartridge was 0.1 mL. Following safe blood collecting guidelines, less than 1% of the
total circulating blood volume was collected per day. Adult male Wistar rats have an
average of blood volume of 60 mL/kg [225,226]. The blood volume in the rat allowed for
a maximum blood volume of 0.6 mL/kg to be collected per day which was enough for
analysis of three samples. A third blood sample was only collected and analyzed if an
error occurred in the analysis during one of the previous samples.
6.2.2c Chest radiographs
To obtain chest radiographs on days 1-3 or days 1-7, rats were anesthetized with
5% isoflurane via nosecone until unresponsive to paw pinch after analysis of the blood
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sample was completed. The rats were then radiographed (PRX 90, Bowie International
LLC, Lake City, IA) in the dorsal-ventral and left lateral positions. Thoracic radiographs
were taken to investigate the presence of pulmonary edema, alveolar consolidation, and
bilateral infiltrates, all of which are signs suggestive of ARDS development. Once
recovered from anesthesia, the animals were returned to their cages.
6.2.3 Histology, BAL, and wet/dry ratio
At the conclusion of the observation period, surviving animals were euthanized by
CO2 inhalation and were necropsied. The chest cavity was opened and the trachea and
lungs were harvested. The trachea was clamped while connective tissue and the heart
were separated from the lungs. The exterior surface of the lungs was swabbed with cotton
gauze to remove excess blood, spread flat, and then photographed.
In phase one, a bronchoalveolar lavage (BAL) was performed by inserting a
gavage needle (FNS-18-2, Kent Scientific Corp, Torrington, CT) into the trachea and
filling the lungs with 7 mL sterile saline while clamped shut. Without removing the
gavage needle, fluid was drawn back into the syringe and transferred into a sterile glass
vacutainer tube (366441, Becton Dickinson and Company, Franklin Lakes, NJ). BAL
fluid samples were centrifuged (Triac centrifuge, Becton Dickinson and Company,
Franklin Lakes, NJ) at 1500 g for 5 minutes to separate the cells. The supernatant fluid
was collected into snap-cap culture tubes (14-956-1D, Fisher Scientific, Pittsburgh, PA)
and frozen at -20°C. BAL fluid samples were analyzed for cytokine concentrations at the
University of Nebraska Medical Center (UNMC). Cytokines IL-6 and TNF-α were
measured in duplicate using an enzyme-linked immunoadsorbent assay (ELISA) kits. IL6 was plated in dilutions of 1:5 and 1:20 (R6000B, R&D Systems, Minneapolis, MN).
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TNF-α was plated in dilutions of 1:2 and 1:10 (88-7340, eBioscience, San Diego, CA).
The absorbance of the ELISA plates were read with a spectrophotometer (Epoch
Microplate Spectrophotometer, BioTek Instruments, Winooski, VT) at 450 nm and
corrected for 570 nm.
Excised lungs of rats were fixed by intratracheal instillation of 5 mL of 10%
buffered formalin, then suspended in 30 mL of formalin. Lungs were submitted to an
independent pathologist for blind sectioning, hematoxylin and eosin (H&E) staining
(Ventana Symphony, Ventana Medical Systems, Inc., Tucson, AZ), and injury scoring.
Lung sections were imaged with a microscope (Eclipse 55i, Nikon Instruments, Melville,
NY) at a magnification 100X after H&E staining for visual comparison and analysis.
Histological lung injury analysis of five lung sections from each animal included alveolar
edema, intra-alveolar hemorrhage, and inflammation score on a 0-3 scale with 0
indicating an absence of pathology and 3 indicating severe pathology [227].
Inflammation scoring was based on the amount of leukocyte infiltration, excluding
eosinophils. Four sections of the right lung were used in histological injury analysis in
ARDS oxygenation rats as the left lung was used for measuring wet and dry weights.
The left lung was used for measuring the wet and dry weights in phase two trials.
Once the lungs were excised from the rat, the left lung was separated by cutting of the left
bronchus. The left lung was immediately weighed on a scale (CX220, Citizen Scales,
Maharashtra, India) to measure the wet weight. The left lung was then placed in an oven
for three days at 60°C and reweighed afterwards for the dry weight [228,229]. The
wet/dry ratio (W/D) was calculated by dividing the wet weight by the dry weight. W/D is
recognized as an indirect measurement of edema and vascular permeability in the lungs.
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Thus, an increased W/D ratio is indicative of compromised lung function from reduced
gas diffusion and exchange [228–231].
6.2.4 Statistics
Log-rank (Mantel-Cox) testing was used to compare the mortality rates between
each experimental group for any differences. Analysis of variance (ANOVA) with
separate means followed by the Tukey multiple comparison test was performed on lung
injury scores, cytokine concentrations, and W/D ratios to test for any differences between
groups. Repeated measures ANOVA was used to compare the SpO2 group means of each
collection period. All tests used the same level of significance (α = 0.05).
6.3 Results
The results of developing the ARDS model in rats included characterizing the
model in two phases. In the ARDS validation phase, the experiments focused on
confirming if the sickness induced in rats with LPS replicated the prominent features of
ARDS. In the ARDS oxygenation phase, the experiments focused on confirming the
severity of hypoxia inflicted to the rats with the established ARDS model.
6.3.1 ARDS validation
All animals were distributed to randomly assigned regimens and successfully
administered the appropriate aerosol solution. The negative control and aerosolized saline
(each n = 3) cohorts experienced no mortalities during the prescribed study periods. Two
deaths occurred in Lv3 (n = 4, 50% mortality) and 3 occurred in Lv7 (n = 8, 37.5%
mortality) for a combined mortality rate of 41.7%. From the log-rank test, the mortality
between the LPS groups was not significant (p > 0.05). In contrast, the difference of
mortality between the LPS and control groups was significant (p < 0.05). All deaths
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transpired within 24 hours of aerosolized LPS administration. Lung injury scores and
BAL data of these rats were transferred from their original LPS group to Lv1 (n = 5) for
analysis.
For several days, all LPS rats showed multiple physical symptoms of sickness
including low activity with slow reaction times, piloerection, and decreased intake of
food and water (Appendix C). LPS rats were also observed to have visible tachypnea
with hypopnea. On day 3, LPS rats showed considerable improvement in physical health
and appearance. Following day 3, rats in the Lv7 group continued to show signs of
physiologic recovery until the final day of the study when they were physically
indistinguishable from controls.
6.3.1a Pulse oximetry
The pulse oximetry data were occasionally imprecise because movement of the
awake animal caused irregular pulse oximeter waveforms. The occurrence of inaccurate
readings from rat or sensor movement were found to be unavoidable without sedating the
animal, which was not done in order to minimize further trauma and not affect oxygen
saturations with methods of anesthesia. The data from irregular waveforms containing
spikes and plateaus were omitted from the averaging for each session. Through practice
in preliminary trials, the best readings were obtained when the sensor was placed over the
fourth metatarsal (Figure 6.3).
The peripheral oxygen saturation for the negative and saline control groups
displayed readings ranging from 85-95% with means consistently above 90% during the
study. However, one day after LPS administration the LPS groups decreased by 17.3%
from the average SpO2 baseline (Figure 6.4). The subsequent SpO2 values obtained from
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the LPS groups remained decreased below 80% in the following days. The decrease in
SpO2 of the LPS group was determined to be significantly different from the control
groups for days 1-7 (p < 0.05).

Figure 6.4: Average peripheral oxygen saturation of ARDS validation trials. Error bars
indicate the standard deviation of the mean.
6.3.1b Venous blood analysis
Blood from the tail vein of the rat was successfully collected and analyzed every
12 hours using the handheld blood analyzer. Overall, four instances occurred where the
blood sampling was omitted at a sampling period because the rat reached the maximum
collected blood volume of 0.6 mL/kg per day [225,226].
The cartridge type used in this study measured and calculated 13 physiological
parameters of blood gases and chemistry. However, none of the parameters were affected
by administering LPS and the venous partial pressures of carbon dioxide (P vCO2) and
oxygen (PvO2) showed no indication that the respiratory function of the LPS rats was
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inhibited (Figure 6.5). The values of the VBGs during the course of the study remained
within similar ranges of 20-60 mmHg. All other parameters of the venous blood failed to
exhibit any trend or correlation between the experimental groups (Appendix C).

Figure 6.5: Average partial pressures of (a) carbon dioxide and (b) oxygen
measurements of venous blood. Error bars indicate the standard deviation of the mean.
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6.3.1c Chest radiographs
Daily chest radiographs were taken of each rat for evaluation of pathognomonic
signs of ARDS. The radiographs of all rats were examined for the presence of pulmonary
edema, alveolar consolidation, and bilateral infiltrates. Radiographic anomalies
associated with ARDS should also stabilize within several days.
The baseline radiographs exhibited no sign of pre-existent or current respiratory
pathology (Figure 6.6). The radiographs of negative and saline control groups did not
present any significant change from baseline throughout the course of the study. LPS
radiographs, however, exhibited common features seen in ARDS – specifically,
development of diffuse bilateral infiltrates. All rats in the LPS cohort developed
radiographic changes within 24 hours of LPS administration. Clinical evidence of
respiratory function and radiographic changes consistent with ARDS did not significantly
change for the Lv7 group until day 3 of the study, after which time the rats in the LPS
cohort began to show signs of recovery.

Figure 6.6: Representative chest radiographs of the healthy baseline lungs (day 0) and
one day after aerosol administration.
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The radiographic image processor used in the validation trials broke down when
trials for the oxygenation phase were being performed. An older image processor was
borrowed from a local veterinary clinic to continue performing x-rays. However, the
quality of the x-ray film and processor was not as high as the previous machine used in
the validation trials. Overall, radiographic features in the oxygenation phase control and
LPS trials match those observed in the validation trials. The baseline radiographs
exhibited no sign of pre-existent or current respiratory pathology and control groups did
not develop any significant changes throughout the study. LPS radiographs exhibited
strong evidence of diffuse bilateral infiltrates within 24 hours of LPS administration. The
entire comprehensive radiographic record for the representative rats is presented in
Appendix C.
6.3.1.d Histology
In validation trials, lung tissue was collected and fixed in formalin for sectioning
as described previously. The H&E stained sections were then evaluated by an
independent pathologist for lung injury scoring. In the trials of phase two, right lung
tissue was collected and fixed in formalin for sectioning in all but one rat in the LPS
group. A lobe of the right lung and the bronchus was damaged when the lungs were
excised from the rat, which resulted in the right lung unable to be inflated and fixed with
formalin. Additionally, three right lungs from LPS rats were submitted for sectioning and
scoring, but never received by the pathologist. The lung samples were possibly collected
or disposed by a different individual.
Histological and gross images of the control rats possessed normal parenchymal
features (Figure 6.7). The H&E sections of control lungs presented little to no sign of
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alveolar edema, intra-alveolar hemorrhage, or leukocyte infiltration. Conversely, the LPS
lung tissue demonstrated edema and intraparenchymal hemorrhage on gross inspection.
LPS H&E sections featured a significant degree of congestion and edema. Additionally,
the alveolar-capillary membranes in the control lung sections were uncompromised while
the LPS lung sections exhibited significant thickening and collapse.
The lung injury scores for the control groups were evaluated as zero or lower than
0.1 in edema and hemorrhage, while LPS rats possessed significantly greater scores at 1
and 3 days (Figure 6.8). Most lung sections of control rats exhibited a slight quantity of
leukocytic infiltration present during the study. The leukocytic infiltration resulted in low
inflammation scores across all control groups. The highest scores in all three areas were
in rats that died 24 hours after aerosolized LPS was administered. Subsequent injury
scores in the LPS rats euthanized 3 days post-insult were decreased and after 7 days LPS

Figure 6.7: Characteristic images of rats’ excised lungs after euthanasia or death (top
row). Representative H&E stained sections (bottom row) from each group were imaged
at a 100X magnification.
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injury scores were similar to the controls, indicating that the rats had almost completely
recovered. The injury scores between the validation and oxygenation trials and between
the negative and saline controls were not significant different (Appendix C).

Figure 6.8: Injury scoring of lung tissue for all ARDS trials. Bars represent mean with
standard error of the mean.
6.3.1e BAL fluid analysis
Analysis of BAL samples was completed at UNMC for concentrations of the
cytokines TNF-α and IL-6. Only one sample from the Lv1 group presented a measureable
concentration of TNF-α (21.5 pg/mL) at a 1:2 dilution. The Lv1 BAL sample was
collected following the rat’s death that occurred approximately 5 hours after LPS was
administered. The TNF-α concentration of all other samples was zero. BAL samples from
the Lv1 group measured significantly higher (p < 0.05) concentrations of IL-6 compared
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to all BAL samples analyzed from other groups (Figure 6.9). The large concentration of
IL-6 was not measured in any other control or LPS group.

Figure 6.9: Mean concentrations of IL-6 in ARDS validation trials. The error bars
represent the standard error of the mean. ELISA for each animal was performed with
dilutions of 1:5 (red) and 1:20 (blue). *Lv1 at both dilutions was significantly greater
than all other groups (p < 0.05).
6.3.2 ARDS oxygenation
From phase one validation trials, rats were observed to begin recovering from the
symptoms of LPS approximately 3 days after administration. As a result, the observation
period for measuring the decreased oxygen saturations was determined to be 3 days to
focus on when the rats were in the most critical condition. All animals were distributed to
randomly assigned regimens and successfully administered the appropriate aerosol
solution. The negative control (n = 6) and aerosolized saline cohorts experienced no
mortalities during the prescribed study periods. However, two rats from the saline control
group (n = 4) were withdrawn from the study. One developed necrosis in the leg where
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the catheter was placed, while blood was unable to be sampled from the catheter of the
other rat withdrawn from the study. Only one death occurred in the LPS group (n = 10)
32 hours after LPS was administered for a mortality rate of 10%. Lung injury scores and
W/D ratio for this rat were separated from the other LPS trials for analysis (LPS1). From
the log-rank test, the mortality between the LPS and control groups was not significant (p
> 0.05) in the oxygenation phase. The mortality between the LPS trials in the validation
and oxygenation phases was also not significant (p > 0.05).
For two days post-insult, nine of the LPS rats presented multiple physical
symptoms of sickness including low activity with slow reaction times, piloerection, and
decreased intake of food and water. One rat exhibited none of the physical indications of
illness displayed by others in the LPS cohorts. All LPS rats were again observed to have
visible tachypnea with hypopnea. On day 3, LPS rats showed considerable improvement
in physical health and appearance.
6.3.2a Pulse oximetry
In phase two, pulse oximetry was performed on the hind paw where the femoral
catheter was not implanted. However, the pulse oximeter demonstrated inconsistencies
from one measuring period to the next, even in the controls. In the validation trials,
measurements were reliably obtained with high reproducibility. A pulse oximeter reading
was recorded; the sensor removed and replaced, and the same or very similar reading
would be measured. Consistent and reproducible measurements were difficult to obtain in
trials of phase two.
The peripheral oxygen saturation for the saline control group ranged from 85-92%
and remained steady during the study (Figure 6.10). However, 12 hours after the aerosol
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procedure the NC and LPS groups decreased from baseline SpO2 by 6% and 9.4%,
respectively. The control group returned to normal in the next 12 hours, while for the
remainder of the observation period the SpO2 readings of LPS rats continued to indicate
the LPS rats were slightly hypoxic. The decreased SpO2 average of the LPS group was
not determined to be significantly different from either control group throughout the
study (p > 0.05). The decrease in average SpO2 for the LPS oxygenation trials was
observed to be approximately half as severe as the decrease from the baseline of phase
one validation trials (9.4% to 17.3%).

Figure 6.10: Average peripheral oxygen saturation of ARDS oxygenation trials. Error
bars indicate the standard deviation of the mean.
6.3.2b Arterial blood gas analysis
Blood from the femoral artery catheter of the rat was collected and analyzed every
12 hours using the handheld blood analyzer. One rat from the saline control group was
withdrawn from the study due to being unable to sample blood from the femoral catheter
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at the beginning of the experiment. The femoral catheter was found to be kinked near
where the catheter was secured in the leg and had clotted. On the last two sample
collections of the study, blood was not sampled from one negative control rat and three
rats in the LPS cohort. When the rats were necropsied, the catheters were found to be
clotted at or near where the catheter was secured in the femoral artery. The femoral
arterial catheters were believed to clot from not being flushed completely with
heparinized saline after the previous collection. No instances occurred where the blood
sampling was omitted for a sampling period because the rats reached their blood
collection limit of 0.6 mL/kg per day [225,226].
The cartridge type used in this study measured and calculated 7 physiological
parameters of blood gases. For 36 hours post-insult, the average partial pressures of
carbon dioxide (PaCO2) in arterial blood of LPS rats increased 29.7% from the average
baseline (Figure 6.11a). Two days after LPS, P aCO2 returned to baseline values. The
PaCO2 of control groups decreased 13-18% from baseline after 12 hours and then
stabilized. After LPS administration, the average partial pressures of oxygen (PaO2)
decreased from baseline by 17.6% at 36 hours and 21.9% at the end of the study (Figure
6.11b). The PaO2 decreased in the NC group at 12 hours and then returned to baseline
levels which corresponded to the decrease measured in the average SpO2 of the NC
group. The PaO2 values for the saline controls remained between 80-90 mmHg during the
entire study. The calculated parameters of bicarbonate (HCO3-), base excess (BE), total
carbon dioxide (tCO2), and oxygen saturation (SO2) followed the trends of PaCO2 or PaO2
(Appendix C).

119

Figure 6.11: Average partial pressures of (a) carbon dioxide and (b) oxygen
measurements of arterial blood. Error bars indicate the standard deviation of the mean.
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6.3.2c Wet/dry ratio
Wet and dry weights of the left lung were measured from all phase two rats.
Healthy negative and saline control animals had average W/D ratios of 4.54 ± 0.25 and
4.47 ± 0.20, respectively (Figure 6.12). The rats aerosolized with LPS had a significantly
increased average W/D of 4.93 ± 0.24 when euthanized 3 days post-insult compared to
the controls (p < 0.05). The LPS rat that died 32 hours after LPS had an W/D of 7.07 and
was significantly increased from all other rats (p < 0.05)

Figure 6.12: Average W/D ratios of ARDS oxygenation trials. Error bars indicate the
standard deviation of the mean.
6.4 Discussion
In this study, we characterized a murine model of ARDS that was developed and
influenced by prior work where ARDS was induced by delivery of aerosolized LPS
directly to the lungs [214–223]. However, prior work primarily focused on the 24-hour
period immediately after the administration of LPS and the measured cytokine responses
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from BAL fluid collected from the lungs. The literature is limited regarding the
prolonged inhibition of respiratory efficiency and the rat’s oxygenation. To better
understand the pathophysiologic timeline of ARDS in a murine model, the experimental
objective was to characterize the development and recovery of respiratory function over a
longer time period than those previously verified [214,215]. The histology and cytokine
results presented herein reveal the classical ARDS model, and periodic measurements of
several unprecedented parameters including arterial and venous blood gas analysis, pulse
oximetry, and chest radiographs.
From mortality and chest radiographs, the ARDS model in rats possessed
analogous aspects observed in clinical ARDS cases. The rat model’s overall mortality
from LPS was 27.3% (6/22) which was within the range of ARDS mortality from recent
clinical reviews [7,9,11,232]. The risk of mortality from ARDS was highest in the 24
hour period following the LPS administration as 5 of the 6 deaths occurred in this period.
Chest radiographs recorded of LPS animals shared similar features such as cloudy
bilateral white-out, alveolar consolidation, and bilateral infiltrates (Figure 6.6, Appendix
C). No novel anomalies appeared in radiographs recorded after day 2, and in fact
radiographs of Lv7 after day 3 or 4 presented considerable improvement overall
(Appendix C). Substantial recovery occurring after day 3 was additionally supported by
lung injury scores and cytokine concentrations. Lung injury scores decreased between
one and three days post LPS, while lung injury scores seven days after LPS were not
significantly different from controls (Figure 6.8). Only BAL fluid collected from the Lv1
group exhibited any significant increase in quantities of IL-6 with the concentration
substantially decreased in Lv3 with barely any trace measured in Lv7 rats (Figure 6.9).
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Though TNF-α concentration is commonly measured, it did not have great importance in
validating the model as only one sample showed any measurable levels. The low
concentration of TNF-α was most likely because the production of TNF-α occurs a short
time after LPS administration and only two BAL samples were collected during the time
TNF-α was expressed [233–235].
The primary goal of characterizing effects of oxygen saturation levels during
ARDS was successful. During the study, arterial blood gases, pulse oximetry, and
radiographs evidenced rats suffered inhibited lung function of considerable degree after
intratracheal LPS. The PaO2 and SpO2 levels of LPS rats decreased drastically within 12
hours post-insult (Figures 6.4, 6.10, 6.11b). LPS chest radiographs 24 hours post-insult
revealed obvious alveolar consolidation and edema indicative of compromised lung
function (Figure 6.6). Additionally, though health appeared to improve by the end of the
studies, evidence that lung function continued to be compromised was observed. The
W/D of LPS rats was significantly increased from the control rats 3 days after LPS was
administered signifying there was residual pulmonary edema and decreased diffusion of
oxygen and carbon dioxide (Figure 6.12). In addition, the average SpO2 and PaO2 of the
LPS groups did not return to baseline values and indicated they were still experiencing
hypoxia at the end of the study. In contrast, VBG sampling did not provide further
information because there were no distinguishable differences in PvO2 or PvCO2 between
groups (Figure 6.5). Therefore, a complete representation of oxygen levels and lung
function in ARDS was achieved solely from pulse oximetry and arterial blood gases as
the measured trends of SpO2 correlated to the trends of PaO2. VBG analysis did not
support the pulse oximetry readings or ABG analysis. VBG sampling was attempted due

123
to the ease of blood collection and the lower cost compared to collecting arterial blood.
Additional surgery and resources were required to sample arterial blood consistently
which added more complications in performing the experiments. More complications in
measuring arterial blood from rats were evident as several animals were withdrawn due
to clotting of the catheter and necrosis from surgery performed in the oxygenation trials.
Overall, similar results were obtained between the validation and oxygenation
trials. The lung injury scores of NC, SC, and LPS were not significantly different in
edema, hemorrhage, and inflammation (Appendix C). The LPS chest radiographs had
homogeneous pathologies though the quality of the images was noticeably different
between phases. The most concerning differences experienced in the oxygenation trials
were the lower mortality rate, shorter physical recovery time, and the less severe decrease
in SpO2 from LPS. The mortality rate decreased from 41.7% in phase one to 10% in phase
two, though the mortality rates were not determined to be statistically significant by the
log-rank test (p > 0.05). The LPS rats in phase two demonstrated less severe physical
symptoms as they appeared healthier 2 days post-insult and one rat was minimally
affected by LPS administration. However, the behavior of the rats was not analytically
scored and was not used to quantify or delineate severity of the illness. Finally, the
baseline decrease in SpO2 of the LPS phase two trials were approximately half of the
decrease from baseline measured in the validation trials of phase one (Figures 6.4, 6.10).
The different decrease of SpO2 was attributed to the lower reliability and larger variance
of pulse oximetry readings in the oxygenation trials. However, the LPS dose used (7
mg/kg) was determined to be adequate for evaluating improvements from supplemental
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oxygen treatments because the SpO2 of rats was sufficiently reduced and supported by
decreased PaO2 and increased PaCO2.
6.5 Conclusion
Intratracheal LPS of 7 mg/kg was successful in producing a murine model of
moderate ARDS based upon radiographic, histological, and cytokine evidence. Analysis
of venous blood was confirmed to be a poor indicator for evaluating ARDS and hypoxia.
The investigations of ARDS also revealed through pulse oximetry and ABG that O2
levels in rats with ARDS were significantly decreased from baseline during the 48 hours
after administration of LPS. The oxygenation of the ARDS animals never fully recovered
during the 3 and 7 day studies. Based on the outcomes from pulse oximetry and ABG
analysis, the ARDS murine model characterized was demonstrated to be effective for
testing novel supplementary oxygen delivery methods. The characterized ARDS model
would subsequently be induced in rats to validate the benefits of PMO therapy in a
respiratory disease model alongside acute hypoxia models elicited by physical lung
injuries.
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Chapter 7: PMO therapy for hypoxia induced by right pneumothorax
in rats
The approach of direct systemic oxygenation by injecting OMBs into the
peritoneal space is a radical change from existing oxygen delivery platforms. The novelty
of PMO therapy thus requires extensive development of procedures and validation in
animal models of respiratory injury and disease. The procedure and apparatus for
infusing OMBs into the peritoneal cavity was created to be simple and straightforward
(Chapter 4). PMO therapy with the Peri3 precludes the need for an extracorporeal loop to
circulate blood, thus potentially circumventing the complications from thrombosis and
intracranial hemorrhage presented by ECMO. In this study, the feasibility of peritoneal
oxygenation with OMBs was examined for treating hypoxia elicited by the physical lung
injury of a right pneumothorax in rats. The lung injury of right pneumothorax is a model
for pulmonary failure in rats that was utilized in prior studies to examine the efficacy of
peritoneal oxygenation. The objective of this study was confirming the hypothesis that
intraperitoneal infusion of oxygen microbubbles delivers oxygen in vivo and significantly
increases the survival time of an animal experiencing acute lung injury. The first attempt
in testing the properties of PMO therapy for treating acute hypoxia was compared to an
intraperitoneal infusion of oxygenated saline solution.
7.1 Design
A controlled laboratory study was performed to test the therapeutic benefit of an
intraperitoneal infusion of oxygen microbubbles in animals experiencing acute lung
injury. The research subjects were male Wistar rats housed 2 per cage and acclimated for
4 days with free access to food and water. Right pneumothorax was chosen as an
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appropriate model for acute lung injury based on prior work reported in the literature
[135]. The right lung of the rat is composed of four lobes, whereas the left lung consists
of a single lobe [55]. Thus, damage to the right lung can cause a drastic reduction in
oxygen intake and respiratory function. Previous studies in rats demonstrated that the
volume of the right lung is approximately 60% of the total lung volume [236], and
collapse of the right lung by pneumothorax is fatal [135]. Two treatments were applied:
oxygen microbubbles or oxygenated saline as a control. Following induction of
pneumothorax, the vital signs observed and measured were intraperitoneal pressure,
infused volume, rectal temperature, heart rate, and oxygen saturation (SpO2).
The animals were randomly assigned to cages by the caretakers and randomly
chosen for treatments. No additional blinding was done in the study. The number of
animals used in this study was determined from work by Matsutani et al. [135] and a
preliminary feasibility study. In Matsutani, a synthetic oxygen carrier was injected into
the intraperitoneal (IP) space of rats for the purpose of systemic oxygenation. The mean
standard deviation and mean effective size were 6.9 and 19.9, respectively [135]. The
same standard deviation was assumed, but half the effective size (μ – μ0 = 10). Using
these values, a target Type I error of 0.05 and a sample size of 6 rats per group yielded a
power of 0.81. In the preliminary feasibility study, a sample size of 4 rats was used in the
oxygen microbubble group, and 3 rats were used in the control group. Using the log-rank
test for comparison of the survival distribution (α = 0.05), a significant difference was
found between the two groups (χ2 = 6.624, p = 0.010). Based on the results of the
preliminary trials, a sample size of 5 rats per group was decided to be adequate for the
lung injury study.
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Data collection was stopped due to either cardiac arrest or achievement of the
primary endpoint. Additional criteria were established to allow for the exclusion of
samples where complications arose. Criteria for exclusion included the occurrence of
unsuccessful pneumothorax or infrequent data points being collected by the veterinary
monitor. No other data were excluded. No test for outliers was used; all data were
included in the study. A primary endpoint of 2 hours following induction of
pneumothorax was selected to avoid complications arising from animal recovery from
anesthesia and the initial lung injury. Complications after recovery from anesthesia and
lung injury were occasionally observed in animals surviving greater than 2 hours in the
preliminary feasibility study. The 2-hour endpoint was calculated to be sufficiently long
to demonstrate a statistically significant increase in mean survival time between animals
receiving PMO therapy and the control group. Prior to the study, the longest mean
survival time for an intraperitoneal oxygenation therapy following pneumothorax
reported in the literature was 33 minutes [135]; thus, a mean survival time exceeding 2
hours was deemed a significant improvement over the current state of the art and of high
clinical utility. No other endpoints were specified and no trials were repeated. Each
animal received only one pneumothorax and one treatment.
Treatments in rats were restricted to a single bolus of approximately 1/5 of the
body weight of the rat. This bolus volume is reported as the maximum volume to safely
inject into the peritoneal cavity of a sedated animal [21,135,226]. The volume and
pressure were simulated in control trials by injecting saline at the same flow rate and
procedure as OMBs. To increase the amount of OMBs which could be delivered,
preliminary trials investigated circulating saline into and out of the peritoneal cavity.
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However, circulation with saline failed due to omental and intestinal tissue obstructing
the needles and catheters attempted.
7.2 Materials and Methods
The materials and methods section details the procedures used to inflict the right
pneumothorax for inducing an acute lung injury and hypoxia. Section 7.2 then overviews
the parameters measured, treatments administered, and the protocol followed during the
experiments. When the observation period of the rats was completed, surviving animals
were euthanized and the experiment ended. Section 7.2 ends with a summary of the
statistical tests used to determine significant differences between treatment groups.
7.2.1 Right pneumothorax lung injury model
All animals were housed and underwent procedures approved by the University of
Nebraska-Lincoln, IACUC. Male Wistar rats (n = 10, m = 430 ± 15 g, Charles River)
were anesthetized in an induction chamber with 5% isoflurane to effect and maintained
on 2% isoflurane. Each rat was weighed, given an IP injection of sodium pentobarbital
solution (50 mg/kg dose), and then placed in the supine position on a warming pad
(T/pump Classic, Gaymar) set at 38°C to maintain body temperature (Figure 7.1). After
the rat was fully sedated and unresponsive to pain delivered by paw pinches, a small
incision into the skin was made to expose the fascia of the abdominal wall. A 12-gauge
indwelling catheter was then inserted into the IP cavity and fitted by a luer lock to tubing
(8.2 mm inner diameter, Tygon) attached to the Peri3 system (Chapter 4) for subsequent
infusions. A 22-gauge indwelling catheter was also inserted into the IP cavity and
connected to two pressure transducers (4426-005G, Measurement Specialties Inc.) for
measuring intra-abdominal pressure via a data acquisition system (myDAQ, LabVIEW,
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National Instruments). A veterinary monitor (SurgiVet Advisor, Smith’s Medical) was
used to monitor vitals of heart rate and peripheral oxygen saturation. The monitor could
read up to a maximum heart rate of 350 bpm and was found to be sufficient for recording
values in an anesthetized rat. A pulse oximetry sensor (V3078, Smith’s Medical) was
clipped to the hind leg of the rat to measure the pulse rate and peripheral oxygen
saturation (SpO2). A temperature probe (WWV3418, Smith’s Medical) was placed
rectally for monitoring body temperature. The treatment bolus of perfusate was pumped
through a fluid warmer (iWarm, Midmark) set at 40.4°C and into the IP space with a
peristaltic pump (Thermo Scientific, FH100M) at 40 mL/min for 1 min, and then at 8
mL/min thereafter. At the time the flow rate was reduced, the rats experienced a right
pneumothorax by perforating the pleura of the pulmonary cavity with a scalpel. Infusion
lasted until distension of the abdomen was noticeable and while the intra-abdominal
pressure was below 5 mmHg (0.67 kPa). When infusion into the peritoneal cavity was
ceased, the total infused volume of perfusate was recorded. The fluids used as a perfusate
were saline as the control and oxygen microbubbles (70 vol% O2 gas volume fraction).

Figure 7.1: The experimental setup for treatment of a right pneumothorax in rats [179].
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During the experiment, temperature, pulse rate, and oxygen saturation (SpO2) of
the blood was monitored in 8-second averages and recorded every 30 seconds for each
rat. The intra-abdominal pressure was monitored and recorded at a frequency of 10
samples per second. Survival time was measured as the elapsed time between right
pneumothorax and cardiac arrest. If still living, the rat was intramuscularly injected with
a second dose of sodium pentobarbital 1 hour following the administration of the
previous dose. The endpoint of data collection occurred when the rat had suffered
functional cardiac arrest or when the predefined endpoint of 2 hours of survival time was
reached. At 2 hours plus 5 minutes, any surviving rats were euthanized by isoflurane
overdose.
7.2.2 Statistical analysis
Kaplan-Meier survival curves were created with a sample size of 5 rats per group
for a representation of the survival rate for the control and oxygen microbubble groups. A
log-rank (Mandel-Cox) test was done to compare the survival distribution of the OMB
group to the control group for a significant difference (α = 0.01).
7.3 Results
In this study, the right pleura in male Wistar rats (n = 10, m = 430 ± 15 g) was
perforated by piercing a scalpel blade between two ribs of the pulmonary cavity
(Appendix D). The injury successfully caused a pneumothorax of the right lung in all but
one of the rats. In one rat from the saline control group, the scalpel wound was
implemented too deep while the rat was inhaling. The scalpel lacerated the lung causing
considerable bleeding and death from hemorrhage shock. Additionally, few data points
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were recorded from the rat with the veterinary monitor. Therefore, the rat was excluded
from the study because both exclusion criteria occurred in the trial.
Infusion of the fluid treatments was completed without leaking from the
abdominal incision and lasted until distension of the abdomen was noticeable. The total
infused volume of OMBs was 107 ± 9 mL, which was not statistically different from the
saline control (Figure 7.2). The intra-abdominal pressure was maintained at less than 5
mmHg (0.67 kPa) gauge throughout the experiment for animals treated with both saline
and OMBs (Figure 7.3). Following pneumothorax, the mean body temperature was 34.5
± 0.8 °C for animals receiving OMBs and 33.0 ± 1.0 °C for those receiving saline (Figure
7.4). These body temperatures were below the normal temperature range of rats (35.937.5°C) [55], but were unlikely a significant factor in causing complications or death
during the experiment [237–239].

Figure 7.2: Total infused fluid volume for rats with pneumothorax [179].
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Figure 7.3: The intra-abdomen pressure (mean ± SD) in rats with pneumothorax [179].

Figure 7.4: The rectal temperature (mean ± SD) in rats with pneumothorax [179].
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Peritoneal infusions of OMBs produced 100% survival to the predetermined
2-hour endpoint in 5 rats experiencing a right pneumothorax, compared to a mean
survival time of only 15.5 ± 8.1 minutes (n = 5) for oxygenated saline and 16.0 ± 4.8
minutes (n = 6) for untreated controls (Figure 7.5). The survival from PMO treatment was
determined to be a significant increase compared to the two other treatment groups (χ2 =
9.701, p = 0.002). Oxygen saturations for animals treated with OMBs were observed to
be between 80-90% throughout the 2-hour timeframe (Figure 7.6). The measured SpO2s
for rats treated with saline dropped precipitously within minutes after pneumothorax.
Furthermore, heart rate for animals treated with OMBs was observed to be range from
240-350 bpm during the 2 hours, while it dropped rapidly within minutes for the controls
treated with saline (Figure 7.7). The values of SpO2 and heart rate measured in OMB
treated rats are considered to be within the normal range of a sedated rat [55,240–242].

Figure 7.5: The survival of treated rats with right pneumothorax [179].
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Figure 7.6: The peripheral oxygen saturation in rats with right pneumothorax [179].

Figure 7.7: The heart rate of rats with right pneumothorax [179].
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7.4 Discussion
The OMBs used in this study were designed for high oxygen carrying capacity
and rapid oxygen delivery to the peritoneum. A 70 vol% suspension of OMBs at 1.0 bar
and 37°C contains an estimated 0.88 mg-O2 mL-1, compared to 0.31, 0.62 and 0.57 mgO2 mL-1 for blood, liposomal hemoglobin, and pure PFC, respectively (Table 3.3).
Furthermore, OMBs provide a greater fraction of oxygen availability to the body. The
entire mass of oxygen can be released to low-oxygen surroundings because complete
microbubble dissolution is thermodynamically favorable. In contrast, complete oxygen
release from PFC and HBOC formulations is restricted by the oxygen solubility of PFC
which depends on the partial pressure of oxygen in the environment and the oxygen
binding affinity of hemoglobin.
However, if available oxygen carrying capacity was the only criterion for
successful peritoneal oxygenation, then ventilation with pure oxygen (1.26 mg-O2 mL-1)
should not have failed to provide clinically relevant oxygenation, as reported by Giffin et
al. [132]. We attribute the limited uptake for pure oxygen ventilation to the problem with
injecting a bolus of free gas into the peritoneal cavity. Surface area is minimized owing to
the high surface free energy (~73 mJ/m2) of the gas/water interface. Thus, one may
compare the transport of a centimeter-scale bubble for pure oxygen ventilation to
hundreds of billions of micrometer-scale bubbles for OMBs. OMBs would then provide a
greater rate of oxygen delivery to the peritoneum compared to the failed method of
peritoneal oxygenation with oxygen ventilation.
Achieving 100% survival to 2 hours with OMBS compared to the 15.5 minute
mean survival time for saline controls was found to be a significant improvement. The
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improvement with OMB treatment indicates a potential for clinical utility in patients
suffering mild to severe hypoxemia where mechanical ventilation is inadequate or
injurious. In neonates, for example, PMO therapy could be used to treat hypoxemia
arising from meconium aspiration syndrome, pulmonary hypertension, congenital
diaphragmatic hernia, sepsis, and cardiac anomalies [243].
There were some limitations to this study. First, there was some concern that the
pneumothorax lung injury model would cause death, not from gas exchange failure, but
from increased oxygen demand from work of breathing, cardiogenic failure from altered
venous return in a depressurized thorax, or from another unanticipated complication due
to the wound. The success of PMO in prolonging life in all five animals suggested that
these complications were secondary to the need for rapid oxygen delivery. Another
limitation to our study was that we only employed a one-way delivery of oxygen, but did
not simultaneously remove carbon dioxide. The lack of carbon dioxide removal could
ultimately result in complications such as hypercapnia and acidosis in cases where the
lungs or ventilation are significantly inhibited.
7.5 Conclusion
Peritoneal oxygenation with oxygen microbubbles produced 100% survival with
normal peripheral oxygen saturations to the 2-hour endpoint for rats suffering fatal
hypoxia from a right pneumothorax lung injury. Whereas, untreated and saline-treated
controls had a mean survival time of only 15.8 ± 6.2 minutes and no animals survived to
the 2-hour endpoint. A single OMB bolus treatment achieved a significant improvement
in oxygenation and survival of rats with pneumothorax injury. The success with a single
OMB bolus indicated that peritoneal microbubble oxygenation therapy is capable of
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delivering oxygen in vivo, increasing survival, and increasing systemic oxygenation. The
improvement in fatally hypoxic rats treated with OMBs provides evidence that PMO
therapy possesses potential clinical utility as an alternative method of supplemental
oxygenation in patients suffering hypoxemia where mechanical ventilation and ECMO is
inadequate or injurious. The next step of validating the clinical potential of PMO therapy
was to evaluate PMO therapy in further experiments with larger animals experiencing
physical injury and acute hypoxia.
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Chapter 8: PMO therapy for asphyxia from tracheal occlusion of
rabbits
In the rat pneumothorax study (Chapter 7), PMO treatment with a single bolus of
OMBs eliminated mortality and maintained normal levels of peripheral oxygen saturation
and heart rate in rats suffering from an otherwise lethal right pneumothorax. The
impressive results with OMBs in hypoxic rats demonstrated the feasibility and oxygen
delivery properties of PMO therapy as a supplemental oxygen treatment. However, rats
have a significantly lower oxygen demand and different peritoneal physiology compared
to larger mammals and humans. Thus, success in rats alone provides insufficient evidence
for the potential of PMO therapy in clinical applications of treating hypoxia. The current
study addresses three critical goals for the further development of PMO technology: 1) to
determine whether PMO can extend life following complete loss of lung function (rather
than partial loss as in the right pneumothorax) without resuscitation; 2) to scale up the
procedure to a larger animal; and 3) to design and test a new delivery system that
circulates OMBs through the peritoneal cavity.
8.1 Design
In this study, a larger animal model was chosen in order to take the next step
toward clinical relevance. Initial in vivo feasibility studies were performed on rats due to
their low cost, biological relevance, and most importantly, small oxygen demand and
correspondingly small perfusate requirements (Chapter 7). If PMO therapy had been
ineffective on rodents, OMB treatments almost certainly would have had no benefit to
humans and the technique would have been abandoned. Due to our success with rats and
in order to produce studies more relevant to pre-clinical trials, larger animal models are
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needed. Study with larger animals requires significantly improving the OMB fabrication
technique in order to supply the OMB flow rates needed for greater oxygen demands of
large animal. Developing the processes and equipment for generating the high flow rate
of OMB perfusate needed for larger animals is a difficult and expensive task, and
therefore was not initiated until feasibility of the therapy with rats was demonstrated.
The choice of the rabbit as the next animal model for this stage of the research
was based on procedures and knowledge from peritoneal dialysis research. Even though
rats and rabbits are both the most commonly used models in peritoneal dialysis research,
rabbits are seen as more clinically relevant to humans [244]. Peritoneal dialysis research
in rabbits is considered more relevant to humans because the ratio of the rabbit’s
intraperitoneal volume to body mass and peritoneal surface area is more similar to
humans than that of rats [112]. Furthermore, the total oxygen demand of rabbits is much
higher than that of rats due to their larger body mass, which allows for more relevant
analysis of PMO therapy in humans [184,186,187,245]. The larger body mass also
increases the total oxygen demand and, thus, requires scale up of the manufacture of
OMBs.
8.2 Materials and Methods
All animal studies were performed in accordance with the University of
Nebraska-Lincoln, IACUC. To evaluate PMO therapy, male New Zealand White rabbits
(n = 19, m = 2.2 ± 0.2 kg) were treated with either intraperitoneal OMBs or saline as the
control. Two infusion methods (bolus or circulation) were tested, resulting in 4 groups:
SB- saline bolus (n = 2); SP- saline perfusion (n = 2); OB- OMB bolus (n = 9); OP- OMB
perfusion (n = 6). The saline groups were limited to two animals each (four animals total)
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as the use of more animals was deemed excessive considering these four trials matched
the well-documented time of death for an untreated asphyxiation rabbit model [246–248].
To model complete respiratory failure, the rabbit was intubated with a cuffed
endotracheal tube (ETT), which could be hermetically sealed by occluding the end with a
rubber membrane and plastic cap. Thus, all gas exchange in the lungs was eliminated,
causing the animal’s oxygen intake, as well as carbon dioxide removal, to occur through
OMBs, and any extension of life was entirely due to PMO therapy. The experimental
endpoint was cardiac arrest determined by cessation of heartbeat and pulse. To prevent
the disruption of hemodynamics, intra-abdominal pressure (IAP) was monitored and kept
below 8 mmHg [125,183]. The criterion for exclusion was the rabbit breathing around the
sealed ETT. During the experiment, body temperature, pulse rate, and SpO2 were
monitored in 8 second averages and recorded every 30 seconds. The IAP and fluid
infusion temperature were monitored and recorded every second. Survival time was
calculated as the time between the ETT being sealed (time = 0) and cardiac arrest (the
experimental endpoint).
Each rabbit was weighed before the procedure and then sedated with 5%
isoflurane to effect through a nosecone. The throat was then sprayed with cetacaine and
intubated with the cuffed ETT (3 mm, JorVet). The ETT cuff was inflated and then
secured by cotton gauze tied around the head and front incisors. The rabbit was placed in
the supine position on a warming pad (T/pump Classic, Gaymar), and the ETT was
attached to the anesthetic machine with the rabbit maintained on 2% isoflurane (Figure
8.1). The abdomen was shaved and sterilized with betadine scrub and alcohol. A
veterinary monitor (SurgiVet Advisor, Smith’s Medical) was used to monitor vitals. A
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Figure 8.1: Schematic of the setup for the trachea occlusion experiments in rabbits [192].
pulse oximetry sensor (V1700, Smith’s Medical) was used to measure the pulse rate and
peripheral oxygen saturation (SpO2). A temperature probe (WWV3418, Smith’s Medical)
monitored body temperature. Both the pulse oximeter and temperature sensors were
placed rectally. An intramuscular injection of ketamine-xylazine solution (35-5 mg/kg
dose, 35 mL/kg solution) was then given to anesthetize the rabbit for the remainder of the
procedure, while the rabbit was weaned off of the isoflurane. Once completely weaned
off isoflurane, the ETT was disconnected from the anesthetic machine and the rabbit was
allowed to breathe room air. Once the rabbit was confirmed unresponsive to pain by paw
pinches, a small incision was made in the upper left quadrant of the abdomen for
insertion of the fluid infusion tubing (3.2 mm inner diameter, Tygon) into the peritoneal
cavity. The abdominal incision was then sutured closed around the infusion tubing. The
infusion tubing was attached to the Peri3 (Chapter 4) for peritoneal infusion of OMB or
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saline treatment. A 12-gauge indwelling catheter was then inserted into the peritoneal
cavity at the upper right quadrant of the abdomen and connected to two pressure
transducers (4426-005G, Measurement Specialties Inc.) for measuring IAP via the Peri3
program (myDAQ, LabVIEW, National Instruments).
8.2.1 Bolus delivery of OMBs
A single static volume of OMBs or saline was injected into the cavity. The OMB
or saline bolus was pumped through an inline fluid warmer (iWarm, Midmark) set at
40.4°C and then into the peritoneal cavity with the Peri3’s peristaltic pump (Thermo
Scientific, FH100M) at 80 mL/min for 4 min, and then at 12.6 mL min-1 kg-1 thereafter.
The ETT was then hermetically sealed upon reduction of the infusion rate of the bolus
treatment. Fluid infusion lasted until the IAP reached 5 mmHg or the rabbit experience
cardiac arrest. When infusion into the peritoneal cavity was ceased, the total infused
volume of the treatment bolus was recorded.
8.2.2 Circulation of OMBs
The setup of the peritoneal circulation technique, where fresh OMBs or saline
were continually perfused through the peritoneal cavity to continuously deliver oxygen,
was similar to that of the bolus setup. However, to remove OMBs from the peritoneal
cavity, a medial incision was made into the peritoneal cavity, and a customized OMB
scavenging port was implanted (Figure 8.2, Appendix E). Suture was then used to close
the incision around the collar of the scavenging port. Tubing (7.9 mm inner diameter,
Tygon) was then attached to the scavenging port for drainage of perfusate from the
peritoneal cavity. The OMB or saline perfusate was then pumped through an inline fluid
warmer (iWarm, Midmark) set at 40.4°C and into the peritoneal cavity with the Peri3’s
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Figure 8.2: Custom scavenge port used for perfusion trials of tracheal occlusion.

Figure 8.3: Control scheme implemented with LabVIEW for the perfusion experiments
[192].
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peristaltic pump (Thermo Scientific, FH100M) at 80 mL/min for 4 min, and then at 12.6
mL min-1 kg-1 thereafter. The IAP was maintained between 3 and 4 mmHg by the Peri3
system using a 36V solenoid (ROB-10391, Sparkfun) driven valve to control the fluid
flow. Once circulation of OMBs or saline was attained, the ETT was hermetically sealed.
Infusion of fluid continued until the time of death, after which the total infused volume
was recorded. The LabVIEW program of the Peri3 automatically regulated the circulation
of fluid in the perfusion trials by simultaneously following two schemes controlled by the
IAP and time (Figure 8.3).
8.2.3 Statistical analysis
Kaplan-Meier survival curves were created to analyze the survival benefit of
OMBs versus saline control. A log-rank (Mandel-Cox) test was performed for significant
differences between the groups’ mean survival times (α = 0.01). Levene’s test was
performed to compare if the variances between the groups’ survival were statistically
different (α = 0.05). Analysis of covariance (ANCOVA) with separate means was
performed to test the overall differences among groups between the rate of change in the
heart rate and SpO2 after the ETT was sealed. Multiple comparison tests of the means
were performed to determine which groups were significantly different (α = 0.05).
8.3 Results
The results from PMO therapy experiments in rabbits comprised two types of
peritoneal treatment administration. In the bolus delivery treatments, the peritoneal cavity
of rabbits was infused with a single bolus of OMBs or saline. In the circulation
treatments, the peritoneal cavity of rabbits was continually infused with fresh OMBs or
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saline with the Peri3 system while the intra-abdominal pressure was maintained below 6
mmHg.
8.3.1 Bolus delivery of OMBs
Peritoneal microbubble oxygenation resulted in a significant increase in the
survival time of rabbits following the endotracheal tube being sealed (Table 8.1). No
animals were observed to breathe past the ETT once sealed. Rabbits treated with a bolus
infusion of saline (SB group) experienced cardiac arrest within 7 minutes. The rabbits
that received a bolus injection of OMBs (OB group) had a mean survival time of
12.2 ± 3.0 minutes, which was determined to be significantly different than the SB group
(χ2 = 12.36, p < 0.01) (Figure 8.4).

Figure 8.4: Kaplan-Meier survival curves of the treatment groups in the tracheal
occlusion of rabbits [192].
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Table 8.1: Mass, infused volume, and survival time data of trachea
occlusion experimental groups [192].
Treatment

n

Mass (kg)

Infused vol. (mL)

Survival time (min)

Saline Bolus (SB)

2

2.53 ± 0.02

336 ± 9

6.5 ± 0.7

OMB Bolus (OB)

9

2.25 ± 0.16

558 ± 66

12.2 ± 3.0

Saline Perfusion (SP)

2

2.03 ± 0.01

431 ± 37

6.8 ± 0.4

OMB Perfusion (OP)

6

2.18 ± 0.12

646 ± 72

10.8 ± 2.4

The temperature of the fluid infused into the peritoneal cavity ranged from 20.5°C
to 28.0°C and the IAP was maintained below 6 mmHg. The body temperature of the SB
and OB groups decreases slightly below the normal body temperature range for rabbits of
38-40°C [249,250]; however, the body temperatures of all treated rabbits were in the
range of 35-40°C during the duration of fluid infusion (Figure 8.5a, c). The slight
decrease in body temperature of the SB and OB groups resulted from the combination of
anesthesia, shaving of the abdomen, and peritoneal infusion of fluid that was slightly
cooler than body temperature. The slight hypothermic condition was not enough to
endanger the rabbit or cause hypothermia based on the duration of the procedure
[251,252].
The SB group had pulse rates of 130-325 bpm, which are within the normal range
for a sedated rabbit [249,250,253], while the OB group with a prolonged survival time
eventually experienced pulse rates below 130 bpm (Figure 8.6a, c). Interestingly, the SB
group experienced a rapid decline in pulse rate following sealing of the ETT, whereas the
OB group appeared to experience a steadier and less drastic decline in pulse rate. Rabbits
infused with OMBs exhibited a short period of stability in pulse rate 5-10 minutes after
the ETT was sealed.
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The SB group experienced a rapid decline in SpO2 following sealing of the ETT,
whereas the OB group experienced a steadier and less drastic decline in S pO2 (Figure
8.7a, c). While the oxygen saturation was below a healthy baseline of 90% in both
groups, there appeared to be an overall improvement in SpO2 for the OB group compared
to the SB group. From a clinical view, however, the rabbits were not systemically
oxygenated well as the SpO2 was around 60% for most of the experiments. Note that a
couple OB trials did have higher O2 levels (~80%). No significant difference in heart rate
or SpO2 was indicated by ANCOVA (Table 8.2).

Figure 8.5: Average body temperature of all treatment groups before and during
experiment: (a) saline bolus, (b) saline perfusion, (c) OMB bolus, (d) OMB perfusion.
The shaded region indicates standard deviation. Where there is no shaded region either
there is only one sample, or the samples values are coinciding at the time (SD = 0). The
dashed line at time zero represents when the ETT was sealed. The cardiac arrest times of
each rabbit are indicated by circles [192].
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SpO2

Heart rate

Table 8.2: Multiple comparison test results of tracheal occlusion using
ANCOVA [192].

a
b

Group 1
SB
SB
SB
SP
SP
OB
SB
SB
SB
SP
SP
OB

Group 2
SP
OB
OP
OB
OP
OP
SP
OB
OP
OB
OP
OP

C.I. a
[-42.01, -3.20]
[-28.37, 0.59]
[-34.20, -4.87]
[-4.88, 22.31]
[-10.73, 16.85]
[-10.48, -0.83]
[-7.56, 7.82]
[-9.42, 1.77]
[-11.59, -0.25]
[-9.50, 1.61]
[-11.68, -0.41]
[-4.07, -0.12]

Significant difference b
YES
NO
YES
NO
NO
YES
NO
NO
YES
NO
YES
YES

There was a significant difference if the confidence interval (C.I.) does not contain zero.
The diagram in the last column shows the overall relationships between the groups. Dashed lines
represent a significant difference, whereas the solid lines represent lack of significant
difference.

8.3.2 Circulation of OMBs
The rabbits circulated with OMBs had a baseline pulse rate of 245 ± 40 bpm and
oxygen saturation of 87 ± 4% when intubated and freely breathing room air. Rabbits that
received saline (SP group) experienced hypoxic cardiac arrest within 7 minutes after
complete asphyxiation by sealing the ETT (Table 8.1). Rabbits circulated with OMBs
(OP group) had a mean survival time of 10.8 ± 2.4 minutes, which was significantly
longer than the SP group (χ2 = 8.33, p < 0.01) (Figure 8.4) . The survival times for the
bolus and perfusion groups were not significantly different for either saline (χ 2 = 0.059, p
> 0.05) or OMBs (χ 2 = 0.705, p > 0.05).
The temperature of the fluid infused into the peritioneal cavity ranged from
20.5°C to 28.0°C, and the IAP was maintained in the range of 2 to 4 mmHg. The body
temperature of the OP treatment group decreased slightly below the normal body
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temperature range for rabbits, but was in the range of 35-40°C during the period of fluid
infusion (Figure 8.5b, d). The body temperature of the SP group, on the other hand,
decreased from 38°C to 31°C. The combination of saline below the rabbits’ body
temperature, the high heat capacity of the saline, and circulation contributed to lower
body temperatures in the SP group. Decreased body temperatures were not seen in the
rabbits in the OP treatment group because OMBs are 70% O2 gas by volume and
therefore had a lower heat capacity than saline.

Figure 8.6: Average pulse rate of all treatment groups before and during experiment: (a)
saline bolus, (b) saline perfusion, (c) OMB bolus, (d) OMB perfusion. The shaded region
indicates standard deviation. Where there is no shaded region either there is only one
sample, or the samples values are coinciding at the time (SD = 0). The dashed line at time
zero represents when the ETT was sealed. The cardiac arrest times of each rabbit are
indicated by circles [192].
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Results between the OMB and saline control groups were similar to those
presented for bolus injection (Figure 8.6b, d). The OP group had heart rates within the
normal range, while the SP group experienced pulse rates below 130 bpm. As in the
bolus treatments, rabbits infused with OMBs exhibited a short period of stability in pulse
rate 5-10 minutes after the ETT was sealed.
The OP group experienced a significant increase in SpO2 compared to all other
treatment groups (Figure 8.7b, d). Interestingly, the decline in SpO2 and heart rate for the
SP group began approximately 4 minutes before the ETT was sealed, when infusion was

Figure 8.7: Average oxygen saturation, measured as SpO2, of all treatment groups before
and during experiment: (a) saline bolus, (b) saline perfusion, (c) OMB bolus, (d) OMB
perfusion. The shaded region indicates standard deviation. Where there is no shaded
region either there is only one sample, or the samples values are coinciding at the time
(SD = 0). The dashed line at time zero represents when the ETT was sealed. The cardiac
arrest times of each rabbit are indicated by circles [192].
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initiated. The reason for the anomaly in decreased heart rate of the SP group was
unidentified. Overall, the measured vitals of heart rate and oxygen saturation in the OMB
treated rabbits indicated less drastic decline than that of the saline treatment groups, but
only the OMB perfusion method was found to significantly increase SpO2 compared to all
other groups (Table 8.2).
8.4 Discussion
The first goal of this study was to determine whether PMO can extend life
following complete loss of lung function. Based on these results, we conclude that PMO
therapy in a complete asphyxiation model significantly increased time to cardiac arrest by
a factor of 1.7. The increase in survival time was shorter than the 6.5-fold increase in
survival time that was previously achieved for PMO therapy in a rat lung injury model
(Chapter 7) [179]. In the prior injury model, however, lung function was estimated to be
limited to about 40% [236], possibly improving over the 2-hour experimental timeframe
as the underlying pneumothorax healed. In the study in asphyxiated rabbits, the sealed
ETT reduced lung function to 0%. The significant improvement in survival time and
oxygenation (SpO2) for PMO-treated animals over controls therefore demonstrated the
potential ability of OMB treatment technology, even in the extreme scenario of complete
lung failure or airway obstruction.
The second goal was to scale up the procedure of OMB treatment from rats to a
larger animal. One of the potential limitations of PMO treatment is the limited amount of
blood flow through the splanchnic circuit. In humans, only 20-30% of the total blood
volume passes through the peritoneal region [113], which is similar to rabbits where total
splanchnic circulation is 22% of the total blood flow [254]. The low splanchnic blood
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flow limits the amount of oxygen that can be transported from the peritoneum, which
may explain the difficulty in maintaining normoxic levels in the complete asphyxiation of
rabbits.
The final goal was to test a new peritoneal delivery system, the Peri3, to circulate
OMBs through the peritoneal cavity. While circulation was achieved, the method of
infusion (bolus vs. circulation) demonstrated no measured impact on survival time in the
complete asphyxiation model. The lack of improvement with OMB circulation was an
unexpected outcome as more OMBs were delivered to rabbits in the perfusion group. In
the circulation infusion method, OMBs fully loaded with oxygen were continuously
delivered into the peritoneal cavity. However, no method was implemented to encourage
complete mixing of OMBs in the peritoneal cavity before OMBs were removed. Fresh
OMBs possibly exited the cavity through the scavenge tubing before completely
releasing their oxygen load. Thus, transfer efficiency may have been negatively impacted
for the continuous infusion method such that circulation of OMBs was analogous to a
single bolus injection. In the future, OMB perfusion will be evaluated more thoroughly
by determination of OMB quality and gas concentrations (O2, CO2, N2) directly before
and after the administration of OMB treatment. Additional refinements of the circulation
technique may be needed to increase mass transfer between the OMB perfusate and
peritoneum.
The variance in survival time of the OMB treated groups merits future
investigation as it was significantly different from the controls (p < 0.05). Several factors
could have caused variability in survival time. For example, rabbit weight, individual
metabolism, and depth of anesthesia all affect O2 consumption. The splanchnic blood

153
flow and vascularization of the peritoneum varied between animals and impacted the
diffusion rate of O2 into the body. Some of these variables could possibly be controlled.
For example, enhancing splanchnic blood flow could be achieved by administration of
drugs such as cisapride [131]. Also, varying IAP levels could be investigated in order to
determine the pressure threshold for vasculature collapse and its effect on OMB diffusion
dynamics.
8.5 Conclusion
From the study of total asphyxiation in rabbits, the current PMO system was
inadequate to provide 100% of a sedated rabbit’s oxygen demand because animals
exhibited a gradual decrease in SpO2 before death. Though total systemic oxygenation
with OMBs was not possible in asphyxiated rabbits, local tissue oxygenation of the
abdomen may have been substantially increased (Appendix E). Additionally, the
pneumothorax experiments demonstrated that PMO could supplement 60% of a rat’s
oxygen demand (Chapter 7). If OMB treatment demonstrates similar efficacy in humans
as in rats and rabbits, PMO therapy may be able to provide supplemental oxygen for
systemic oxygenation in a wide variety of respiratory injuries which result in hypoxia.
PMO therapy was subsequently investigated in an ARDS hypoxia model of rats (Chapter
6) to validate PMO therapy for cases of hypoxia attributed to respiratory diseases
including asthma, sepsis, pneumonia, and ARDS.
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Chapter 9: Oxygenation in a sedated rat with ARDS via a single OMB
bolus
PMO therapy was validated to provide beneficial oxygenation in hypoxic models
of physical lung injury. The last form of hypoxic model investigated in this work was
validating PMO therapy in an animal model of respiratory disease. The respiratory
disease selected for evaluating PMO therapy was ARDS in rats because of the extensive
literature that exists detailing the ARDS rat model and because the current medical
methods are ill-suited for treating hypoxia attributed to ARDS. However, the volume of
blood that can be sampled from a rat is limited to approximately 2-3 samples per day
without altering the hematocrit and oxygen capacity of the circulating blood
[55,225,226]. The low number of blood samples restricts how comprehensive of an
oxygen profile that is measured from an individual rat induced with ARDS. Therefore,
when comparing PMO therapy to other treatments, the blood samples must be taken at
times when the improvement in systemic oxygenation from OMB treatment is greatest.
To determine when the oxygen saturation in the blood peaks from injection of an OMB
bolus, an experiment was conducted in rats suffering from ARDS. Discovering when the
oxygen increase from an OMB bolus treatment was greatest would determine the optimal
time to sample blood and pulse oximetry for the best representation of clinical benefit of
PMO in a long term ARDS study. Also, the time after OMB infusion when improvement
in oxygenation has peaked would be relevant for approximating the minimum number of
OMB boluses that would be optimal for maintaining elevated oxygen levels for the
longest duration.
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9.1 Design
In previous work investigating the oxygen diffusion through the peritoneum,
healthy rats were sedated with an IP injection of ketamine-xylazine and injected with a 60
mL bolus of OMBs for determining diffusion of gases in vivo [191]. Over 20 minutes, 10
mL samples of OMBs were removed from the peritoneal cavity every 5 minutes. The
OMBs removed after 20 minutes of dwelling in the peritoneal cavity contained ~76% O2
and the SpO2 of the rats was still increasing. Because the oxygen was not completely
diffused from the OMBs and most of the OMBs were removed from the peritoneal
cavity, the maximum increase in systemic oxygenation from an OMB bolus could
possibly occur after 20 minutes in healthy rats. Also, the only decrease in systemic
oxygenation was the respiratory depression from anesthesia because the rats in the
experiment were healthy. In hypoxic rats with ARDS, the oxygen saturation of the blood
will be decreased causing the concentration gradient of oxygen between the OMBs and
blood to be increased. An increased oxygen gradient would theoretically result in a faster
diffusion rate of oxygen from the OMBs and entering the blood. If the diffusion rate of
oxygen from the OMBs is greater in hypoxic rats, the estimated time the systemic
oxygenation peaks from an OMB bolus would be within 30 minutes of the OMB
injection into the peritoneal cavity. The duration of the experiment was set at 60 minutes
to ensure that the peak of increased oxygenation would be measured. A duration of 60
minutes for the experiment was also the approximate interval that a single IP injection of
ketamine-xylazine would sedate a rat [255]. Seven blood samples were collected during
the experiment because the blood volume required for analyzing seven samples
represents less than 10% of the circulating blood volume of a 500 g rat, which is the
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maximum volume that can be removed within a 24 hour period without negatively
effecting the hemodynamics of the rat or oxygen capacity of the blood [225,226]. The
volume collected for seven blood samples also allowed for extra samples to be collected.
A 10 minute interval time between each collection point was required for sufficient time
to analyze each sample immediately after the blood was collected.
The experiment for investigating the increase of oxygen from an OMB bolus was
performed 16 hours after LPS administration. The experiment was chosen to be
performed when the rats were most critically ill and hypoxic to ensure the greatest
oxygen gradient and rate of oxygen diffusion from OMBs. Thus, PMO therapy would
theoretically be more effective and the oxygenation increase from OMB treatment easier
to discern. Additionally, enough time was allowed to implant the femoral arterial
catheter, wean off isoflurane and oxygen anesthesia, and conduct the experiment before
the rat was at the greatest risk of dying from ARDS. The mortality from ARDS in the
model characterized was 27.3% with three rats dying 21-24 hours and four rats dying 2132 hours post-insult (Chapter 6). Thus, rats were most critically ill from aerosolized LPS
~20 hours after administration. Thus, sixteen hours post LPS insult was selected as the
rats were suffering the highest degree of hypoxia and there was sufficient time for the
experiment to be completed while the rats had minimal risk of dying during the
experiment.
9.1.1 Treatments to be administered
The maximum bolus volumes that will be administered for future long-term
peritoneal OMB treatments in a ~500 gram conscious rat were determined to be 50 mL
(Chapter 5.1). Thus, to determine when oxygenation from PMO therapy in a rat with
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ARDS would be optimum, a 50 mL bolus of OMBs was infused into the peritoneal
cavity. OMBs used in evaluation of PMO therapy are composed of 30% saline, thus each
OMB dose of 50 mL contains 15 mL saline [179,191,192,197]. Therefore, 15 mL saline
was infused to represent a control treatment with an equivalent fluid volume to OMBs.
To replicate a treatment that possessed the same gas and fluid volumes, inert gas
microbubbles (IMBs) were used. IMBs are equivalent to OMBs in their manufacturing
process, PEG surface structure, and lipid monolayer composition. Instead of O2, the
phospholipid membrane of IMBs encapsulates a biologically inert gas, sulfur
hexafluoride (SF6). A 50 mL bolus of IMBs was infused as a control for the physical
properties of OMBs and to further confirm that the therapeutic benefits of OMBs for
hypoxia are attributes of the OMBs’ oxygen carrying and delivery properties.
9.2 Materials and Methods
All animal studies were performed in accordance with the University of
Nebraska-Lincoln, IACUC. Male Wistar rats (n = 14, m = 530.4 ± 27.7 g) were housed
individually with free access to food and water. The animals were randomly assigned
housing by the animal facility staff and allowed to acclimate 4 days before the study. Rats
were sedated and induced with ARDS as described previously (Section 6.2.1). LPS
(Escherichia coli 0111:B4, L 2630, Sigma-Aldrich, St. Louis, MO) at a dose of 7 mg/kg
was administered into the lungs through the trachea with a rodent aerosolizer
(MicroSprayer®Aerosolizer IA-1B-R, PennCentury, Inc., Wyndmoor, PA). Rats were
returned to their home cage and allowed to recover from anesthesia and endotoxin shock.
Approximately 16 hours after LPS administration, rats were sedated in an induction
chamber with 5% isoflurane. When they were fully sedated and unresponsive to a paw
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pinch, the rats were removed from the chamber and placed in the prone position on a
warming pad set at 38°C (T/pump Classic, Gaymar Industries, Inc., Orchard Park, NY).
The pulse oximeter sensor (PhysioSuite MouseSTAT®, Kent Scientific Corporation,
Torrington, CT) was positioned on the rat’s hind paw to monitor and record the vitals of
SpO2 and heart rate for the duration of the experiment (Figure 9.1).
The right hind leg was then shaved and sterilized with povidone-iodine and
isopropyl alcohol scrubs. A small skin incision was made into the leg to expose and
isolate the femoral artery. The artery was ligated distally and lightly pinched to limit
blood loss when a small cut was made into the artery for inserting a femoral catheter
(504118, World Precision Instruments, Sarasota, FL). The catheter was secured into the
artery with suture and sealed with a 21G needle (Monoject 250 #8881250172, Covidien,
Minneapolis, MN) and injection plug (SRIP2V Surflo, Terumo Medical, Somerset, NJ).

Figure 9.1: Setup of the study to determine the peak oxygenation from OMB bolus in a
rat with ARDS.
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The leg incision was loosely sutured closed and covered with sterile gauze wetted with
sterile saline. The rat was then given an IP injection of ketamine-xylazine (18-2 mg/kg)
and weaned off of isoflurane and 100% O2. Once the oxygen levels of the rat stabilized
while breathing room air, the baseline blood sample was collected and analyzed (ABL80
FLEX CO-OX, Radiometer, Brea, CA). The rat was randomly treated with an
intraperitoneal bolus of OMBs, IMBs, or saline (t = 0 min). The volume injected was 50
mL of OMBs, IMBs, or the fluid volume equivalent 15 mL of saline. Blood samples were
then collected every 10 minutes for 60 minutes for a total of 7 blood samples including
the baseline.
At the end of 60 minutes or when the rat began to awaken from the anesthetic
ketamine-xylazine, the rat was euthanized by carbon dioxide inhalation following
approved IACUC guidelines. The lungs were excised with the right lung fixed for
histology and injury scoring, while the left lung was weighed to measure wet/dry ratios
both as described previously (Chapter 6.2.3). The histological scores and W/D ratios
were used to confirm degree of lung injury to previous LPS insulted rats.
9.2.1 Statistics
The PaO2 and FO2Hb were fitted with a repeated measures model where the
within-subjects variable was time. Statistical difference was then determined with the
Tukey-Kramer multiple comparison test. Analysis of variance (ANOVA) with separate
means followed by the Tukey multiple comparison test was performed on lung injury
scores and wet/dry ratios to test for any differences between groups. All tests used the
same level of significance (α = 0.05).
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9.3 Results
Male Wistar rats (n = 14, m = 530.4 ± 27.7 g) were aerosolized with LPS and
developed physical symptoms of ARDS similar to previously characterized trials
(Chapter 6.3). Rats were sedated and successfully implanted with a femoral artery
catheter for short term blood sampling approximately 16 hours after LPS administration.
However, five rats died after IP injection of ketamine-xylazine while being weaned off of
100% O2. The remaining nine rats (n = 9, m = 525.6 ± 25.5 g) had a baseline blood
sample collected and randomly injected with 15 mL saline or 50 mL of OMBs or IMBs.
In one rat treated with OMBs, samples collected 40, 50, and 52 minutes after the bolus
was injected were excluded as air contaminated the sample during analysis. This OMB
treated rat also began to awaken 52 minutes after the OMB bolus was infused so, was
euthanized before a sample was collected at 60 minutes after the bolus. Two other blood
samples were excluded from the study due to air contamination in a saline treated rat at 0
minutes and in an IMB treated rat 10 minutes after bolus injection.
Pulse oximetry was used for monitoring the vitals of the rats during the procedure.
Average SpO2 readings indicated rats were moderately to severely hypoxic at the start of
the experiment when the bolus was injected (Figure 9.2a). As the depth of anesthesia
decreased over the experiment, oxygenation of the rats recovered to be mildly hypoxic.
Stepwise shifts in SpO2 and heart rate values indicated times when the sensor on the paw
was disturbed by injecting the peritoneal bolus or collecting blood samples. The average
SpO2 values of the rats injected with OMBs increased immediately after infusion and 510 minutes earlier than the rats treated with saline that experienced a continued decrease
in SpO2s shortly after peritoneal infusion. Average SpO2 readings from the rats infused
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with IMBs increased after injection, but were noticeably erratic during the experiments.
The heart rates measured were depressed from anesthesia, but remained within the
accepted range (Figure 9.2b) [55,240–242]. The average heart rate of OMB rats increased
45 minutes after bolus injection, which corresponded to the effective time limit for
anesthesia with an IP of ketamine-xylazine. In contrast, the average heart rates of IMB
and saline treated rats decreased approximately 45 minutes after intraperitoneal bolus
infusion.

Figure 9.2: Average (a) SpO2 and (b) heart rate recorded by pulse oximeter after
peritoneal bolus injection.
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The PaCO2 of rats were slightly elevated from normal levels at the start and
marginally decreased toward the end of the experiment (Figure 9.3a). The PaO2 and
FO2Hb values matched those from the pulse oximeter and indicated that rats experienced
moderate to severe hypoxia at the start of the experiment (Figure 9.3b, 9.4). The PaO2s
and FO2Hbs of OMB rats increased after the bolus injection (t=0 min) and the 10 minute
samples. In contrast, the PaO2 and FO2Hb of rats infused with IMBs and saline decreased
at 10 minutes and increased at 20 minutes.

Figure 9.3: Average (a) PaCO2 and (b) PaO2 analyzed from blood samples after bolus
injection. Error bars indicate the standard deviation of the mean.
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Figure 9.4: Average oxygen saturation of hemoglobin in blood samples analyzed by
hemoximetry after bolus injection. Error bars indicate the standard deviation of the mean.
9.3.1 Slopes of blood oxygenation
To determine when the increased oxygenation from intraperitoneal OMBs was
greatest, the rate the oxygen levels changed was evaluated and compared to rats treated
with intraperitoneal IMBs and saline. The average slopes of blood oxygenation were
evaluated from the baseline when bolus was injected (t=0 min) to subsequent sample
times and between two consecutively collected sample times. From the baseline to each
sample point, the average PaO2 and FO2Hb slopes were positive for the OMB treated rats
(Figure 9.5). The greatest magnitude of the average PaO2 slopes was 0.55±0.17
mmHg/min at 20 minutes after OMB injection, while the average FO2Hb slopes had a
peak magnitude of 0.94±0.37 %/min after 10 minutes. The average slopes of blood
oxygenation from the bolus injection of saline were negative at 10 minutes and were
positive at the 20 minute sample, while the average slopes of blood oxygenation for rats
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injected with IMB boluses were negative during the entire experiment. For the OMB and
saline trials, the average slopes of blood oxygenation in the interval between each blood
sample corresponded to the average slopes measured between the baseline and each
sample point (Figure 9.6). The greatest average magnitude in the PaO2 interval slopes was
0.65±0.21 mmHg/min at 10-20 minutes after OMB injection while the average FO2Hb
slopes had a peak magnitude of 0.94±0.37 %/min from 0-10 minutes. The average

Figure 9.5: The mean rate (a) PaO2 and (b) FO2Hb changed from the baseline after the
bolus was injected (t=0). A time offset of ±1 minute was added to prevent overlap. Error
bars indicate the standard deviation of the mean.
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interval slopes of blood oxygenation in IMB rats corresponded to the trend of the saline
infused group and had a positive rate of change in blood oxygen values between the 10
and 20 minute samples.

Figure 9.6: The mean rate (a) PaO2 and (b) FO2Hb changed between each sample period.
Error bars indicate the standard deviation of the mean.

166
9.3.2 Histology, lung injury scoring, and W/D
Lung tissue was collected and fixed in formalin for sectioning as described
previously in Chapter 6.2.3. The H&E stained images were then evaluated by an
independent pathologist for lung injury scoring. The lung injury scores were not
significantly different between the IP bolus treatments of OMBs, IMBs, and saline
(Figure 9.7). Overall, edema scores averaged below 0.5 and were not statistically
different than edema scores from rats euthanized 3 days after being aerosolized with LPS
(LPS3). Edema scores were significantly less severe compared to the scores of rats that
died one day after LPS administration (LPS1). Only slight indications of hemorrhage

Figure 9.7: The lung injury scores from the bolus diffusion study (OMB1, IMB1, Sal1)
compared to the ARDS characterization study (LPS1, LPS3). Error bars indicate the
standard error of the mean.
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were observed from two sections of OMB and IMB lungs and were scored with an injury
score of one. Inflammation scores from the rats treated with an OMB bolus were not
significantly different than LPS3 rats (p < 0.05), but significantly less severe overall
compared to LPS1 rats (p > 0.05). In contrast, rats injected with peritoneal IMBs and
saline were not significantly different to rats that had died one day after LPS
administration (p > 0.05).
The left lungs of all rats infused with an intraperitoneal bolus were collected and
weighed for wet and dry weights. A corrupted data file resulted in the loss of the dry
weights for the OMB treated rats. The wet/dry ratios of IMB and saline treated rats were
4.92 ± 0.20 and 4.70 ± 0.25, respectively, and were not significantly different from each
other. The combined W/D of IP treated rats with ARDS (LPS+IP) was 4.81 ± 0.23 and
significantly less than LPS1 rats (p < 0.05), but not statistically different than the LPS3
rats (Figure 9.8).

Figure 9.8: The W/D ratios from the bolus diffusion study (LPS+IP) compared to the
ARDS characterization study (LPS1, LPS3). Error bars indicate the standard deviation of
the mean.
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9.4 Discussion
To discover when the oxygen increase from an OMB bolus treatment occurred, an
experiment administering intraperitoneal boluses was conducted in rats suffering from
ARDS. Rats inflicted with ARDS were confirmed as moderately to severely hypoxic
from pulse oximetry, arterial blood gases, and hemoximetry approximately 16 hours postLPS. At the beginning of the experiments, baseline values of SpO2, PaO2, and FO2Hb
were ~70%, 50 mmHg, and 60%, respectively, for OMB and saline trials (Figure 9.2a,
9.3b, 9.4). In contrast, SpO2, PaO2, and FO2Hb values in IMB rats indicated only mild
hypoxia of ~85%, 70 mmHg, and 85%. The degree of hypoxia was attributed to a
combination of ARDS induced with LPS and respiratory depression from ketaminexylazine anesthesia. Ketamine-xylazine cocktails used for sedating rats were reported to
decrease the PaO2 to 63-73 mmHg or by approximately 24% for 60 minutes after
injection [56,255,256]. The enduring hypoxia at the end of the experiment was attributed
to respiratory injury of ARDS as the oxygen levels remained indicative of hypoxia when
the effects of ketamine-xylazine were ceasing.
A high mortality occurred in the study after injection of ketamine-xylazine
(35.7%, 5/14). The high mortality was considered a result of the combined stress from
ARDS and anesthetic, however, a defective batch of ketamine was suspected as an
additional factor. The mortality rates from ketamine-xylazine anesthesia from our earlier
studies in healthy rats corresponded the reported mortality of 16.7% (1/6) [257].
However, a mortality rate of ~33% from ketamine-xylazine cocktails administered to
male rats was reported by other facilities and UNL’s clinical veterinarian when the study
was conducted (unpublished data). Though a defective batch of ketamine was never
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officially confirmed, when the UNL facility switched to a different batch of ketamine, the
mortality rate in male rats was decreased to the reported mortality rate of anesthetic
ketamine cocktails.
Immediately after the injection of the OMB boluses, rats experienced an increase
in SpO2, PaO2, and FO2Hb while the measurements of systemic oxygen in the saline and
IMB infused rats did not increase until 20 minutes after (Figure 9.2a, 9.3b, 9.4). To
determine when the increased oxygenation from peritoneal infusion of OMBs was
maximal, the rate the blood oxygen levels changed was evaluated and compared. Average
slopes for blood oxygenation were evaluated from the baseline when the bolus was
injected (t=0 min) to subsequent sample periods and from the interval between each
collected sample. When the peritoneal bolus was injected to each subsequent sample
point, the average PaO2 and FO2Hb slopes were positive for the OMB treated rats (Figure
9.5). For the OMB trials, the greatest magnitude of the PaO2 slopes was at 20 minutes
after OMB injection and in the 10-20 minute interval, while the average slopes of FO2Hb
peaked 10 minutes after OMBs were infused. The average magnitude of the slopes for
blood oxygenation stabilized 30 minutes after the OMB treatment. Thus, the time when
blood oxygenation reflected the greatest increase from OMB bolus treatment was 20
minutes after injected into the peritoneal cavity. However, no statistical differences were
determined in the PaO2 and FO2Hb values or their average slopes between the treatment
groups of saline, IMBs, and OMBs (p < 0.05).
The slopes from the bolus injection of IMBs remained negative the entire duration
of the experiments. The negative slopes for blood oxygenation were considered a result
from multiple contributing factors. High oxygenation values were measured in rats
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infused with IMBs at the start of the experiments and was attributed to IMB rats possibly
suffering less lung injury, being healthier, or not being sedated as deeply. Additionally,
IMBs infused into the peritoneal cavity was considered to be a diffusion “sink” for
oxygen as the IMB perfusate contained an oxygen concentration of approximately zero
percent. The oxygen in the blood then diffused into the IMBs within the cavity due to the
concentration gradient and contributed to the greater negative slopes for blood
oxygenation measured in the interval immediately after IMB infusion.
This study was limited by several issues. The first was that the sample sizes of the
treatment groups were considerably decreased by the high mortality from the
combination of anesthetic drugs and LPS. The data obtained from the study were
sufficient to achieve the objective, but the differences observed between treatment groups
and oxygenation at sample times were not statistically significant. Another limitation was
how the rats were affected by ketamine-xylazine. All individuals reacted slightly
differently to the injectable drugs either in the time to become sedated, depth of
anesthesia reached, and recovery time. Thus, all experiments began the same time after IP
injection with ketamine-xylazine. Overall, rats started to recover from anesthesia 65
minutes after IP infusion of the treatment bolus. The final limitation was that the rats in
the IP bolus groups were not evidenced to be as affected by LPS as previous trials
performed in the ARDS characterization study. From the lung injury scores and W/D
ratios, the degree of injury in LPS+IP rats corresponded more to rats with ARDS
euthanized 3 days after LPS than ARDS rats 24 hours post-insult (Figure 9.7, 9.8).
However, samples collected from rats 24 hours after LPS (LPS1) were the most severely
injured as they died from ARDS. The LPS1 rats were possibly not a true indication for
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the typical severity of lung injury 24 hours after aerosolized LPS. The IMB rats from this
study were further evidence that the severity of lung injury from LPS was decreased. The
three IMB rats were only mildly hypoxic from the combination of LPS and anesthetsia
throughout the duration of the experiments.
9.5 Conclusion
This experiment in rats suffering from ARDS investigated when the oxygen
saturation in the blood peaks from a peritoneal injection of the OMB bolus. The greatest
increase in blood oxygenation from an OMB bolus treatment was determined to be the
optimal time for sampling blood and pulse oximetry. Intratracheal LPS of 7 mg/kg
produced mild hypoxia 16 hours after administration and when combined with an IP
injection of ketamine-xylazine, the respiratory depression was increased to moderate to
severe hypoxia. Analysis of pulse oximetry, arterial blood gases, and hemoximetry
completely characterized the oxygen saturation of the rats in the experiments. Lung
injury scores, W/D ratios, and pulse oximetry indicated the severity in ARDS induced by
aerosolized LPS was possibly decreased from the ARDS characterization study (Chapter
6). The slope comparison of blood oxygen levels confirmed that the diffusion of oxygen
from OMBs within the peritoneal cavity was maximal 20 minutes after infusion of the
OMB bolus. Thus, blood and pulse oximeter samples should be collected 20 minutes
after infusion of the OMB bolus in rats with ARDS to measure the optimal improvement
in systemic oxygenation due to peritoneal OMB treatment. The best representation of
clinical benefit of PMO therapy was consequently capable of being validated in a long
term study with hypoxic rats inflicted our characterized model of ARDS.
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Chapter 10: PMO therapy for improving the oxygenation of rats
inflicted with ARDS
PMO treatment with OMBs was demonstrated to provide a significant
improvement in studies of acute hypoxia attributed to physical trauma. When PMO
therapy was administered to rats with a lethal right pneumothorax, the rats maintained
normal levels of peripheral oxygen saturation and 0% mortality. In treating asphyxiated
rabbits, the survival time until cardiac arrest occurred was increased by approximately 1.7
compared to saline treated controls. The current study addresses the goal for the further
validation of PMO therapy in treating rats with hypoxia induced by a respiratory disease
model. A characterized ARDS model in rats was previously confirmed to elicit
significant and prolonged hypoxia from pulse oximetry and arterial blood gas analysis
(Chapter 6). Additionally, the optimal improvement in systemic oxygenation due to PMO
therapy was determined to occur 20 minutes after peritoneal infusion of the OMB bolus
by blood and pulse oximeter samples collected in sedated rats with ARDS (Chapter 9).
Thus, PMO therapy was administered to rats experiencing ARDS to validate that
prolonged periods of hypoxia from a respiratory disease can be alleviated by providing
supplemental oxygenation with repeated boluses of OMBs.
10.1 Design
The treatments investigated were OMBs for PMO therapy, saline as a fluid
volume control, and IMBs as a microbubble control. The reasoning for administering
these peritoneal infusates and volumes was described previously (Chapters 5.1 and 9.1.1).
An intraperitoneal catheter, the Jackson-Pratt catheter, was selected to be
implanted for delivering treatment boluses due to the JP catheters high effectiveness at
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removing OMBs from the peritoneal cavity in previous studies [191]. However, in
preliminary trials completed, the JP catheters failed to drain saline and OMBs from the
abdominal cavity after seven days designated as a recovery period from the catheter
implant surgery. The failure of the catheters forced a premature end to the preliminary
trials because the drainage of previous saline and OMB bolus infusions was not
accomplished. The infusion of additional treatments through the JP catheter was still
possible, so the treatment regimen was altered to avoid causing high abdominal pressures
that pose a risk to the animal [21,123–126]. While a new peritoneal catheter was
investigated, a reduced bolus regimen was implemented to evaluate the effectiveness of
PMO therapy in treating rats with ARDS. The reduced bolus regimen decreased the
volume of the fresh treatment bolus by 20% from the previous bolus volume
administered. Thus, the current bolus to be delivered, Vi, depended upon the volume of
the previous bolus treatment infused, Vi-1 by the equation:
𝑉𝑖 = 0.8 ∗ 𝑉𝑖−1

[Eq. 10.1]

The maximum treatment dose was administered 3 hours after LPS insult with 50 mL for
the OMB and IMB treatments and 15 mL for the saline treatments. The reduced bolus
regimen decreased the bolus volume of the treatment as the rat recovered from ARDS
and permitted time for the fluid volume of an infused bolus to be adequately absorbed
[201–203].
10.2 Materials and Methods
All animal studies were performed in accordance with the University of
Nebraska-Lincoln, IACUC. Male Wistar rats (n = 10, m = 490.0 ± 26.2 g) were housed
individually with free access to food and water. The animals were randomly assigned
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housing by the animal facility staff and acclimated for 4 days after arrival at the facility.
Rats were sedated and implanted with a femoral artery catheter as described in Chapter
6.2.2b and a JP peritoneal catheter as described in Chapter 5.2.1. Both catheters were
implanted using the same incision in the upper right leg and subcutaneously routed to the
same back incision for external access. Rats were allowed to recover from the catheter
surgery for seven days with the femoral arterial catheter being flushed with heparinized
saline every 12 hours (Figure 10.1). ARDS was induced in all rats with 7 mg/kg LPS
(Escherichia coli 0111:B4, L 2630, Sigma-Aldrich, St. Louis, MO) as described
previously (Section 6.2.1). While rats were sedated, LPS was administered into the lungs
through the trachea with a rodent aerosolizer (MicroSprayer®Aerosolizer IA-1B-R,
PennCentury, Inc., Wyndmoor, PA). Rats were randomly to a treatment group receiving
IP boluses of OMBs, IMBs, or saline and returned to their home cage to recover from the
aerosol administration procedure. Three hours after LPS aerosol insult, all rats were
infused with an initial bolus of 15 mL of saline, 50 mL of OMBs, or 50 mL of IMBs.

Figure 10.1: Timeline of surgical procedures and daily sampling schedule conducted in
the PMO treatment of ARDS trials.
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Arterial blood and pulse oximetry was collected 20 minutes after the treatment bolus as
this time after infusion was determined to be when the increase in oxygen saturation due
to a bolus of OMBs was maximal (Chapter 9).
10.2.1 Daily sample collection
Daily sample collection for mass, pulse oximetry, chest radiographs, and arterial
blood followed the same procedure as the ARDS characterization trials detailed in
Chapter 6. Baseline measurements were collected for samples 12 hours before aerosol
administration of LPS on day 0. After LPS administration, weight, pulse oximetry, and
blood were sampled approximately every 12 hours while chest radiographs were recorded
in the morning every 24 hours (Figure 10.1). Every collection session started with
measuring the respiratory rate three times in 20 second intervals while the rat was resting
in its cage. The rat was then removed from the cage to measure its mass and infuse the
intraperitoneal treatment bolus through the JP catheter. The rat was returned to its cage
for 20 minutes when pulse oximetry and arterial blood was collected.
The rat was restrained, but not sedated for pulse oximetry (PhysioSuite
MouseSTAT®, Kent Scientific Corporation, Torrington, CT) and the collection of
arterial blood. The pulse oximeter sensor was positioned on the rat’s hind paw with the
end of the pulse oximeter clip over the fourth metatarsal (Figure 6.3). Measurements
were monitored in 5 second averages and recorded every second when the pulse oximeter
waveform was sinusoidal and consistent. The measurements recorded in a period greater
than one minute were averaged to establish a single value for the session.
Blood samples were collected from the femoral artery catheter and analyzed for
blood gases and hemoximetry (ABL80 FLEX CO-OX, Radiometer, Brea, CA). The
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sample volume required for performing the blood analysis was 0.1 mL. Safe blood
collecting guidelines were followed with less than 1% of the total circulating blood
volume and a maximum of three samples collected per day [225,226]. A third blood
sample was collected if an error occurred in the analysis during one of collection points.
Rats were anesthetized with 5% isoflurane in an induction chamber to perform
chest radiographs on days 1-3 after pulse oximetry and arterial blood was collected. The
rats were radiographed (PRX 90, Bowie International LLC, Lake City, IA) in the dorsalventral and left lateral positions. Thoracic radiographs were recorded to investigate the
effect of IP treatments on the presence of pulmonary edema, alveolar consolidation, and
bilateral infiltrates. Once the radiographs were imaged, the rat as returned to its cages to
recover from anesthesia.
10.2.2 Histology and wet/dry ratio
The lungs were fixed by intratracheal instillation of 5 mL of 10% buffered
formalin, and then suspended in 30 mL of formalin. Lungs were submitted to an
independent pathologist for blind sectioning, hematoxylin and eosin (H&E) staining
(Ventana Symphony, Ventana Medical Systems, Inc., Tucson, AZ), and injury scoring.
Lung sections were imaged with a microscope (Eclipse 55i, Nikon Instruments, Melville,
NY) at a magnification 100X after H&E staining for visual comparison and analysis.
Histological lung injury analysis of four right lung sections from each animal included
alveolar edema, intra-alveolar hemorrhage, and inflammation score on a 0-3 scale with 0
indicating an absence of pathology and 3 indicating severe pathology [227].
Inflammation scoring was based on the amount of leukocyte infiltration, excluding
eosinophils.
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The left lung was used for measuring the wet and dry weights. Once the lungs
were excised from the rat, the left lung was separated by cutting of the left bronchus. The
left lung was immediately weighed on a scale (CX220, Citizen Scales, Maharashtra,
India) to measure the wet weight. The left lung was then placed in an oven for three days
at 60°C and reweighed afterwards for the dry weight [228,229].
10.2.3 Statistics
Log-rank (Mantel-Cox) test was used to compare the mortality rates between each
experimental group for any differences. Analysis of variance (ANOVA) with separate
means followed by the Tukey multiple comparison test was performed on lung injury
scores and wet/dry ratios to test for any differences between groups. Repeated measures
ANOVA was used to compare the SpO2 group means of each collection period. All tests
used the same level of significance (α = 0.05).
10.3 Results
Male Wistar rats (n = 10, m = 490.0 ± 26.2 g) were successfully implanted with a
femoral artery and peritoneal catheter with no dropouts from failure of the femoral
catheter occurring. Rats were aerosolized with LPS and developed physical symptoms of
ARDS similar to previously characterized trials (Chapters 6 and 9). No rats died from the
respiratory illness that resulted due to aerosolized LPS. However, during the study five of
the rats were not infused with the entire bolus volume predetermined by the reduced
bolus regimen (Eq. 10.1) as the JP peritoneal catheters began to leak from the back
incision. Partial treatment boluses were infused through the failed catheters until fluid
leaked (Table 10.1). The partial bolus volumes infused with the failed JP catheter were
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recorded; however, the amount of the treatment actually delivered into the peritoneal
cavity successfully was unknown.
The average respiratory rate in breaths per minute (bpm) was measured in all rats
prior to being removed from their cage for sample collection. The respiratory rates of rats
inflicted with ARDS increased in all groups 12 hours after LPS (Figure 10.2). At 24
hours after LPS, the average respiratory rate of the IMB and saline groups increased
39.1% and 48.8% from the baseline, respectively. The respiratory rate for OMB treated
rats experienced the greatest increase of 71.6% from the baseline 36 hours post-insult.
The average respiratory rate of all groups plateaued at 36 hours and decreased until the
end of the observation period.
Table 10.1: Volumes infused into the peritoneal cavity in the PMO -ARDS
trials.
Time
Treatment
after LPS
#
(hours)
1
2
3
4
5
6
7

3
12
24
36
48
60
72

Volume infused in
functional catheters
(mL)

Volume infused in failed peritoneal
catheters (mL)

OMB/IMB

Saline

OMB
#1

OMB IMB IMB
#2
#1
#2

50
40
32
25.6
20.5
16.4
13.1

15
12
9.6
7.7
6.1
4.9
3.9

27
21.6
17.3
13.8
11.1
8.8
7.1

50
35
24
19.2
15.4
12.3
9.8

20
16
12.8
10.3
8.2
6.6
5.3

50
40
14
0
0
0
0

Saline
#1
7
5.6
4.5
3.6
2.9
2.3
1.8
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Figure 10.2: The average respiratory rate counted for the PMO-ARDS rats. Error bars
indicate the standard deviation of the mean.
10.3.1 Pulse oximetry and blood oxygenation
Pulse oximetry measurements indicated the rats developed mild hypoxia 3 hours
after the administration of LPS (Figure 10.3). The OMB treated group experienced a
maximum decrease of 6.3% in the average SpO2 at 3 hours post-insult and subsequently
returned to the baseline 36 hours after LPS. The average SpO2 of the IMB group
decreased 12.4% from baseline at 12 hours post-insult and frequently fluctuated with the
lowest average SpO2 observed 36 hours post-LPS. The average SpO2 for the saline infused
rats exhibited the greatest decrease from the baseline at 14.0% after 12 hours, but then the
average SpO2 with saline treatment increased for the remainder of the experiment.
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Figure 10.3: Average peripheral oxygen saturation of PMO-ARDS trials. Error bars
indicate the standard deviation of the mean.
At 3 hours post-insult, the average partial pressures of carbon dioxide in arterial
blood (PaCO2) increased 42.1% and 37.2% from the average baseline for the OMB and
saline groups, respectively (Figure 10.4a). The average PaCO2 in the two treatment
groups returned to baseline values 12 hours after LPS administration. The PaCO2 of the
IMB treated rats decreased 13.5% from baseline after 12 hours then remained consistent
for the duration of the observation period. Three hours post-insult, the average partial
pressures of oxygen (PaO2) increased 26.5%, 11.3%, and 13.3% for the OMB, IMB, and
saline groups, respectively (Figure 10.4b). The PaO2 for all groups subsequently
decreased at 12 hours and returned to baseline values. The average PaO2 of saline and
OMB treated groups indicated that rats experienced mild hypoxia 48 hours after
administration of LPS, while the IMB treated group exhibited similar fluctuations in the
measured average of PaO2 and SpO2.
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Figure 10.4: Average partial pressures of (a) carbon dioxide and (b) oxygen
measurements of arterial blood. Error bars indicate the standard deviation of the mean.
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Figure 10.5: Average oxygen saturation of hemoglobin in blood samples analyzed by
hemoximetry 20 minutes after bolus treatments. Error bars indicate the standard deviation
of the mean.
The hemoximetry results from collected blood samples exhibited little differences
between the three peritoneal treatments for ARDS (Figure 10.5). The averages for
fraction of oxyhemoglobin (FO2Hb) were ~95% in the IMB and saline groups during the
entire study except for a decreased in the average FO2Hb of the IMB group at 12 hours
after LPS administration. The OMB treated group was ~95% until 36 hours post-insult
when the average FO2Hb decreased a total 3.2% from baseline by the end of the 72 hour
observation period.
10.3.2 Chest radiographs
The baseline radiographs exhibit no sign of pre-existent or current respiratory
pathology (Figure 10.6). The radiographs of the PMO-ARDS groups exhibited some
features of diffuse bilateral infiltrates. However, the development of the diffuse bilateral
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infiltrates was not as pronounced as those seen in the radiographs of the LPS trials of the
ARDS characterization study.

Figure 10.6: Representative chest radiographs of the healthy baseline (day 0) and one
day after aerosol administration.
10.3.3 Histology, lung injury scoring, and W/D
The excised lungs of PMO-ARDS rats appeared to possess limited visual features
of congestion and edema (Figure 10.7). The H&E sections of the lungs exhibited minimal
signs of alveolar edema or intra-alveolar hemorrhage with moderate degrees of leukocyte
infiltration. The sections in all treatment groups showed slight thickening of the alveolarcapillary membranes.
Lung tissue was successfully collected and fixed in formalin for sectioning when
the rats were euthanized 3 days after aerosolized LPS. The H&E stained images were
then evaluated by an independent pathologist for lung injury scoring. The lung injury
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scores were not significantly different between the bolus treatments of OMBs, IMBs, and
saline (Figure 10.8). Overall, edema scores of the PMO-ARDS rat lungs averaged mostly
below 0.25 and were significantly less (p < 0.05) than the edema scores from the lungs of
rats in the ARDS characterization study collected at the same time after LPS (LPS3).
Three sections of OMB lungs and one section of IMB and saline lungs were scored with
an injury score of one due to slight indications of hemorrhage. The inflammation scores
from the saline bolus treated rats were less severe overall compared to OMB and IMB
rats though it was not significant. Inflammation of IP saline treated rats was significantly
less than rats from the ARDS characterization study (p < 0.05).
The left lungs of all rats in the PMO-ARDS study were collected and weighed for
wet and dry weights. The W/D ratios of OMB, IMB, and saline treated rats were
5.15±0.31, 5.50±0.20, and 5.19±0.21 respectively, and were not significantly different
from each other (Figure 10.9). The W/D of IMB treated rats was significantly greater
than the previous ARDS study of LPS3 rats (p < 0.05).

Figure 10.7: Characteristic images of rats’ excised lungs (top row). Representative H&E
stained sections (bottom row) from each group were imaged at a 100X magnification.
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Figure 10.8: Injury scoring of lung sections for all IP treatments of ARDS compared to
scores of previous ARDS trials collected 3 days after LPS. Bars represent mean with
standard error of the mean.

Figure 10.9: Average W/D ratios of PMO-ARDS trials. Error bars indicate the standard
deviation of the mean.
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10.4 Discussion
In this study, rats with ARDS were treated with intraperitoneal bolus injections of
OMBs, IMBs, or saline every 12 hours for 3 days after aerosolized with LPS. Due to the
failure of the Jackson-Pratt catheters in preliminary trials, a reduced bolus regimen was
implemented to infuse peritoneal treatment without causing harmful intra-abdominal
pressures. The reduced bolus regimen involved each bolus treatment to be decreased by
20% from the previous treatment where the initial bolus volume was 50 mL for the OMB
and IMB groups and 15 mL for the saline group. The oxygen levels were measured by
pulse oximetry, ABG analysis, and hemoximetry to determine if there was an increase in
oxygenation due to PMO therapy with OMBs.
Immediately after aerosolized with the LPS, rats experienced a decreased S pO2
and an increased PaO2, and PaCO2 (Figure 10.3, 10.4). Pulse oximetry suggested that the
rats developed mild hypoxia 3 hours after the administration of LPS. However, P aO2
averages were above normal levels and FO2Hb averages were on the margin between
normal levels and mild hypoxia for the entire duration of the study. The average SpO2 of
saline and IMB treated groups decreased 14.0% and 12.4% from the baseline after 12
hours of ARDS, where the saline group started to return to the baseline while the IMB
group fluctuated around 85% (Figure 10.3). The average SpO2 of the OMB treated group
decreased 6.3% from the baseline at 3 hours post-insult which was half the decrease in
SpO2 experienced by the other two groups. Additionally, the average PaO2 for the OMB
group increased approximately twice as much as the IMB and saline groups (26.5% vs.
11.3% and 13.3%). Therefore, PMO therapy slightly increased the oxygen saturation of
rats inflicted with ARDS because the rats infused with OMBs exhibited a smaller
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decrease SpO2 and a greater increase in PaO2 compared to rats administered the saline and
IMB treatments. However, the difference in the two parameters of oxygenation was not
significant (p > 0.05). The increased levels of SpO2 and PaO2 of the OMB group may
have resulted from the greater increase in the respiratory rate of OMB rats compared to
the saline and IMB treatment groups (Figure 10.2).
A significant complication that occurred in the study was half of the peritoneal
catheters implanted into the rats leaked on the first or second bolus treatment (Table
10.1). When the bolus was infused into a failed catheter, the fluid leaked from the back
incision where the access port of the peritoneal catheter was secured. The failure of the
catheters also occurred in the parallel study performed to discover a replacement for the
Jackson-Pratt catheter currently used (Section 9.4). The failure of the JP catheters
prevented the complete treatment volume to be infused in one saline, two IMB, and two
OMB trials. The measured SpO2 values were not distinguishable between the individual
PMO therapy trials with a partial or complete bolus volume of OMBs. However, rats
inflicted with ARDS and infused with a complete OMB bolus through a working catheter
exhibited increased in blood oxygen levels throughout the study. When only a partial
OMB bolus was infused, the PaO2 and FO2Hb of rats steadily decreased 24 hours postLPS (Appendix E). The difference revealed between the blood oxygen trends of complete
OMB bolus treatments and partial boluses with a leaking catheter merits further
consideration. The importance of using a more effective peritoneal catheter was further
evidenced by the bolus treatments of IMBs. The SF6 gas contained in IMBs was unable to
be removed with the peritoneal catheter resulting in the SF6 gas remained in the cavity for
extended periods (Appendix E). The residual SF6 gas caused an increase in abdominal
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pressure that may have altered hemodynamics and respiratory function by compromising
the function of the diaphragm [123,258]. In future implants of the peritoneal catheters,
the access port of the catheters will be secured more thoroughly by fixing the access port
to the subcutaneous tissue below the back incision. The peritoneal catheter will also be
routed from the abdomen to the back incision less tightly to decrease tension on the
suture, skin, and fascia. Also, the flat fluted drain catheter was selected for use in future
trials in rats to drain bolus treatments that were infused (Chapter 9).
The final limitation of the study was several factors indicated that the severity of
ARDS inflicted to the rats was substantially reduced. Though the same dose of LPS (7
mg/kg) and procedure was used to induce ARDS in the rats, the severity of hypoxia was
decreased from moderate to mild and the infiltrates in the chest radiographs were not as
prominent (Figure 10.6). Additionally, the edema scores of the lungs in the PMO-ARDS
trials were significantly less than those from the ARDS characterization trials even
though both sets of trials were collected 3 days after the LPS was administered (Figure
10.8). The decreased severity of the ARDS model thus requires further investigation to
determine the cause.
10.5 Conclusion
The purpose of this study was to verify PMO therapy as a potential treatment for
delivering oxygen to rats experiencing prolonged hypoxia due to respiratory disease.
Previously, an ARDS model in rats was developed with intratracheally aerosolized LPS
which was characterized by prolonged moderate hypoxia. However, in this study only
mild hypoxia was induced in the rats experiencing ARDS that caused the possible impact
of OMB boluses on oxygenation more difficult to evaluate. When ARDS was treated in
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rats with a reduced bolus regimen of OMBs, rats experienced greater averages in PaO2
and SpO2 compared to control treatments of saline and IMBs. Another hindrance of
evaluating the benefit of PMO therapy for ARDS was the failure of half the peritoneal
catheters implanted. The peritoneal catheters leaked from the back incision which
decreased the treatment volume infused and created suspicion that the bolus treatments
were successfully delivered to the peritoneal cavity. The ARDS rats treated with a
complete OMB bolus regimen through a functional peritoneal catheter experienced an
increase in blood oxygenation sustained for the entire study, while rats treated through a
leaking peritoneal catheter experienced decreased blood oxygenation 24 hours after LPS
insult. Despite the mild severity of ARDS and leaking peritoneal catheters, rats with
ARDS administered PMO therapy exhibited evidence of increased oxygenation in a
hypoxic model of respiratory disease.
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Chapter 11: Conclusions
Peritoneal microbubble oxygenation (PMO) therapy is a novel method of
extrapulmonary oxygenation that involves infusing oxygen microbubbles (OMBs) into
the abdominal cavity where the peritoneum functions as a membrane for gas exchange
and diffusion. The ultimate goal of PMO therapy is to provide supplemental oxygen in
cases of respiratory failure and disease where the use of mechanical ventilation and
ECMO is inadequate or injurious for the patient. In this work, multiple aspects of
progressing PMO therapy towards future clinical trials were explored. Techniques for
infusing OMBs into the peritoneal cavity were developed for administrating PMO
therapy in animal trials. Then, acute respiratory distress syndrome (ARDS) in rats was
characterized for evaluating PMO therapy in a clinically relevant disease model of
hypoxia. Finally, PMO therapy was implemented as a means of delivering supplemental
oxygen to hypoxic animals with critical lung injury.
The first major goal of the research was to develop methods for infusing OMBs
into the peritoneal cavity. Peritoneal infusion was achieved in animal studies by
developing an automated device to infuse fluid treatments and evaluating catheters for
prolonged function in rats. The Peri3 was the automated system created that safely and
accurately administered a bolus treatment or circulated perfusate to the peritoneal cavity.
The Peri3 system was composed of a peristaltic pump, pressure sensors, solenoid, and a
LabVIEW interface. The Peri3 design was light weight and durable to facilitate transport
between the lab and animal facilities. The Peri3 was also designed with the flexibility to
be used in different injury models and animals. The Peri3 device successfully maintained
intra-abdominal pressures below 6 mmHg and administered PMO therapy to sedated rats
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and rabbits. Future iterations of the Peri3 system were developed for OMB treatment of
conscious rats and underwent successful preliminary testing [191]. Another aspect of
infusing OMBs into the peritoneal cavity that was investigated was determining the most
effective catheter for performing prolonged PMO therapy in rats with multiple injections
of OMBs. Through testing of four catheters implanted in the peritoneal cavity of rats for
12 days, the flat fluted drain catheter (072210, Bard Medical, Covington, GA) was
determined to be effective for administering long-term PMO therapy. The flat fluted
catheter was selected to be implanted for future PMO studies in animals.
To evaluate the benefit of PMO therapy in treating hypoxia resulting from
respiratory disease, a model of ARDS was replicated and characterized in rats. The
pathology of ARDS was reproduced in rats by aerosolizing LPS (7 mg/kg) into the lungs.
The characterized ARDS model elicited a mortality rate of 27.3%, significant
inflammation of the alveolocapillary membrane, pulmonary edema, and mild to moderate
hypoxemia. The ARDS model in rats was determined to induce hypoxia with a severity
sufficient for evaluating PMO therapy and other methods of supplemental oxygen
delivery.
Finally, PMO therapy was investigated in hypoxic animal models to validate that
OMB infusion into the peritoneal cavity delivered oxygen in vivo, increased survival, and
increased systemic oxygenation. To validate these properties of PMO therapy, OMBs
were administered as peritoneal treatment for hypoxia in three animal models. The first
animal study was a lung injury model of hypoxia in rats induced by a right
pneumothorax. The pneumothorax of the right lung proved to be a fatal injury as rats
experienced decreased peripheral oxygen saturation and death after 15.8 ± 6.2 minutes
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(n = 11) without OMB treatment [179]. The rats injected with a 107 ± 9 mL bolus of
OMBs (n = 5) survived for 2 hours after pneumothorax to the designed endpoint of the
experiment. PMO therapy of rats with a right pneumothorax demonstrated a 100%
survival and increased SpO2s levels that were normal for healthy sedated rats. Thus, the
infusion of OMBs was confirmed to deliver O2 in vivo and that PMO therapy was
feasible for treating hypoxia by supplying oxygen to the bloodstream. The drastic
improvement of surviving to 2 hours with OMBS compared to the 15.8 minute mean
survival time for controls indicated a significant clinical benefit for mild to severe
hypoxia.
The second hypoxic animal model replicated asphyxia by occluding the trachea of
rabbits. The goal of this study was to test the limits of PMO therapy in a model of
complete respiratory failure more relevant to future clinical trials. Rabbits administered
intraperitoneal treatment of saline suffered cardiac arrest 6.6 ± 0.6 minutes (n = 4) after
the trachea was occluded, while asphyxiated rabbits infused with OMBs survived for a
significantly greater time of 11.7 ± 2.8 minutes. Several observed outcomes of PMO
therapy in asphyxiated rabbits were acknowledged to merit further investigation. The
variance in survival time of OMB treatment and the SpO2 values of OMB perfusion was
significantly increased compared to saline treated controls. Though total systemic
oxygenation with OMBs was not possible in asphyxiated rabbits, local tissue oxygenation
of the abdomen may have substantially increased despite being unable to breathe
(Appendix E). Increasing the diffusion of O2 from the OMBs into the blood of the
splanchnic circuit was hypothesized to possibly improve oxygenation and survival. The
OMB circulation system could be more rigorously optimized by testing how much
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oxygen and CO2 was in the OMBs drained from the peritoneal cavity. The OMB
circulation system could possibly be improved by mixing the OMBs while dwelling in
the cavity to promote the unloading and diffusing of O2. The study in asphyxiation of
rabbits revealed the current system for PMO therapy was able to increase survival, but
inadequate to provide 100% of a sedated rabbit’s oxygen demand because asphyxiated
rabbits exhibited a gradual decrease in SpO2 before death.
The third model evaluated PMO therapy in the ARDS model of hypoxia
characterized in rats. OMBs were confirmed to rapidly deliver O2 to the bloodstream
when infused into the peritoneal cavity of hypoxic rats as the SpO2, PaO2, and FO2Hb
increased within 10 minutes of OMB injection. In contrast, ARDS rats with hypoxia
treated with intraperitoneal saline and IMB did not experience an increase in oxygenation
until they began to recover from anesthesia ~20 minutes after peritoneal injection of the
bolus. The optimal time to sample blood for analysis and pulse oximetry was determined
to be 20 minutes after OMBs were injected from comparison of the slopes of blood
oxygenation. Finally, PMO therapy of rats inflicted with ARDS was administered by
repeated infusions of OMBs boluses. As fluid was not able to be drained from the
peritoneal cavity, the volume of each bolus treatment was reduced by 20% to prevent a
hazardous elevation of intra-abdominal pressures. Despite the hypoxia from ARDS not as
severe as previous trials and peritoneal catheters that leaked infusate from the back
incision, ARDS rats administered PMO therapy exhibited evidence of increased
oxygenation. ARDS rats treated with repeated infusion of OMB boluses experienced a
decrease in average SpO2 of 6.3% from the baseline, while the saline and IMBs treated
rats decreased an average of 14.0% and 12.4% from the baseline. The ARDS rats treated
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with OMBs also experienced an increase in average PaO2 that was twice as much as the
IMB and saline groups (26.5% vs. 11.3% and 13.3%). In addition, ARDS rats treated
with a complete OMB bolus regimen through a functional peritoneal catheter experienced
an increased blood oxygenation that was sustained for the entire study. In contrast, the
rats treated with OMBs through a leaking peritoneal catheter experienced decreased
blood oxygenation 24 hours after LPS insult.
The ultimate objective of this dissertation was to demonstrate that PMO therapy is
a viable treatment option for delivering supplemental oxygen during incidents of hypoxia.
The ultimate objective of the research was accomplished by validating PMO therapy in
three animal models of hypoxia where survival time and systemic oxygenation was
significantly increased with peritoneal infusion of OMBs. Thus, PMO therapy was
concluded to be a potential as a treatment for supplemental extrapulmonary oxygenation
that merits further investigation.
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11.1 Future work
Further work must be done to extend the technology for circulation, removal, and
replenishment of the OMBs in the peritoneal cavity. These engineering challenges are not
major obstacles for ultimate clinical translation given the precedent set by methods of
peritoneal dialysis. Instead from the result of this work, the challenge of OMB circulation
and drainage applies specifically to small animal models and in long term studies where
the animal will be required to be conscious during the treatment. Prior to translation,
however, peritoneal microbubble oxygenation must be examined in additional lung injury
and large animal models.
Additional research must be done to investigate peritoneal microbubble
oxygenation in larger animals, such as swine, where the ratio of the peritoneal area to
total body mass is closer to that of humans. The investigation of PMO therapy in large
animals will contribute towards validating the limits of oxygen diffusion from peritoneal
oxygenation and determining the clinical relevance of PMO therapy as a hypoxic
treatment. To mitigate the limitations of lower surface area ratio and low blood flow in
the splanchnic circuit, the pleural cavity can be perfused to increase the surface area and
blood available for O2 transfer. Pleural microbubble oxygenation is possible by
collapsing one lung with a chest tube and circulating OMBs through the intrapleural
space. As shown in this work, supportive oxygenation through a serous membrane is
feasible due to the high O2 carrying capacity and rapid diffusion capability provided by
OMBs.
The manufacturing of OMBs is another aspect of future research for improving
PMO therapy. Clinical utilization of PMO therapy requires the mass production of OMBs
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to be cost effective and efficient for large scale manufacture. The storage of OMBs also
requires improvement as glass serum bottles and the current shelf life of 2 weeks is not
practical for clinical applications. Research is being conducted in increasing the storage
duration of OMBs and transporting OMBs in gas impermeable plastic containers similar
to IV bags. The safety of OMBs must be evaluated with extensive toxicology studies to
guarantee the prolonged biocompatibility of OMBs as health risks are a significant
limitation of other artificial oxygen carriers. An important aspect of OMBs that requires
investigation is determining if the phospholipids of the OMB membranes are
decomposed, removed, or incorporated into the body without generating harmful
products or if the phospholipids are retained. The OMBs should also be confirmed to not
cause oxygen toxicity or generate large concentrations of reactive oxygen species.
OMBs have demonstrated significant effectiveness at in vivo oxygen delivery.
Thus, OMBs can be investigated for use in other biomedical applications where a demand
for oxygen delivery exists. OMBs can be used to supplement and improve the organ
preservation techniques of static cold storage and machine perfusion. The OMBs would
be added to current organ preservations solutions for delivering oxygen to the tissue and
reducing the incidence of ischemic damage organs experience during transport. In an
unpublished preliminary study we performed, the lobes of rat livers were preserved in
OMBs for 16 hours without developing any histological indications of ischemic injury.
An additional biomedical application of OMBs is cancer treatment. Cancer cells exhibit
increased vulnerability to radiation treatment and cytotoxic drugs when hypoxic
conditions surrounding the tumor are reduced. Thus, an administration of a small volume
of OMBs to the site of the tumor would significantly decrease local tissue hypoxia and
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allow cancer cells to be killed more effectively. OMBs also possess potential for
biomedical research in the field of tissue engineering. OMBs would be utilized for
oxygen delivery to tissue engineered constructs and organs by circulating solutions with
OMBs through the scaffolds or microchannels.
With further research and investigation, PMO therapy possesses substantial
potential as a treatment for supplemental extrapulmonary oxygenation and OMBs can be
utilized for multiple biomedical applications.

198

References
[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]
[9]
[10]

[11]

Loss, S. H., de Oliveira, R. P., Maccari, J. G., Savi, A., Boniatti, M. M., Hetzel,
M. P., Dallegrave, D. M., Balzano, P. de C., Oliveira, E. S., Höher, J. A., Torelly,
A. P., and Teixeira, C., 2015, “The Reality of Patients Requiring Prolonged
Mechanical Ventilation: A Multicenter Study,” Rev. Bras. Ter. Intensiva, 27(1),
pp. 26–35.
Demoule, A., Girou, E., Richard, J.-C., Taillé, S., and Brochard, L., 2006,
“Increased Use of Noninvasive Ventilation in French Intensive Care Units,”
Intensive Care Med., 32(11), pp. 1747–1755.
Linko, R., Okkonen, M., Pettilä, V., Perttilä, J., Parviainen, I., Ruokonen, E.,
Tenhunen, J., Ala-Kokko, T., Varpula, T., and FINNALI-study group, 2009,
“Acute Respiratory Failure in Intensive Care Units. FINNALI: A Prospective
Cohort Study,” Intensive Care Med., 35(8), pp. 1352–1361.
Wunsch, H., Angus, D. C., Harrison, D. A., Linde-Zwirble, W. T., and Rowan, K.
M., 2011, “Comparison of Medical Admissions to Intensive Care Units in the
United States and United Kingdom,” Am. J. Respir. Crit. Care Med., 183(12), pp.
1666–1673.
Wunsch, H., Wagner, J., Herlim, M., Chong, D. H., Kramer, A. A., and Halpern,
S. D., 2013, “ICU Occupancy and Mechanical Ventilator Use in the United
States,” Crit. Care Med., 41(12), pp. 2712–2719.
Vincent, J.-L., Akça, S., de Mendonça, A., Haji-Michael, P., Sprung, C., Moreno,
R., Antonelli, M., and Suter, P. M., 2002, “The Epidemiology of Acute
Respiratory Failure in Critically Ill Patients,” Chest, 121(5), pp. 1602–1609.
Choi, W.-I., Shehu, E., Lim, S. Y., Koh, S. O., Jeon, K., Na, S., Lim, C.-M., Lee,
Y.-J., Kim, S. C., Kim, I. H., Kim, J. H., Kim, J. Y., Lim, J., Rhee, C. K., Park, S.,
Kim, H. C., Lee, J. H., Lee, J. H., Park, J., Koh, Y., and Suh, G. Y., 2014,
“Markers of Poor Outcome in Patients with Acute Hypoxemic Respiratory
Failure,” J. Crit. Care, 29(5), pp. 797–802.
Gunning, K. E. J., 2006, “Respiratory Failure,” Found. Years, 2(6), pp. 251–256.
Ragaller, M., and Richter, T., 2010, “Acute Lung Injury and Acute Respiratory
Distress Syndrome,” J. Emerg. Trauma Shock, 3(1), pp. 43–51.
Vasilyev, S., Schaap, R. N., and Mortensen, J., 1995, “Hospital Survival Rates of
Patients with Acute Respiratory Failure in Modern Respiratory Intensive Care
Units : An International, Multicenter, Prospective Survey,” CHEST J., 107(4), pp.
1083–1088.
Luhr, O. R., Antonsen, K., Karlsson, M., Aardal, S., Thorsteinsson, A., Frostell,
C. G., and Bonde, J., 1999, “Incidence and Mortality after Acute Respiratory
Failure and Acute Respiratory Distress Syndrome in Sweden, Denmark, and

199

[12]

[13]

[14]
[15]
[16]

[17]
[18]

[19]
[20]

[21]

[22]
[23]

[24]
[25]
[26]
[27]

Iceland. The ARF Study Group,” Am. J. Respir. Crit. Care Med., 159(6), pp.
1849–1861.
Flaatten, H., Gjerde, S., Guttormsen, A. B., Haugen, O., Høivik, T., Onarheim,
H., and Aardal, S., 2003, “Outcome after Acute Respiratory Failure Is More
Dependent on Dysfunction in Other Vital Organs than on the Severity of the
Respiratory Failure,” Crit. Care, 7(4), pp. R72–R77.
Esan, A., Hess, D. R., Raoof, S., George, L., and Sessler, C. N., 2010, “Severe
Hypoxemic Respiratory Failure: Part 1—ventilatory Strategies,” Chest, 137(5),
pp. 1203–1216.
Matthay, M. A., and Zemans, R. L., 2011, “The Acute Respiratory Distress
Syndrome: Pathogenesis and Treatment,” Annu. Rev. Pathol., 6, pp. 147–163.
Matthay, M. A., Ware, L. B., and Zimmerman, G. A., 2012, “The Acute
Respiratory Distress Syndrome,” J. Clin. Invest., 122(8), pp. 2731–2740.
Walkey, A. J., Reardon, C. C., Sulis, C. A., Nace, R. N., and Joyce-Brady, M.,
2009, “Epidemiology of Ventilator-Associated Pneumonia in a Long-Term Acute
Care Hospital,” Infect. Control Hosp. Epidemiol., 30(4), pp. 319–324.
Gattinoni, L., Carlesso, E., and Langer, T., 2011, “Clinical Review:
Extracorporeal Membrane Oxygenation,” Crit. Care, 15(6), p. 243.
Factora, F. N. F., Bustamante, S., Spiotta, A., and Avitsian, R., 2011, “Intracranial
Hemorrhage Surgery on Patients on Mechanical Circulatory Support: A Case
Series,” J. Neurosurg. Anesthesiol., 23(1), pp. 30–34.
Lewandowski, K., 2000, “Extracorporeal Membrane Oxygenation for Severe
Acute Respiratory Failure,” Crit. Care, 4(3), pp. 156–168.
Carr, S. R., Cantor, J. P., Rao, A. S., Lakshman, T. V., Collins, J. E., and
Friedberg, J. S., 2006, “Peritoneal Perfusion with Oxygenated Perfluorocarbon
Augments Systemic Oxygenation,” CHEST J., 130(2), pp. 402–411.
Matsutani, N., Takase, B., Nogami, Y., Ozeki, Y., Ishihara, M., and Maehara, T.,
2008, “The Peritoneum as a Novel Oxygenation Organ: Revitalization of
Intraperitoneal Oxygenation,” Shock, p. 1.
Gokal, R., 2000, Textbook of Peritoneal Dialysis, Springer.
Abdel-Aal, A. K., Dybbro, P., Hathaway, P., Guest, S., Neuwirth, M., and
Krishnamurthy, V., 2014, “Best Practices Consensus Protocol for Peritoneal
Dialysis Catheter Placement by Interventional Radiologists,” Perit. Dial. Int., p.
pdi.2013.00029.
Maton, A., 1993, Human Biology and Health, Pearson Prentice Hall.
Guyton, A. C., 2006, Textbook of Medical Physiology, Elsevier España.
Saladin, K. S., 2007, Anatomy and Physiology: The Unity of Form and Function,
McGraw-Hill/Higher Education.
West, J. B., 2008, Respiratory Physiology: The Essentials, Lippincott Williams &
Wilkins.

200
[28]
[29]

[30]
[31]
[32]
[33]

[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]

[42]
[43]
[44]
[45]

Stanfield, C. L., 2010, Principles of Human Physiology, Benjamin-Cummings
Publishing Company.
Wagner, P. D., 2015, “The Physiological Basis of Pulmonary Gas Exchange:
Implications for Clinical Interpretation of Arterial Blood Gases,” Eur. Respir. J.,
45(1), pp. 227–243.
2014, “Functions of the Circulatory System,” Heartzine, (online).
Jindal, S. E., 2012, Handbook of Pulmonary and Critical Care Medicine, JP
Medical Ltd.
Cruickshank, S., and Hirschauer, N., 2004, “The Alveolar Gas Equation,” Contin.
Educ. Anaesth. Crit. Care Pain, 4(1), pp. 24–27.
Weed, R. I., Reed, C. F., and Berg, G., 1963, “Is Hemoglobin an Essential
Structural Component of Human Erythrocyte Membranes?,” J. Clin. Invest., 42,
pp. 581–588.
Pittman, R. N., 2011, Regulation of Tissue Oxygenation, Morgan & Claypool Life
Sciences, San Rafael, CA.
McLellan, S. A., and Walsh, T. S., 2004, “Oxygen Delivery and Haemoglobin,”
Contin. Educ. Anaesth. Crit. Care Pain, 4(4), pp. 123–126.
Rhoades, R., and Bell, D. R., 2009, Medical Physiology: Principles for Clinical
Medicine, Lippincott Williams & Wilkins.
Longmore, M., Wilkinson, I., and Davidson, E., 2010, Oxford Handbook of
Clinical Medicine, Oxford University Press.
Bordow, R. A., Ries, A. L., and Morris, T. A., 2005, Manual of Clinical Problems
in Pulmonary Medicine, Lippincott Williams & Wilkins.
Kacmarek, R. M., 2011, “The Mechanical Ventilator: Past, Present, and Future,”
Respir. Care, 56(8), pp. 1170–1180.
Benditt, J. O., 2009, “Novel Uses of Noninvasive Ventilation,” Respir. Care,
54(2), pp. 212–222.
Esteban, A., Anzueto, A., Alía, I., Gordo, F., Apezteguía, C., Pálizas, F., Cide, D.,
Goldwaser, R., Soto, L., Bugedo, G., Rodrigo, C., Pimentel, J., Raimondi, G., and
Tobin, M. J., 2000, “How Is Mechanical Ventilation Employed in the Intensive
Care Unit? An International Utilization Review,” Am. J. Respir. Crit. Care Med.,
161(5), pp. 1450–1458.
Marcy, T., 1999, Medical Management of Pulmonary Diseases, CRC Press.
Thurlbeck, W. M., 1967, “Internal Surface Area and Other Measurements in
Emphysema,” Thorax, 22(6), pp. 483–496.
Notter, R. H., 2000, Lung Surfactants: Basic Science and Clinical Applications,
CRC Press.
Chan, E. D., Chan, M. M., and Chan, M. M., 2013, “Pulse Oximetry:
Understanding Its Basic Principles Facilitates Appreciation of Its Limitations,”
Respir. Med., 107(6), pp. 789–799.

201
[46]
[47]
[48]
[49]
[50]

[51]

[52]

[53]

[54]
[55]
[56]
[57]

[58]
[59]

[60]

DeMeulenaere, S., 2007, “Pulse Oximetry: Uses and Limitations,” J. Nurse Pract.,
3(5), pp. 312–317.
Langton, J. A., and Hutton, A., 2009, “Respiratory Gas Analysis,” Contin. Educ.
Anaesth. Crit. Care Pain, 9(1), pp. 19–23.
Williams, A. J., 1998, “Assessing and Interpreting Arterial Blood Gases and
Acid-Base Balance,” BMJ, 317(7167), pp. 1213–1216.
Sinex, J. E., 1999, “Pulse Oximetry: Principles and Limitations,” Am. J. Emerg.
Med., 17(1), pp. 59–66.
Rodkey, F. L., Hill, T. A., Pitts, L. L., and Robertson, R. F., 1979,
“Spectrophotometric Measurement of Carboxyhemoglobin and Methemoglobin in
Blood,” Clin. Chem., 25(8), pp. 1388–1393.
Barker, S. J., and Tremper, K. K., 1987, “The Effect of Carbon Monoxide
Inhalation on Pulse Oximetry and Transcutaneous PO2,” Anesthesiology, 66(5),
pp. 677–679.
Barker, S. J., Tremper, K. K., and Hyatt, J., 1989, “Effects of
Methemoglobinemia on Pulse Oximetry and Mixed Venous Oximetry,”
Anesthesiology, 70(1), pp. 112–117.
Dukić, L., Kopčinović, L. M., Dorotić, A., and Baršić, I., 2016, “Blood Gas
Testing and Related Measurements: National Recommendations on Behalf of the
Croatian Society of Medical Biochemistry and Laboratory Medicine,” Biochem.
Medica, 26(3), pp. 318–336.
Singh, V., Khatana, S., and Gupta, P., 2013, “Blood Gas Analysis for Bedside
Diagnosis,” Natl. J. Maxillofac. Surg., 4(2), pp. 136–141.
Suckow, M. A., Weisbroth, S. H., and Franklin, C. L., 2005, The Laboratory Rat,
Academic Press.
Fish, R. E., 2008, Anesthesia and Analgesia in Laboratory Animals, Academic
Press.
Subramanian, R. K., Sidharthan, A., Maneksh, D., Ramalingam, L., Manickam,
A. S., Kanthakumar, P., and Subramani, S., 2013, “Normative Data for Arterial
Blood Gas and Electrolytes in Anesthetized Rats,” Indian J. Pharmacol., 45(1),
pp. 103–104.
Wang, Y., Xu, H., Zhang, J., and Li, G., 2008, “Electrochemical Sensors for
Clinic Analysis,” Sensors, 8(4), pp. 2043–2081.
Trulock, E. P., 1990, “Arterial Blood Gases,” Clinical Methods: The History,
Physical, and Laboratory Examinations, H.K. Walker, W.D. Hall, and J.W.
Hurst, eds., Butterworths, Boston.
Severinghaus, J. W., and Bradley, A. F., 1958, “Electrodes for Blood pO2 and
pCO2 Determination,” J. Appl. Physiol., 13(3), pp. 515–520.

202
[61]

[62]
[63]

[64]

[65]

[66]

[67]

[68]

[69]
[70]
[71]

[72]

[73]
[74]

Clark, L. C., Wolf, R., Granger, D., and Taylor, Z., 1953, “Continuous Recording
of Blood Oxygen Tensions by Polarography,” J. Appl. Physiol., 6(3), pp. 189–
193.
Walker, H. K., Hall, W. D., and Hurst, J. W., eds., 1990, Clinical Methods: The
History, Physical, and Laboratory Examinations, Butterworths, Boston.
Touger, M., Gallagher, E. J., and Tyrell, J., 1995, “Relationship between Venous
and Arterial Carboxyhemoglobin Levels in Patients with Suspected Carbon
Monoxide Poisoning,” Ann. Emerg. Med., 25(4), pp. 481–483.
Rechetzki, K. F., Henneberg, R., da Silva, P. H., and do Nascimento, A. J., 2012,
“Reference Values for Methemoglobin Concentrations in Children,” Rev. Bras.
Hematol. E Hemoter., 34(1), pp. 14–16.
Gehring, H., Duembgen, L., Peterlein, M., Hagelberg, S., and Dibbelt, L., 2007,
“Hemoximetry as The ‘gold Standard’? Error Assessment Based on Differences
among Identical Blood Gas Analyzer Devices of Five Manufacturers,” Anesth.
Analg., 105(6 Suppl), p. S24–30, tables of contents.
Siggaard-Andersen, O., Wimberley, P. D., Fogh-Andersen, N., and Gøthgen, I.
H., 1990, “Arterial Oxygen Status Determined with Routine pH/Blood Gas
Equipment and Multi-Wavelength Hemoximetry: Reference Values, Precision,
and Accuracy,” Scand. J. Clin. Lab. Investig. Suppl., 203, pp. 57–66.
Coulange, M., Barthelemy, A., Hug, F., Thierry, A. L., and De Haro, L., 2008,
“Reliability of New Pulse CO-Oximeter in Victims of Carbon Monoxide
Poisoning,” Undersea Hyperb. Med. J. Undersea Hyperb. Med. Soc. Inc, 35(2),
pp. 107–111.
Feiner, J. R., Rollins, M. D., Sall, J., Eilers, H., Au, P., and Bickler, P. E., 2013,
“Accuracy of Carboxyhemoglobin Detection by Pulse CO-Oximetry During
Hypoxemia,” Anesth. Analg., 117(4), pp. 847–858.
Hasan, A., 2010, “Historical Aspects of Mechanical Ventilation,” Understanding
Mechanical Ventilation, Springer London, pp. 1–8.
Chen, K., Sternbach, G. L., Fromm, R. E., Jr, and Varon, J., 1998, “Mechanical
Ventilation: Past and Present,” J. Emerg. Med., 16(3), pp. 453–460.
Lassen, H. C. A., 1953, “A Preliminary Report on the 1952 Epidemic of
Poliomyelitis in Copenhagen with Special Reference to the Treatment of Acute
Respiratory Insufficiency,” Lancet, 1(6749), pp. 37–41.
Louis, B., Leroux, K., Isabey, D., Fauroux, B., and Lofaso, F., 2010, “Effect of
Manufacturer-Inserted Mask Leaks on Ventilator Performance,” Eur. Respir. J.,
35(3), pp. 627–636.
Geddes, L. A., 2007, “The History of Artifical Respiration [Retrospectroscope],”
IEEE Eng. Med. Biol. Mag., 26(6), pp. 38–41.
Truwit, J. D., and Epstein, S. K., 2011, Practical Guide to Mechanical
Ventilation, John Wiley & Sons.

203
[75]
[76]

[77]
[78]

[79]

[80]

[81]

[82]

[83]

[84]
[85]

Chatburn, R. L., 2007, “Classification of Ventilator Modes: Update and Proposal
for Implementation,” Respir. Care, 52(3), pp. 301–323.
Amato, M. B. P., Barbas, C. S. V., Medeiros, D. M., Magaldi, R. B., Schettino, G.
P., Lorenzi-Filho, G., Kairalla, R. A., Deheinzelin, D., Munoz, C., Oliveira, R.,
Takagaki, T. Y., and Carvalho, C. R. R., 1998, “Effect of a Protective-Ventilation
Strategy on Mortality in the Acute Respiratory Distress Syndrome,” N. Engl. J.
Med., 338(6), pp. 347–354.
Hemmila, M. R., and Napolitano, L. M., 2006, “Severe Respiratory Failure:
Advanced Treatment Options,” Crit. Care Med., 34(9 Suppl), pp. S278-290.
Kübler, A., Maciejewski, D., Adamik, B., and Kaczorowska, M., 2013,
“Mechanical Ventilation in ICUs in Poland: A Multi-Center Point-Prevalence
Study,” Med. Sci. Monit. Int. Med. J. Exp. Clin. Res., 19, pp. 424–429.
Carlucci, A., Richard, J. C., Wysocki, M., Lepage, E., Brochard, L., and SRLF
Collaborative Group on Mechanical Ventilation, 2001, “Noninvasive versus
Conventional Mechanical Ventilation. An Epidemiologic Survey,” Am. J. Respir.
Crit. Care Med., 163(4), pp. 874–880.
Azevedo, L. C., Park, M., Salluh, J. I., Rea-Neto, A., Souza-Dantas, V. C.,
Varaschin, P., Oliveira, M. C., Tierno, P. F. G., Dal-Pizzol, F., Silva, U. V.,
Knibel, M., Nassar, A. P., Jr, Alves, R. A., Ferreira, J. C., Teixeira, C., Rezende,
V., Martinez, A., Luciano, P. M., Schettino, G., Soares, M., and The ERICC
(Epidemiology of Respiratory Insufficiency in Critical Care) investigators, 2013,
“Clinical Outcomes of Patients Requiring Ventilatory Support in Brazilian
Intensive Care Units: A Multicenter, Prospective, Cohort Study,” Crit. Care Lond.
Engl., 17(2), p. R63.
Luhr, O. R., Antonsen, K., Karlsson, M., Aardal, S., Thorsteinsson, A., Frostell,
C. G., and Bonde, J., 1999, “Incidence and Mortality after Acute Respiratory
Failure and Acute Respiratory Distress Syndrome in Sweden, Denmark, and
Iceland. The ARF Study Group,” Am. J. Respir. Crit. Care Med., 159(6), pp.
1849–1861.
Grap, M. J., and Munro, C. L., 1997, “Ventilator-Associated Pneumonia: Clinical
Significance and Implications for Nursing,” Heart Lung J. Acute Crit. Care, 26(6),
pp. 419–429.
Pneumatikos, I. A., Dragoumanis, C. K., and Bouros, D. E., 2009, “VentilatorAssociated Pneumonia or Endotracheal Tube-Associated Pneumonia? An
Approach to the Pathogenesis and Preventive Strategies Emphasizing the
Importance of Endotracheal Tube,” Anesthesiology, 110(3), pp. 673–680.
Parker, J. C., Hernandez, L. A., and Peevy, K. J., 1993, “Mechanisms of
Ventilator-Induced Lung Injury,” Crit. Care Med., 21(1), pp. 131–143.
Anzueto, A., Frutos-Vivar, F., Esteban, A., Alía, I., Brochard, L., Stewart, T.,
Benito, S., Tobin, M. J., Elizalde, J., Palizas, F., David, C. M., Pimentel, J.,

204

[86]

[87]
[88]
[89]

[90]

[91]

[92]

[93]

[94]

[95]

González, M., Soto, L., D’Empaire, G., and Pelosi, P., 2004, “Incidence, Risk
Factors and Outcome of Barotrauma in Mechanically Ventilated Patients,”
Intensive Care Med., 30(4), pp. 612–619.
Levine, S., Nguyen, T., Taylor, N., Friscia, M. E., Budak, M. T., Rothenberg, P.,
Zhu, J., Sachdeva, R., Sonnad, S., Kaiser, L. R., Rubinstein, N. A., Powers, S. K.,
and Shrager, J. B., 2008, “Rapid Disuse Atrophy of Diaphragm Fibers in
Mechanically Ventilated Humans,” N. Engl. J. Med., 358(13), pp. 1327–1335.
Gibbon, J. H., and Hill, J. D., 1982, “Part I. The Development of the First
Successful Heart-Lung Machine,” Ann. Thorac. Surg., 34(3), pp. 337–341.
Wolfson, P. J., 2003, “The Development and Use of Extracorporeal Membrane
Oxygenation in Neonates,” Ann. Thorac. Surg., 76(6), pp. S2224–S2229.
Hill, J. D., O’Brien, T. G., Murray, J. J., Dontigny, L., Bramson, M. L., Osborn, J.
J., and Gerbode, F., 1972, “Prolonged Extracorporeal Oxygenation for Acute
Post-Traumatic Respiratory Failure (Shock-Lung Syndrome). Use of the Bramson
Membrane Lung,” N. Engl. J. Med., 286(12), pp. 629–634.
Bartlett, R. H., Gazzaniga, A. B., Jefferies, M. R., Huxtable, R. F., Haiduc, N. J.,
and Fong, S. W., 1976, “Extracorporeal Membrane Oxygenation (ECMO)
Cardiopulmonary Support in Infancy,” Trans. - Am. Soc. Artif. Intern. Organs,
22, pp. 80–93.
Zapol, W. M., Snider, M. T., Hill, J. D., Fallat, R. J., Bartlett, R. H., Edmunds, L.
H., Morris, A. H., Peirce, E. C., 2nd, Thomas, A. N., Proctor, H. J., Drinker, P.
A., Pratt, P. C., Bagniewski, A., and Miller, R. G., Jr, 1979, “Extracorporeal
Membrane Oxygenation in Severe Acute Respiratory Failure. A Randomized
Prospective Study,” JAMA J. Am. Med. Assoc., 242(20), pp. 2193–2196.
Bartlett, R. H., Roloff, D. W., Cornell, R. G., Andrews, A. F., Dillon, P. W., and
Zwischenberger, J. B., 1985, “Extracorporeal Circulation in Neonatal Respiratory
Failure: A Prospective Randomized Study,” Pediatrics, 76(4), pp. 479–487.
Bartlett, R. H., Gazzaniga, A. B., Toomasian, J., Coran, A. G., Roloff, D., Rucker,
R., and Corwin, A. G., 1986, “Extracorporeal Membrane Oxygenation (ECMO)
in Neonatal Respiratory Failure. 100 Cases.,” Ann. Surg., 204(3), pp. 236–245.
O’Rourke, P. P., Crone, R. K., Vacanti, J. P., Ware, J. H., Lillehei, C. W., Parad,
R. B., and Epstein, M. F., 1989, “Extracorporeal Membrane Oxygenation and
Conventional Medical Therapy in Neonates With Persistent Pulmonary
Hypertension of the Newborn: A Prospective Randomized Study,” Pediatrics,
84(6), pp. 957–963.
Peek, G. J., Mugford, M., Tiruvoipati, R., Wilson, A., Allen, E., Thalanany, M.
M., Hibbert, C. L., Truesdale, A., Clemens, F., Cooper, N., Firmin, R. K., and
Elbourne, D., 2009, “Efficacy and Economic Assessment of Conventional
Ventilatory Support versus Extracorporeal Membrane Oxygenation for Severe

205

[96]

[97]
[98]

[99]

[100]
[101]

[102]
[103]

[104]
[105]

[106]

[107]

Adult Respiratory Failure (CESAR): A Multicentre Randomised Controlled
Trial,” The Lancet, 374(9698), pp. 1351–1363.
Töpfer, L., Menk, M., Weber-Carstens, S., Spies, C., Wernecke, K.-D., Uhrig, A.,
Lojewski, C., Jörres, A., and Deja, M., 2014, “Influenza A (H1N1) vs Non-H1N1
ARDS: Analysis of Clinical Course,” J. Crit. Care, 29(3), pp. 340–346.
Paden, M. L., Rycus, P. T., and Thiagarajan, R. R., 2014, “Update and Outcomes
in Extracorporeal Life Support,” Semin. Perinatol., 38(2), pp. 65–70.
Chauhan, S., and Subin, S., 2011, “Extracorporeal Membrane Oxygenation, an
Anesthesiologist′s Perspective: Physiology and Principles. Part 1,” Ann. Card.
Anaesth., 14(3), p. 218.
Fraser, J. F., Shekar, K., Diab, S., Dunster, K., Foley, S. R., McDonald, C. I.,
Passmore, M., Simonova, G., Roberts, J. A., Platts, D. G., Mullany, D. V., and
Fung, Y. L., 2012, “ECMO – the Clinician’s View,” ISBT Sci. Ser., 7(1), pp. 82–
88.
Brodie, D., and Bacchetta, M., 2011, “Extracorporeal Membrane Oxygenation for
ARDS in Adults,” N. Engl. J. Med., 365(20), pp. 1905–1914.
Bermudez, C. A., Rocha, R. V., Sappington, P. L., Toyoda, Y., Murray, H. N.,
and Boujoukos, A. J., 2010, “Initial Experience With Single Cannulation for
Venovenous Extracorporeal Oxygenation in Adults,” Ann. Thorac. Surg., 90(3),
pp. 991–995.
Butt, W., and MacLaren, G., 2013, “Extracorporeal Membrane Oxygenation,”
F1000Prime Rep., 5.
Barrett, C. S., Jaggers, J. J., Cook, E. F., Graham, D. A., Yarlagadda, V. V.,
Teele, S. A., Almond, C. S., Bratton, S. L., Seeger, J. D., Dalton, H. J., Rycus, P.
T., Laussen, P. C., and Thiagarajan, R. R., 2013, “Pediatric ECMO Outcomes:
Comparison of Centrifugal Versus Roller Blood Pumps Using Propensity Score
Matching,” ASAIO J., 59(2), pp. 145–151.
Lim, M. W., 2006, “The History of Extracorporeal Oxygenators,” Anaesthesia,
61(10), pp. 984–995.
Sidebotham, D., Allen, S. J., McGeorge, A., Ibbott, N., and Willcox, T., 2012,
“Venovenous Extracorporeal Membrane Oxygenation in Adults: Practical
Aspects of Circuits, Cannulae, and Procedures,” J. Cardiothorac. Vasc. Anesth.,
26(5), pp. 893–909.
Hemmila, M. R., Rowe, S. A., Boules, T. N., Miskulin, J., McGillicuddy, J. W.,
Schuerer, D. J., Haft, J. W., Swaniker, F., Arbabi, S., Hirschl, R. B., and Bartlett,
R. H., 2004, “Extracorporeal Life Support for Severe Acute Respiratory Distress
Syndrome in Adults,” Ann. Surg., 240(4), pp. 595–607.
Brogan, T. V., Thiagarajan, R. R., Rycus, P. T., Bartlett, R. H., and Bratton, S. L.,
2009, “Extracorporeal Membrane Oxygenation in Adults with Severe Respiratory
Failure: A Multi-Center Database,” Intensive Care Med., 35(12), pp. 2105–2114.

206
[108] Peek, G. J., Moore, H. M., Moore, N., Sosnowski, A. W., and Firmin, R. K.,
1997, “Extracorporeal Membrane Oxygenation for Adult Respiratory Failure,”
CHEST J., 112(3), pp. 759–764.
[109] Turner, D. A., and Cheifetz, I. M., 2013, “Extracorporeal Membrane Oxygenation
for Adult Respiratory Failure,” Respir. Care, 58(6), pp. 1038–1052.
[110] Nolph, K. D., 2013, Peritoneal Dialysis, Springer Science & Business Media.
[111] Chagnac, A., Herskovitz, P., Weinstein, T., Elyashiv, S., Hirsh, J., Hammel, I.,
and Gafter, U., 1999, “The Peritoneal Membrane in Peritoneal Dialysis Patients
Estimation of Its Functional Surface Area by Applying Stereologic Methods to
Computerized Tomography Scans,” J. Am. Soc. Nephrol., 10(2), pp. 342–346.
[112] Pawlaczyk, K., Kuzlan, M., Wieczorowska-Tobis, K., Pawlik-Juzków, H.,
Breborowicz, A., Knapowski, J., and Oreopoulos, D. G., 1996, “SpeciesDependent Topography of the Peritoneum,” Adv. Perit. Dial. Conf. Perit. Dial.,
12, pp. 3–6.
[113] Takala, J., 1996, “Determinants of Splanchnic Blood Flow.,” Br. J. Anaesth.,
77(1), pp. 50–58.
[114] Perko, M. J., Nielsen, H. B., Skak, C., Clemmesen, J. O., Schroeder, T. V., and
Secher, N. H., 1998, “Mesenteric, Coeliac and Splanchnic Blood Flow in Humans
during Exercise,” J. Physiol., 513(3), pp. 907–913.
[115] Matheson, P. J., Wilson, M. A., and Garrison, R. N., 2000, “Regulation of
Intestinal Blood Flow,” J. Surg. Res., 93(1), pp. 182–196.
[116] Daugirdas, J. T., Blake, P. G., and Ing, T. S., 2007, Handbook of Dialysis,
Lippincott Williams & Wilkins.
[117] Barash, P. G., 2009, Clinical Anesthesia, Lippincott Williams & Wilkins.
[118] Albanese, A. M., Albanese, E. F., Miño, J. H., Gómez, E., Gómez, M.,
Zandomeni, M., and Merlo, A. B., 2009, “Peritoneal Surface Area: Measurements
of 40 Structures Covered by Peritoneum: Correlation between Total Peritoneal
Surface Area and the Surface Calculated by Formulas,” Surg. Radiol. Anat.,
31(5), pp. 369–377.
[119] Gehr, P., Bachofen, M., and Weibel, E. R., 1978, “The Normal Human Lung:
Ultrastructure and Morphometric Estimation of Diffusion Capacity,” Respir.
Physiol., 32(2), pp. 121–140.
[120] Hasleton, P. S., 1972, “The Internal Surface Area of the Adult Human Lung.,” J.
Anat., 112(Pt 3), pp. 391–400.
[121] Gump, F. E., Price, J. B., and Kinney, J. M., 1970, “Whole Body and Splanchnic
Blood Flow and Oxygen Consumption Measurements in Patients with
Intraperitoneal Infection.,” Ann. Surg., 171(3), pp. 321–328.
[122] Schmidt, J. A., Bilge, F. H., Colacino, J. M., and von Recum, A. F., 1989,
“Peritoneal Oxygenation of Normoxic and Hypoxic Dogs,” ASAIO Trans. Am.
Soc. Artif. Intern. Organs, 35(1), pp. 35–39.

207
[123] Diebel, L. N., Wilson, R. F., Dulchavsky, S. A., and Saxe, J., 1992, “Effect of
Increased Intra-Abdominal Pressure on Hepatic Arterial, Portal Venous, and
Hepatic Microcirculatory Blood Flow,” J. Trauma, 33(2), pp. 279-282; discussion
282-283.
[124] Ishizaki, Y., Bandai, Y., Shimomura, K., Abe, H., Ohtomo, Y., and Idezuki, Y.,
1993, “Safe Intraabdominal Pressure of Carbon Dioxide Pneumoperitoneum
during Laparoscopic Surgery,” Surgery, 114(3), pp. 549–554.
[125] Sánchez-Etayo, G., Borrat, X., Escobar, B., Hessheimer, A., Rodriguez-Laiz, G.,
and Taura, P., 2012, “Effect of Intra-Abdominal Pressure on Hepatic
Microcirculation: Implications of the Endothelin-1 Receptor,” J. Dig. Dis., 13(9),
pp. 478–485.
[126] Schilling, M. K., Redaelli, C., Krähenbühl, L., Signer, C., and Büchler, M. W.,
1997, “Splanchnic Microcirculatory Changes during CO2 Laparoscopy,” J. Am.
Coll. Surg., 184(4), pp. 378–382.
[127] Naeije, R., and Chesler, N., 2012, “Pulmonary Circulation at Exercise,” Compr.
Physiol., 2(1), pp. 711–741.
[128] Dexter, L., Dow, J. W., Haynes, F. W., Whittenberger, J. L., Ferris, B. G.,
Goodale, W. T., and Hellems, H. K., 1950, “Studies of the Pulmonary Circulation
in Man at Rest,” J. Clin. Invest., 29(5), pp. 602–613.
[129] Morgan, B. C., Guntheroth, W. C., Breazeale, D., and McGough, G. A., 1968,
“Failure to Achieve Oxygen Supplementation with Hydrogen Peroxide,”
Pediatrics, 41(2), pp. 531–533.
[130] Barr, J., Livne, A., Lushkov, G., Vinograd, I., Efrati, Y., Ballin, A., Lahat, E., and
Eshel, G., 1994, “Peritoneal Ventilation: An Animal Model of Extrapulmonary
Ventilation in Experimental Adult Respiratory Distress Syndrome,” Pediatr. Res.,
35(6), pp. 682–684.
[131] Barr, J., Lushkov, G., Strauss, S., Gurevitch, S., Lahat, E., Bistritzer, T., Klin, B.,
and Eshel, G., 1996, “Peritoneal Ventilation in Rabbits: Augmentation of Gas
Exchange with Cisapride,” Thorax, 51(1), pp. 82–86.
[132] Giffin, D. M., Gow, K. W., Warriner, C. B., Walley, K. R., and Phang, P. T.,
1998, “Oxygen Uptake during Peritoneal Ventilation in a Porcine Model of
Hypoxemia,” Crit. Care Med., 26(9), pp. 1564–1568.
[133] Zhang, J.-Y., Wang, X.-H., Wang, L.-J., Xu, B., and Zheng, M., 2010, “Effect of
Oxygenation of Transperitoneal Ventilation on the Death Time after Asphyxiation
in Rabbits,” Minerva Anestesiol., 76(11), pp. 913–917.
[134] Klein, J., Faithfull, N. S., Salt, P. J., and Trouwborst, A., 1986, “Transperitoneal
Oxygenation with Fluorocarbons,” Anesth. Analg., 65(7), pp. 734–738.
[135] Matsutani, N., Takase, B., Nogami, Y., Ozeki, Y., Kaneda, S., Maehara, T.,
Kikuchi, M., and Ishihara, M., 2010, “Efficacy of Peritoneal Oxygenation Using a

208

[136]
[137]
[138]

[139]

[140]
[141]

[142]

[143]

[144]
[145]
[146]

[147]

[148]
[149]

Novel Artificial Oxygen Carrier (TRM-645) in a Rat Respiratory Insufficiency
Model,” Surg. Today, 40(5), pp. 451–455.
Awad, J. A., Brassard, A., Caron, W. M., and Cadrin, C., 1970, “Intraperitoneal
Oxygenation with Hydrogen Peroxide,” Int. Surg., 54(4), pp. 276–282.
Weers, J. G., 1993, “A Physicochemical Evaluation of Perfluorochemicals for
Oxygen Transport Applications,” J. Fluor. Chem., 64(1–2), pp. 73–93.
Remy, B., Deby-Dupont, G., and Lamy, M., 1999, “Red Blood Cell Substitutes:
Fluorocarbon Emulsions and Haemoglobin Solutions,” Br. Med. Bull., 55(1), pp.
277–298.
Clark, L. C., Jr, and Gollan, F., 1966, “Survival of Mammals Breathing Organic
Liquids Equilibrated with Oxygen at Atmospheric Pressure,” Science, 152(3730),
pp. 1755–1756.
Riess, J. G., 2006, “Perfluorocarbon-Based Oxygen Delivery,” Artif. Cells Blood
Substit. Biotechnol., 34(6), pp. 567–580.
Simmonds, P. G., Greally, B. R., Olivier, S., Nickless, G., Cooke, K. M., and
Dietz, R. N., 2002, “The Background Atmospheric Concentrations of Cyclic
Perfluorocarbon Tracers Determined by Negative Ion-Chemical Ionization Mass
Spectrometry,” Atmos. Environ., 36(13), pp. 2147–2156.
Breidenich, C., Magraw, D., Rowley, A., and Rubin, J. W., 1998, “The Kyoto
Protocol to the United Nations Framework Convention on Climate Change,” Am.
J. Int. Law, 92(2), pp. 315–331.
Tao, Z., and Ghoroghchian, P. P., 2014, “Microparticle, Nanoparticle, and Stem
Cell-Based Oxygen Carriers as Advanced Blood Substitutes,” Trends Biotechnol.,
32(9), pp. 466–473.
Henkel-Honke, T., and Oleck, M., 2007, “Artificial Oxygen Carriers: A Current
Review,” AANA J., 75(3), pp. 205–211.
Nosé, Y., 2004, “Is There a Role for Blood Substitutes in Civilian Medicine: A
Drug for Emergency Shock Cases?,” Artif. Organs, 28(9), pp. 807–812.
Canaud, B., Aljama, P., Tielemans, C., Gasparovic, V., Gutierrez, A., and
Locatelli, F., 2005, “Pathochemical Toxicity of Perfluorocarbon-5070, a Liquid
Test Performance Fluid Previously Used in Dialyzer Manufacturing, Confirmed
in Animal Experiment,” J. Am. Soc. Nephrol., 16(6), pp. 1819–1823.
Sakai, H., Sou, K., Horinouchi, H., Kobayashi, K., and Tsuchida, E., 2009,
“Review of Hemoglobin-Vesicles as Artificial Oxygen Carriers,” Artif. Organs,
33(2), pp. 139–145.
Alayash, A. I., 2014, “Blood Substitutes: Why Haven’t We Been More
Successful?,” Trends Biotechnol., 32(4), pp. 177–185.
Palmer, A. F., and Intaglietta, M., 2014, “Blood Substitutes,” Annu. Rev. Biomed.
Eng., 16(1), pp. 77–101.

209
[150] Chen, J.-Y., Scerbo, M., and Kramer, G., 2009, “A Review of Blood Substitutes:
Examining The History, Clinical Trial Results, and Ethics of Hemoglobin-Based
Oxygen Carriers,” Clin. Sao Paulo Braz., 64(8), pp. 803–813.
[151] Mozzarelli, A., Ronda, L., Faggiano, S., Bettati, S., and Bruno, S., 2010,
“Haemoglobin-Based Oxygen Carriers: Research and Reality towards an
Alternative to Blood Transfusions,” Blood Transfus., 8(Suppl 3), pp. s59–s68.
[152] Kaneda, S., Ishizuka, T., Goto, H., Kimura, T., Inaba, K., and Kasukawa, H.,
2009, “Liposome-Encapsulated Hemoglobin, TRM-645: Current Status of the
Development and Important Issues for Clinical Application,” Artif. Organs, 33(2),
pp. 146–152.
[153] Natanson, C., Kern, S. J., Lurie, P., Banks, S. M., and Wolfe, S. M., 2008, “CellFree Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and
Death: A Meta-Analysis,” JAMA, 299(19), pp. 2304–2312.
[154] Burhop, K., Gordon, D., and Estep, T., 2004, “Review of Hemoglobin-Induced
Myocardial Lesions,” Artif. Cells. Blood Substit. Immobil. Biotechnol., 32(3), pp.
353–374.
[155] Rameez, S., Banerjee, U., Fontes, J., Roth, A., and Palmer, A. F., 2012,
“Reactivity of Polymersome Encapsulated Hemoglobin with Physiologically
Important Gaseous Ligands: Oxygen, Carbon Monoxide, and Nitric Oxide,”
Macromolecules, 45(5), pp. 2385–2389.
[156] Abe, H., Azuma, H., Yamaguchi, M., Fujihara, M., Ikeda, H., Sakai, H., Takeoka,
S., and Tsuchida, E., 2007, “Effects of Hemoglobin Vesicles, a Liposomal
Artificial Oxygen Carrier, on Hematological Responses, Complement and
Anaphylactic Reactions in Rats,” Artif. Cells. Blood Substit. Immobil.
Biotechnol., 35(2), pp. 157–172.
[157] Li, T., Jing, X., and Huang, Y., 2011, “Polymer/Hemoglobin Assemblies:
Biodegradable Oxygen Carriers for Artificial Red Blood Cells,” Macromol.
Biosci., 11(7), pp. 865–875.
[158] Blomley, M. J. K., Cooke, J. C., Unger, E. C., Monaghan, M. J., and Cosgrove, D.
O., 2001, “Microbubble Contrast Agents: A New Era in Ultrasound,” BMJ,
322(7296), pp. 1222–1225.
[159] Porter, T. R., and Xie, F., 2001, “Therapeutic Ultrasound for Gene Delivery,”
Echocardiogr. Mt. Kisco N, 18(4), pp. 349–353.
[160] Unger, E. C., Hersh, E., Vannan, M., and McCreery, T., 2001, “Gene Delivery
Using Ultrasound Contrast Agents,” Echocardiogr. Mt. Kisco N, 18(4), pp. 355–
361.
[161] Van Liew, H. D., and Raychaudhuri, S., 1997, “Stabilized Bubbles in the Body:
Pressure-Radius Relationships and the Limits to Stabilization,” J. Appl. Physiol.
Bethesda Md 1985, 82(6), pp. 2045–2053.

210
[162] Kim, D. H., Klibanov, A. L., and Needham, D., 2000, “The Influence of Tiered
Layers of Surface-Grafted Poly(ethylene Glycol) on Receptor−Ligand-Mediated
Adhesion between Phospholipid Monolayer-Stabilized Microbubbles and Coated
Glass Beads,” Langmuir, 16(6), pp. 2808–2817.
[163] Borden, M. A., and Longo, M. L., 2002, “Dissolution Behavior of Lipid
Monolayer-Coated, Air-Filled Microbubbles: Effect of Lipid Hydrophobic Chain
Length,” Langmuir, 18(24), pp. 9225–9233.
[164] Borden, M. A., and Longo, M. L., 2004, “Oxygen Permeability of Fully
Condensed Lipid Monolayers,” J. Phys. Chem. B, 108(19), pp. 6009–6016.
[165] Chen, C. C., and Borden, M. A., 2010, “Ligand Conjugation to Bimodal PEG
Brush Layers on Microbubbles,” Langmuir ACS J. Surf. Colloids, 26(16), pp.
13183–13194.
[166] Garg, S., Thomas, A. A., and Borden, M. A., 2013, “The Effect of Lipid
Monolayer in-Plane Rigidity on in Vivo Microbubble Circulation Persistence,”
Biomaterials, 34(28), pp. 6862–6870.
[167] Kwan, J. J., and Borden, M. A., 2010, “Microbubble Dissolution in a Multigas
Environment,” Langmuir, 26(9), pp. 6542–6548.
[168] Kwan, J. J., and Borden, M. A., 2012, “Lipid Monolayer Dilatational Mechanics
during Microbubble Gas Exchange,” Soft Matter, 8(17), pp. 4756–4766.
[169] Kwan, J. J., and Borden, M. A., 2012, “Lipid Monolayer Collapse and
Microbubble Stability,” Adv. Colloid Interface Sci., 183–184, pp. 82–99.
[170] Kwan, J. J., Kaya, M., Borden, M. A., and Dayton, P. A., 2012, “Theranostic
Oxygen Delivery Using Ultrasound and Microbubbles,” Theranostics, 2(12), pp.
1174–1184.
[171] Kheir, J. N., Scharp, L. A., Borden, M. A., Swanson, E. J., Loxley, A., Reese, J.
H., Black, K. J., Velazquez, L. A., Thomson, L. M., Walsh, B. K., Mullen, K. E.,
Graham, D. A., Lawlor, M. W., Brugnara, C., Bell, D. C., and McGowan, F. X.,
2012, “Oxygen Gas-Filled Microparticles Provide Intravenous Oxygen Delivery,”
Sci. Transl. Med., 4(140), p. 140ra88.
[172] Castro, C. I., and Briceno, J. C., 2010, “Perfluorocarbon-Based Oxygen Carriers:
Review of Products and Trials,” Artif. Organs, 34(8), pp. 622–634.
[173] Kimura, T., Kurosawa, H., Goto, H., Kora, S., Ogata, Y., and Amano, Y., 1998,
“Oxygen Carrying Capacity and Oxygen Supply Rate of Artificial Oxygen
Carrier, Neo Red Cell (NRC),” Artif. Cells. Blood Substit. Immobil. Biotechnol.,
26(5–6), pp. 455–464.
[174] Swanson, E. J., Mohan, V., Kheir, J., and Borden, M. A., 2010, “PhospholipidStabilized Microbubble Foam for Injectable Oxygen Delivery,” Langmuir,
26(20), pp. 15726–15729.
[175] Notter, R. H., and Wang, Z., 1997, “Pulmonary Surfactant: Physical Chemistry,
Physiology, and Replacement,” Rev. Chem. Eng., 13(4), pp. 1–118.

211
[176] Duncan, P. B., and Needham, D., 2004, “Test of the Epstein-Plesset Model for
Gas Microparticle Dissolution in Aqueous Media: Effect of Surface Tension and
Gas Undersaturation in Solution,” Langmuir ACS J. Surf. Colloids, 20(7), pp.
2567–2578.
[177] Epstein, P. S., and Plesset, M. S., 1950, “On the Stability of Gas Bubbles in
Liquid‐Gas Solutions,” J. Chem. Phys., 18(11), pp. 1505–1509.
[178] Kuhl, T. L., Leckband, D. E., Lasic, D. D., and Israelachvili, J. N., 1994,
“Modulation of Interaction Forces between Bilayers Exposing Short-Chained
Ethylene Oxide Headgroups.,” Biophys. J., 66(5), pp. 1479–1488.
[179] Feshitan, J. A., Legband, N. D., Borden, M. A., and Terry, B. S., 2014, “Systemic
Oxygen Delivery by Peritoneal Perfusion of Oxygen Microbubbles,”
Biomaterials, 35(9), pp. 2600–2606.
[180] Ward, C. A., Findlay, R. D., and Rizk, M., 1982, “Statistical Rate Theory of
Interfacial Transport. I. Theoretical Development,” J. Chem. Phys., 76(11), pp.
5599–5605.
[181] Ward, C. A., 1977, “The Rate of Gas Absorption at a Liquid Interface,” J. Chem.
Phys., 67(1), pp. 229–235.
[182] Deen, W. M., 2011, Analysis of Transport Phenomena, Oxford University Press,
Oxford, New York.
[183] Sümpelmann, R., Schuerholz, T., Marx, G., Härtel, D., Hecker, H., Ure, B. M.,
and Jesch, N. K., 2006, “Haemodynamic, Acid–base and Blood Volume Changes
during Prolonged Low Pressure Pneumoperitoneum in Rabbits,” Br. J. Anaesth.,
96(5), pp. 563–568.
[184] Bishop, C. M., 1999, “The Maximum Oxygen Consumption and Aerobic Scope
of Birds and Mammals: Getting to the Heart of the Matter,” Proc. R. Soc. Lond. B
Biol. Sci., 266(1435), pp. 2275–2281.
[185] Olfert, I. M., Balouch, J., and Mathieu-Costello, O., 2004, “Oxygen Consumption
During Maximal Exercise in Fischer 344 × Brown Norway F1 Hybrid Rats,” J.
Gerontol. A. Biol. Sci. Med. Sci., 59(8), pp. B801–B808.
[186] Fok, T.-F., Gu, G., To, K.-F., Xu, F., Ng, P.-C., and Yin, J., 2001, “Oxygen
Consumption by Lungs with Acute and Chronic Injury in a Rabbit Model,”
Intensive Care Med., 27(9), pp. 1532–1538.
[187] Gaustad, S. E., Rolim, N., and Wisløff, U., 2010, “A Valid and Reproducible
Protocol for Testing Maximal Oxygen Uptake in Rabbits,” Eur. J. Cardiovasc.
Prev. Rehabil., 17(1), pp. 83–88.
[188] Erickson, H. H., Faraci, F. M., and Olsen, S. C., 1984, “Effect of Exercise on
Oxygen Consumption, Heart Rate, and the Electrocardiogram of Pigs,” Med. Sci.
Sports Exerc., 16(4), pp. 406–410.

212
[189] Rasanen, J., 1992, “Supply-Dependent Oxygen Consumption and Mixed Venous
Oxyhemoglobin Saturation during Isovolemic Hemodilution in Pigs.,” CHEST J.,
101(4), pp. 1121–1124.
[190] Van Milgen, J., Noblet, J., Dubois, S., and Bernier, J.-F., 1997, “Dynamic Aspects
of Oxygen Consumption and Carbon Dioxide Production in Swine,” Br. J. Nutr.,
78(03), pp. 397–410.
[191] Hatoum, L., 2016, “Diffusion Modeling and Device Development for Peritoneal
Membrane Oxygenation,” Mech. Mater. Eng. -- Diss. Theses Stud. Res.
[192] Legband, N. D., Feshitan, J. A., Borden, M. A., and Terry, B. S., 2015,
“Evaluation of Peritoneal Microbubble Oxygenation Therapy in a Rabbit Model
of Hypoxemia,” IEEE Trans. Biomed. Eng., 62(5), pp. 1376–1382.
[193] Legband, N., Feshitan, J., Borden, M., and Terry, B., 2014, “Peritoneal
Microbubble Oxygenation: An Extrapulmonary Respiration Treatment in
Rabbits,” J. Med. Devices, 8(3), pp. 030944–030944.
[194] Murphy, C. M., and O’Brien, F. J., 2010, “Understanding the Effect of Mean Pore
Size on Cell Activity in Collagen-Glycosaminoglycan Scaffolds,” Cell Adhes.
Migr., 4(3), pp. 377–381.
[195] O’Brien, F. J., 2011, “Biomaterials & Scaffolds for Tissue Engineering,” Mater.
Today, 14(3), pp. 88–95.
[196] Loh, Q. L., and Choong, C., 2013, “Three-Dimensional Scaffolds for Tissue
Engineering Applications: Role of Porosity and Pore Size,” Tissue Eng. Part B
Rev., 19(6), pp. 485–502.
[197] Legband, N., Hatoum, L., Thomas, A., Kreikemeier-Bower, C., Hostetler, D.,
Buesing, K., Borden, M., and Terry, B., 2016, “Peritoneal Membrane
Oxygenation Therapy for Rats With Acute Respiratory Distress Syndrome,” J.
Med. Devices, 10(2), pp. 020905-020905-2.
[198] Flessner, M. F., 2009, “Peritoneal Ultrafiltration: Physiology and Failure,”
Contributions to Nephrology, C. Ronco, C. Crepaldi, and D.N. Cruz, eds.,
KARGER, Basel, pp. 7–14.
[199] Aguirre, A. R., Abensur, H., Aguirre, A. R., and Abensur, H., 2014, “Physiology
of Fluid and Solute Transport across the Peritoneal Membrane,” J. Bras. Nefrol.,
36(1), pp. 74–79.
[200] Devuyst, O., and Rippe, B., 2014, “Water Transport across the Peritoneal
Membrane,” Kidney Int., 85(4), pp. 750–758.
[201] Wang, T., Chen, C., Heimbürger, O., Waniewski, J., Bergström, J., and Lindholm,
B., 1997, “Hyaluronan Decreases Peritoneal Fluid Absorption in Peritoneal
Dialysis.,” J. Am. Soc. Nephrol., 8(12), pp. 1915–1920.
[202] Kuzlan, M., Pawlaczyk, K., Wieczorowska-Tobis, K., Korybalska, K.,
Breborowicz, A., and Oreopoulos, D. G., 1997, “Peritoneal Surface Area and Its
Permeability in Rats,” Perit. Dial. Int., 17(3), pp. 295–300.

213
[203] Claassen, V., 2013, Neglected Factors in Pharmacology and Neuroscience
Research: Biopharmaceutics, Animal Characteristics, Maintenance, Testing
Conditions, Elsevier.
[204] Cohen, P. R., Martinelli, P. T., Schulze, K. E., and Nelson, B. R., 2007, “The
Purse-String Suture Revisited: A Useful Technique for the Closure of Cutaneous
Surgical Wounds,” Int. J. Dermatol., 46(4), pp. 341–347.
[205] Cohen, P. R., Martinelli, P. T., Schulze, K. E., and Nelson, B. R., 2007, “The
Cuticular Purse String Suture: A Modified Purse String Suture for the Partial
Closure of Round Postoperative Wounds,” Int. J. Dermatol., 46(7), pp. 746–753.
[206] Joo, J., Custis, T., Armstrong, A. W., King, T. H., Omlin, K., Kappel, S. T., and
Eisen, D. B., 2015, “Purse-String Suture vs Second Intention Healing: Results of
a Randomized, Blind Clinical Trial,” JAMA Dermatol., 151(3), pp. 265–270.
[207] Ash, S. R., and Janle, E. M., 1993, “T-Fluted Peritoneal Dialysis Catheter,” Adv.
Perit. Dial. Conf. Perit. Dial., 9, pp. 223–226.
[208] Ash, S. R., Sutton, J. M., Mankus, R. A., Rossman, J., de Ridder, V., Nassvi, M.
S., and Ross, J., 2002, “Clinical Trials of the T-Fluted (Ash Advantage) Peritoneal
Dialysis Catheter,” Adv. Ren. Replace. Ther., 9(2), pp. 133–143.
[209] Dell’Aquila, R., Chiaramonte, S., Rodighiero, M. P., Spano’, E., Loreto, P. D.,
Kohn, C. O., Cruz, D., Polanco, N., Kuang, D., Corradi, V., Cal, M. D., and
Ronco, C., 2007, “Rational Choice of Peritoneal Dialysis Catheter,” Perit. Dial.
Int., 27(2), pp. S119–S125.
[210] Dowling, D. P., Miller, I. S., Ardhaoui, M., and Gallagher, W. M., 2011, “Effect
of Surface Wettability and Topography on the Adhesion of Osteosarcoma Cells
on Plasma-Modified Polystyrene,” J. Biomater. Appl., 26(3), pp. 327–347.
[211] Litbarg, N. O., Gudehithlu, K. P., Sethupathi, P., Arruda, J. A. L., Dunea, G., and
Singh, A. K., 2007, “Activated Omentum Becomes Rich in Factors That Promote
Healing and Tissue Regeneration,” Cell Tissue Res., 328(3), pp. 487–497.
[212] Dondossola, E., Holzapfel, B. M., Alexander, S., Filippini, S., Hutmacher, D. W.,
and Friedl, P., 2016, “Examination of the Foreign Body Response to Biomaterials
by Nonlinear Intravital Microscopy,” Nat. Biomed. Eng., 1, p. 0007.
[213] Anderson, J. M., Rodriguez, A., and Chang, D. T., 2008, “Foreign Body Reaction
to Biomaterials,” Semin. Immunol., 20(2), pp. 86–100.
[214] Wheeldon, E. B., Walker, M. E., Murphy, D. J., and Turner, C. R., 1992,
“Intratracheal Aerosolization of Endotoxin in the Rat: A Model of the Adult
Respiratory Distress Syndrome (ARDS),” Lab. Anim., 26(1), pp. 29–37.
[215] van Helden, H. P. M., Kuijpers, W. C., Steenvoorden, D., Go, C., Bruijnzeel, P. L.
B., van Eijk, M., and Haagsman, H. P., 1997, “Intratracheal Aerosolization of
Endotoxin (LPS) in the Rat: A Comprehensive Animal Model to Study Adult
(Acute) Respiratory Distress Syndrome,” Exp. Lung Res., 23(4), pp. 297–316.

214
[216] van Rozendaal, B. A., van de Lest, C. H., van Eijk, M., van Golde, L. M.,
Voorhout, W. F., van Helden, H. P., and Haagsman, H. P., 1999, “Aerosolized
Endotoxin Is Immediately Bound by Pulmonary Surfactant Protein D in Vivo,”
Biochim. Biophys. Acta, 1454(3), pp. 261–269.
[217] Moxley, M. A., Baird, T. L., and Corbett, J. A., 2000, “Adoptive Transfer of
Acute Lung Injury,” Am. J. Physiol. - Lung Cell. Mol. Physiol., 279(5), pp.
L985–L993.
[218] Jansson, A.-H., Eriksson, C., and Wang, X., 2004, “Lung Inflammatory
Responses and Hyperinflation Induced by an Intratracheal Exposure to
Lipopolysaccharide in Rats,” Lung, 182(3), pp. 163–171.
[219] Perng, W.-C., Wu, C.-P., Chu, S.-J., Kang, B.-H., and Huang, K.-L., 2004,
“Effect of Hyperbaric Oxygen on Endotoxin-Induced Lung Injury in Rats,” Shock
Augusta Ga, 21(4), pp. 370–375.
[220] Chu, S.-J., Li, M.-H., Hsu, C.-W., Tsai, S.-H., Lin, S.-H., and Huang, K.-L., 2007,
“Influence of Hyperbaric Oxygen on Tumor Necrosis Factor-α and Nitric Oxide
Production in Endotoxin-Induced Acute Lung Injury in Rats,” Pulm. Pharmacol.
Ther., 20(6), pp. 684–690.
[221] Haitsma, J. J., Lachmann, B., and Papadakos, P. J., 2009, “Additives in
Intravenous Anesthesia Modulates Pulmonary Inflammation in a Model of LPSInduced Respiratory Distress,” Acta Anaesthesiol. Scand., 53(2), pp. 176–182.
[222] Li, Y., and Wei, H., 2009, “Lipopolysaccharide ‘two-Hit’ Induced Refractory
Hypoxemia Acute Respiratory Distress Model in Rats,” J. Huazhong Univ. Sci.
Technolog. Med. Sci., 29(4), pp. 470–475.
[223] Fu, P.-K., Yang, C.-Y., Tsai, T.-H., and Hsieh, C.-L., 2012, “Moutan Cortex
Radicis Improves Lipopolysaccharide-Induced Acute Lung Injury in Rats through
Anti-Inflammation,” Phytomedicine, 19(13), pp. 1206–1215.
[224] Jou, I.-M., Tsai, Y.-T., Tsai, C.-L., Wu, M.-H., Chang, H.-Y., and Wang, N.-S.,
2000, “Simplified Rat Intubation Using a New Oropharyngeal Intubation
Wedge,” J. Appl. Physiol., 89(5), pp. 1766–1770.
[225] Morton, D. B., Abbot, D., Barclay, R., Close, B. S., Ewbank, R., Gask, D., Heath,
M., Mattic, S., Poole, T., Seamer, J., Southee, J., Thompson, A., Trussell, B.,
West, C., and Jennings, M., 1993, “Removal of Blood from Laboratory Mammals
and Birds: First Report of the BVA/FRAME/RSPCA/UFAW Joint Working
Group on Refinement,” Lab. Anim., 27(1), pp. 1–22.
[226] Diehl, K. H., Hull, R., Morton, D., Pfister, R., Rabemampianina, Y., Smith, D.,
Vidal, J. M., van de Vorstenbosch, C., and European Federation of
Pharmaceutical Industries Association and European Centre for the Validation of
Alternative Methods, 2001, “A Good Practice Guide to the Administration of
Substances and Removal of Blood, Including Routes and Volumes,” J. Appl.
Toxicol. JAT, 21(1), pp. 15–23.

215
[227] Erdem, M. K., Yurdakan, G., and Yilmaz-Sipahi, E., 2014, “The Effects of
Ketamine, Midazolam and Ketamine/Xylazine on Acute Lung Injury Induced by
α-Naphthylthiourea in Rats,” Adv. Clin. Exp. Med. Off. Organ Wroclaw Med.
Univ., 23(3), pp. 343–351.
[228] Garcia, A. N., Vogel, S. M., Komarova, Y. A., and Malik, A. B., 2011,
“Permeability of Endothelial Barrier: Cell Culture and In Vivo Models,”
Permeability Barrier, K. Turksen, ed., Humana Press, Totowa, NJ, pp. 333–354.
[229] Wagner, E. M., Karagulova, G., Jenkins, J., Bishai, J., and McClintock, J., 2006,
“Changes in Lung Permeability after Chronic Pulmonary Artery Obstruction,” J.
Appl. Physiol., 100(4), pp. 1224–1229.
[230] Smedira, N., Gates, L., Hastings, R., Jayr, C., Sakuma, T., Pittet, J. F., and
Matthay, M. A., 1991, “Alveolar and Lung Liquid Clearance in Anesthetized
Rabbits,” J. Appl. Physiol., 70(4), pp. 1827–1835.
[231] Fukuda, N., Folkesson, H. G., and Matthay, M. A., 2000, “Relationship of
Interstitial Fluid Volume to Alveolar Fluid Clearance in Mice: Ventilated vs. in
Situ Studies,” J. Appl. Physiol., 89(2), pp. 672–679.
[232] Fitzgerald, M., Millar, J., Blackwood, B., Davies, A., Brett, S. J., McAuley, D. F.,
and McNamee, J. J., 2014, “Extracorporeal Carbon Dioxide Removal for Patients
with Acute Respiratory Failure Secondary to the Acute Respiratory Distress
Syndrome: A Systematic Review,” Crit. Care, 18(3), pp. 1–11.
[233] Xavier, A. M., Isowa, N., Cai, L., Dziak, E., Opas, M., McRitchie, D. I., Slutsky,
A. S., Keshavjee, S. H., and Liu, M., 1999, “Tumor Necrosis Factor-Alpha
Mediates Lipopolysaccharide-Induced Macrophage Inflammatory Protein-2
Release from Alveolar Epithelial Cells. Autoregulation in Host Defense,” Am. J.
Respir. Cell Mol. Biol., 21(4), pp. 510–520.
[234] Hoareau, L., Bencharif, K., Rondeau, P., Murumalla, R., Ravanan, P., Tallet, F.,
Delarue, P., Cesari, M., Roche, R., and Festy, F., 2010, “Signaling Pathways
Involved in LPS Induced TNFalpha Production in Human Adipocytes,” J.
Inflamm., 7, p. 1.
[235] Reis, J., Guan, X. Q., Kisselev, A. F., Papasian, C. J., Qureshi, A. A., Morrison,
D. C., Van Way, C. W., Vogel, S. N., and Qureshi, N., 2011, “LPS-Induced
Formation of Immunoproteasomes: TNF-α and Nitric Oxide Production Are
Regulated by Altered Composition of Proteasome-Active Sites,” Cell Biochem.
Biophys., 60(1–2), pp. 77–88.
[236] Wagner, E. M., Jenkins, J., Perino, M. G., Sukkar, A., and Mitzner, W., 2011,
“Lung and Vascular Function during Chronic Severe Pulmonary Ischemia,” J.
Appl. Physiol., 110(2), pp. 538–544.
[237] Yanamoto, H., Nagata, I., Niitsu, Y., Zhang, Z., Xue, J.-H., Sakai, N., and
Kikuchi, H., 2001, “Prolonged Mild Hypothermia Therapy Protects the Brain
Against Permanent Focal Ischemia,” Stroke, 32(1), pp. 232–239.

216
[238] Lagina, A. T., Calo, L., Deogracias, M., Sanderson, T., Kumar, R., Wider, J., and
Sullivan, J. M., 2013, “Combination Therapy With Insulin-like Growth Factor-1
and Hypothermia Synergistically Improves Outcome After Transient Global Brain
Ischemia in the Rat,” Acad. Emerg. Med., 20(4), pp. 344–351.
[239] Logue, E. S., McMichael, M. J., and Callaway, C. W., 2007, “Comparison of the
Effects of Hypothermia at 33°C or 35°C after Cardiac Arrest in Rats,” Acad.
Emerg. Med., 14(4), pp. 293–300.
[240] Greene, S. A., 2002, Veterinary Anesthesia and Pain Management Secrets,
Elsevier Health Sciences.
[241] Sirois, M., 2014, Laboratory Procedures for Veterinary Technicians, Elsevier
Health Sciences.
[242] Thomas, R. G., and Morgan, B. N., 1970, The Effects of Age, Weight, Strain and
Anesthesia upon the Breathing Patterns in Two Strains of Rats, Lovelace
Foundation for Medical Education and research, Albuquerque.
[243] Kim, E. S., and Stolar, C. J., 2000, “ECMO in the Newborn,” Am. J. Perinatol.,
17(7), pp. 345–356.
[244] Garosi, G., and Paolo, N. D., 2001, “The Rabbit Model in Evaluating the
Biocompatibility in Peritoneal Dialysis,” Nephrol. Dial. Transplant., 16(3), pp.
664–665.
[245] Ikegawa, H., Kuwagata, Y., Hayakawa, K., Noguchi, K., Ogura, H., and
Sugimoto, H., 2012, “Effects of Exchange Transfusion With LiposomeEncapsulated Hemoglobin on VO2/DO2,” Artif. Organs, 36(2), pp. 130–138.
[246] Herber, F. J., 1948, “Metabolic Changes of Blood and Tissue Gases during
Asphyxia,” Am. J. Physiol., 152(3), pp. 687–695.
[247] Levy, L. S., 1971, “Physiological Changes during Electrical Asphyxiation,” Br. J.
Ind. Med., 28(2), pp. 164–171.
[248] Zhang, J.-Y., Wang, X.-H., Wang, L.-J., Xu, B., and Zheng, M., 2010, “Effect of
Oxygenation of Transperitoneal Ventilation on the Death Time after Asphyxiation
in Rabbits,” Minerva Anestesiol., 76(11), pp. 913–917.
[249] Suckow, M. A., Schroeder, V., and Douglas, F. A., 2010, The Laboratory Rabbit,
Taylor & Francis.
[250] Varga, M., 2013, Textbook of Rabbit Medicine, Elsevier Health Sciences.
[251] Staikou, C., Paraskeval, A., Donta, I., Theodossopoulos, T., Anastassopoulou, I.,
and Kontos, M., 2011, “The Effects of Mild Hypothermia on Coagulation Tests
and Haemodynamic Variables in Anaesthetized Rabbits,” West Indian Med. J.,
60(5), pp. 513–518.
[252] Jiang, S., He, X., Wang, J. ’an, Zhou, G., Zhang, M., Ba, L., Yang, J., and Zhao,
X., 2013, “Therapeutic Mild Hypothermia Improves Early Outcomes in Rabbits
Subjected to Traumatic Uncontrolled Hemorrhagic Shock,” J. Surg. Res., 179(1),
pp. 145–152.

217
[253] Raekallio, M., Ansah, O. B., Kuusela, E., and Vainio, O., 2002, “Some Factors
Influencing the Level of Clinical Sedation Induced by Medetomidine in Rabbits,”
J. Vet. Pharmacol. Ther., 25(1), pp. 39–42.
[254] Alexander, N., and DeQuattro, V., 1974, “Gastrointestinal and Mesenteric
Hemodynamic Patterns in Neurogenic Hypertensive Rabbits,” Circ. Res., 35(4),
pp. 646–651.
[255] Eke, A., and Delpy, D. T., 2000, Oxygen Transport to Tissue XXI, Springer
Science & Business Media.
[256] Nemoto, E. M., and LaManna, J. C., 2012, Oxygen Transport to Tissue XVIII,
Springer Science & Business Media.
[257] Smith, W., 1993, “Responses of Laboratory Animals to Some Injectable
Anaesthetics,” Lab. Anim., 27(1), pp. 30–39.
[258] Papavramidis, T. S., Kotidis, E., Ioannidis, K., Cheva, A., Lazou, T., Koliakos,
G., Karkavelas, G., and Papavramidis, S. T., 2012, “The Effects of Chronically
Increased Intra-Abdominal Pressure on the Rabbit Diaphragm,” Obes. Surg.,
22(3), pp. 487–492.

218

Appendices
Appendix A
Table A.1: Bill of materials for the Peri3 device.
Component
FH100M
myDAQ

Manufacturer

Supplier

Thermo
Scientific
National
Instruments

Thermo
Scientific
National
Instruments

Part No.

Quantity

Price per
unit ($)

72-320-084

1

2899.00

---

2

179.00

DB-25 M/F
cable
DB-25 Male
connector
MS4426005G

Cables 2 Go

Amazon

B000051183

1

4.47

Winford
Engineering
Measurement
Specialties

Winford
Engineering

BRKSD25M-C

1

23.50

Digikey

223-1095-ND

2

36.33

iWarm

Midmark

---

396.42350.2

1

299.00

K
thermocouple

UXcell

Amazon

B005CG2W3U

1

3.58

AD595AQ

Burr-Brown

Digikey

AD595AQ-ND

1

15.42

PCB

UNL EE Shop

UNL EE
Shop

---

1

0.00

Sparkfun

ROB-10391

1

14.95

UNL EE
Shop

RSDC-DC108-000

1

2.00

Amazon

B0042RHT4M

1

11.09

Solid state
relay
24 V power
adapter

ZonHen
Electric
Appliances
Continental
Industries
ElectroHarmonix

Acrylic case

BallQube

Amazon

B000LBB63S

1

15.99

1/8” Tygon
tubing

Tygon

McMaster

5155T16

25 ft

0.42

Solenoid

TOTAL

$3730.16
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A.1 Pinout diagrams

Figure A.1: Pinout diagram of FH100M peristaltic pump.

220

Figure A.2: Pinout diagram of myDAQ.

Figure A.3: Pinout diagram of pressure transducer (MS4426-005G).

221

Figure A.4: Pinout diagram of thermocouple amplifier and cold junction compensator
chip (AD595AQ-ND).
A.2 Equations for design of Peri3
A.2.1 Pressure conversion for pressure transducer MS4426-005G (volts to mmHg)
Vs

– supply voltage to pressure transducer (typically = 14.95 V)
1 psi 51.7419 mmHg 1000 mV
𝐶=|
|
|
|
mV
1 psi
𝑉𝑠

C

– conversion factor (3461 mmHg/V)

Vo

– voltage output from the pressure transducer [V]

P

– intra-abdominal pressure [mmHg]
𝑃 = 𝑉𝑜 ∙ 𝐶

[Eq. A.1]

A.2.2 Temperature conversion for thermocouple amplifier and compensator chip (Volts
to °C)

222
C

– conversion factor

Vo

– voltage output from the thermocouple amplifier [V]

T

– inflow temperature [°C]
𝑉𝑜 =

1 °C 1000 mV
°C
|
| = 100
10 mV
1V
V
𝑇 = 𝑉𝑜 ∙ 𝐶

[Eq. A.2]

A.2.3 Patient inputs to needed flow rate (input voltage for pump)
VO2 – resting oxygen consumption rate of patient [mLO2/(kg x min)]
Rat: 12

Rabbit: 8.5

Pig: 7

ρO2 – density of oxygen at STP = 1.3 mg/mL
BO2OMB – O2 carrying capacity of OMBs = 0.88 mgO2/mL
DOMB

– OMB demand of patient [mL/(kg x min)]
Rat: 17.73 Rabbit: 12.557

Pig: 10.34

m

– mass of patient [kg]

Q

– flow rate of OMBs patient requires [mL/min]

n

– number of lines needed

C

– conversion factor [(V x min)/mL]
n = 1: 0.0625

Vi

n = 2: 0.0313

n = 3: 0.0208

n = 4: 0.0156

– voltage input to pump

𝐷𝑂𝑀𝐵 =

𝑉𝑂2 ∙𝜌𝑂2
𝐵𝑂2𝑂𝑀𝐵

𝑄 = 𝐷𝑂𝑀𝐵 ∙ 𝑚

[Eq. A.3]
[Eq. A.4]

10 rpm
10 V 1
𝐶= |
|
| |
8 mL/min 200 rpm 𝑛
𝑉𝑖 = 𝑄 ∙ 𝐶

[Eq. A.5]
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A.3 SolidWorks

Figure A.5: Part drawings of electronics case.

224

Figure A.6: Part drawings of 3D printed tubing mount of the solenoid assembly.

225
A.4 LabVIEW code

Figure A.7: Entire LabVIEW program for controlling the Peri3.

226
A.4.1 Temperature measurement
Functions of code
1) Separate voltage supply to thermocouple amplifier
2) Filter for both graphical feedback and stored date
3) Write data and time stamp to Excel file

Figure A.8: Subroutine of Peri3 LabVIEW program for temperature measurement.
A.4.2 Pressure measurement
Functions of code
1) Applying the different calibration equations for each transducer to the
measured pressures
2) Convert back and forth between data arrays and matrices
3) Array and matrix manipulations
4) Filter for both graphical feedback and stored date
5) Write voltage output and converted pressure data to Excel file with time stamp

Figure A.9: Subroutine of Peri3 LabVIEW program for pressure measurement.

227
A.4.3 Solenoid Control
Functions of code
1) Manual override switches
2) Shift register to “remember” the current position of the solenoid
3) Digital output for the solid state relay

Figure A.10: Subroutine controlling the solenoid for regulating intraperitoneal volume in
the Peri3 LabVIEW program.
A.4.4 Pump control
Functions of code
1) Infusion at accelerated rate for a set time to fill IPC quickly
2) Ring input for drop down of different possible patient species
3) Case structure (similar to ifelse statements) for different conversions for pump
input voltages based on required flow rate and the corresponding number of
infusion lines
4) Stop pump when program stopped

228

Figure A.11: Subroutine controlling the pump in the Peri3 LabVIEW program.

Appendix B
B.1 Design of a custom catheter for prolonged peritoneal infusion and drainage
The goal of a newly designed catheter was to mimic T-fluted catheters, which
exhibited high efficiencies at fluid removal from studies of peritoneal dialysis in dogs and
humans [207,208]. The flutes provide an external path for capillary movement along the
outside of the catheter rather than an internal path [209]. The goal of fluted catheter
designs is to provide a large surface area for fluid to flow limiting the potential to have
fluid flow obstructed by tissue. The original design comprised 4 lengths of 2 mm outer
diameter tubing (EW-06449-10, Cole Parmer, Vernon Hills, IL) twisted around each
other and secured at 3.2 cm (1.25 inch) intervals with narrow segments of heat shrink
tubing (Figure 6.1). The twisting of the segments tightened the segments together and
increased the rigidity of the catheter much like a braided rope. The custom design
replicated the function and structure of flutes the grooves created between the segments
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of tubing. The custom design was also created to allow for an inexpensive alternative that
could be easily manufactured on site. The custom design was then compared against
fluted catheters similar to those found successful in peritoneal dialysis of dogs and that
were currently available for purchase.

Figure B.1: Build and design of the custom catheter.
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Appendix C
C.1 Phase 1: ARDS validation

Figure C.1: Mass loss from baseline.
C.1.1 Blood chemistry

Figure C.2: Concentration of potassium (K).

231

Figure C.3: Concentration of glucose.

Figure C.4: Concentration of ionized calcium (Ca).

232

Figure C.5: Concentration of sodium (Na).

Figure C.6: Concentration of hemoglobin.
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5
Figure C.7: Hematocrit of the blood.
C.1.2 Blood acid/base

Figure C.8: Concentration of base excess (BE).
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Figure C.9: Concentration of bicarbonate (HCO3-).

Figure C.10: Blood pH.
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Figure C.11: Calculated concentration of total carbon dioxide (tCO2).
C.1.3 Pulse oximetry

Figure C.12: Heart rate.

236

Figure C.13: Perfusion of blood in the rat’s paw.
C.2 Phase 2: ARDS oxygenation
C.2.1 Blood gases

Figure C.14: Calculated oxygen saturation.

237
C.2.2 Blood acid/base

Figure C.15: Concentration of base excess (BE).

Figure C.16: Concentration of bicarbonate (HCO3-).

238

Figure C.17: Blood pH.

Figure C.18: Calculated concentration of total carbon dioxide (tCO2).
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C.2.3 Pulse oximetry

Figure C.19: Heart rate.

Figure C.20: Perfusion of blood in the paw.
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C.3 Chest radiographs

Figure C.21: Complete chest radiograph record for representatives of negative (Nv3) and
saline controls (Sv3).

241

Figure C.22: Chest radiograph record for seven days of a representative given LPS.

242

Figure C.23: Complete chest radiograph record for representatives of ARDS validation
(Lv3) and oxygenation (LPS) trials.

243
C.4 Lung injury scores

Figure C.24: Lung injury scores of all ARDS characterization groups.
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Appendix D

Figure D.1: Actual experimental setup of OMB treatment in a rat with a right
pneumothorax.
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Appendix E
E.1 SolidWorks

Figure E.1: Part drawings of scavenge port used in perfusion trials of asphyxia in rabbits.

246
E.2 Tissue oxygenation

Figure E.2: Local tissue oxygenation of rabbits’ abdomen (a) before asphyxia and OMB
infusion and (b) after asphyxiated and treated with PMO.
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Appendix F
F.1 Oxygenation of PMO-ARDS rats given OMBs

Figure F1: The peripheral oxygen saturation of rats with ARDS given PMO therapy with
catheters that worked (PMO #1, #2) and catheters that failed (Failed #1, #2).
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Figure F2: The partial pressure of oxygen in rats with ARDS given PMO therapy with
catheters which worked (PMO #1, #2) and catheters that failed (Failed #1, #2).
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Figure F3: The oxyhemoglobin fraction in rats with ARDS given PMO therapy with
catheters which worked (PMO #1, #2) and catheters that failed (Failed #1, #2).
F.2 Chest radiographs of IMB treated rats

Figure F4: Retention of gas in PMO-ARDS rats treated with IMB boluses.

